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PREFACE 
XXIX 
Hippocrates214 stated the general law that "blood which spills 
into a cavity must decay". From his writings, it is clear that 
he was referring to blood in the peritoneal or pleural cavities and 
to the subsequent inflammatory response that such deposits elicited. 
Since his work predates the invention of the ophthalmoscope by some 
twenty-two centuries, he probably had little knowledge of haemorrhage 
into the vitreous cavity. Had he been aware of this condition, he 
might have regarded it an exception to his rule. 
Blood may clear rapidly and completely from the vitreous cavity 
with full restoration of vision, provided the retina is intact. Con-
versely, the vitreous may remain opaque for weeks, months or even 
permanently in the most serious cases, resulting in blindness. The 
relative increase in blindness due to bleeding into the vitreous humour 
can be attributed to the prevalence of diabetic retinopathy with which 
vitreous haemorrhage is closely associated. Moreoever, the proenosis 
for sight is unpredictable in this condition. 
Aside from the obvious serious visual effects of vitreous opacities 
due to blood, the failure of blood to clear from the vitreous is intrigu-
ing, since it implies a failure of the normal scavenging mechanisms of 
the body in removing unwanted tissue debris. The studies described in 
this thesis were initiated by this apparent defect in the normal healing 
process and by the lack of knowledge generally on the fate of blood in 
the vitreous. Previous studies of human material have shown that 
persistent vitreous opacities contain suspensions of degenerate red 
cells plus dense collagenous vitreous bands or "membranes". Experimental 
studies have also demonstrated that several processes such as haemolysis, 
. and fl'broblastic activity occur during the reabsorption phagocytoslS 
of vitreous clots in rabbits. Despite this boiy of work, a cause (or 
xxx 
causes) for the delayed resolution of vitreous clots has not been 
identified. 
Studies of the interaction between blood and tissues involve 
several physiological systems including coagulation, fibrinolysis, 
haemolysis, the inflammatory response and the wound healing response, 
which are all closely interrelated. The present work is an experi-
mental study which was designed to examine a number of these systems in 
relation to the interaction between blood and vitreous. 
Plan of Thesis 
The thesis is divided into four parts. In Part 1, the clinical 
background of vitreous haemorrhage is outlined and a brief description 
of the normal vitreous body is included. Part 2 comprises an investi-
gation of the mechanism of blood coagulation in the vitreous. Part 3 
contains experimental data which delineates the role of fibrinolysis in 
the resolution of vitreous blood clots. In Part 4, a study of the 
sequential pathological changes occurring within experimental vitreous 
clots is described and an attempt is made to resolve the controversy 
concerning the source ani formation of vitreous "membranes". A summary 
of the findings is reported on page XXXI and a short appendix is included 
which sets this experimental work into the context of therapy of human 
vitreous haemorrhage (Chapter 15). 
XXXI 
SUMMARY 
XXXII 
This thesis explores the pathophysiological mechanisms involved in 
the clearance of vitreous blood clots from the eye. The work presented 
i~ an experimental study of various aspects of the blooi-vitreous inter-
action, including coagulation and fibrinolytic mechanisms in the vitreous, 
and the morphological changes which occur during lysis of experimental 
vitreous blood clots in vivo. 
Initial investigations were aimed at establishing the mechanism of 
blood coagulation in the vitreous. The effects of vitreous and its 
components on humoral and cellular coagulation mechanisms were studied. 
The presence of humoral procoagulant activity in normal vitreous was 
sought using standard cell-free plasma-derived coagulation assays. 
Where necessary, purified coagulation factors were prepared and used to 
identify specific coagulation factor activities in the vitreous. It 
was found that the vitreous contained minimal tissue thromboplastin. In 
addition, trace amounts of a Hageman factor-like activity were detected in 
normal vitreous both by clotting studies and by activation of pre-kallikrein. 
No other coagulation factor activities were detected. Pure hyaluronic 
acid, which is essentially the sole glycosaminoglycan of vitreous, had 
little effect on the intrinsic system blood clotting mechanism when 
tested with activated plasma. However, both hyaluronic acid and vitreous 
induced a significant shortening of the recalcification time of non-
activated plasma. A role for hyaluronic acid in the activation of Hage-
man factor was suggested by these results. 
The role of platelets in fibrin formation within the vitreous was 
also investigated. Both rabbit and bovine vitreous collagens caused 
rapid platelet aggregation in spite of their unusual nature. However, 
evidence for fibrin formation as a direct result of platelet activation 
and in the absence of other mechanisms, could not be established. It 
t I t d t herefore that intravitreal clotting occurs in vivo through was pos u a e 
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activation of blood-derived Hageman factor by the vitreous, or more 
specifically, by its glycosaminoglycan component, the process being 
amplified by rapid platelet aggregation. Tissue thromboplastin may 
contribute to the reaction in a minor fashion, It is possible, 
therefore, that coagulation in the vitreous is initiated via the 
intrinsic clotting pathway, differing from clotting in other injured 
tissues where release of tissue thromboplastin is considered of major 
import ance. 
The second phase of the study consisted of an investigation of the 
role of fibrinolysis in clearing vitreous blood clots. Fibrinolytic 
activity, as well as components of the plasminogen-plasmin system, 
were assayed in normal vitreous using established techniques. Plasmino-
gen activator activity in the vitreous from all species tested was found 
to be minimal (equivalent to 15 Ploug units of urokinase per ml of 
vitreous). Accordingly, an experimental model of vitreous haemorrhage 
was developed to assess the role of fibrinolysis within resolving vitreous 
clots. A standard volume (0.2 ml) of autologous whole blood was in-
jected into the rabbit eye, and the opacification of the vitreous, as 
seen by ophthalmoscopy, was correlated with the level of intravitreal 
fibrinolysis. Fibrinolysis was estimated by measuring the concentration 
of fibrin and fibrin degradation products (FDP) within vitreous clots after 
various time intervals. It was shown that fibrin remained within the 
vitreous for at least five weeks and that FDP generation was low (5-20 
f g/ml ) • Thus, although fibrinolysis occurred within the vitreous, 
the level of activity compared poorly with that in other tissues. 
. t US1·ng the same animal model, in which intrinsic a further experlmen , 
In 
t · actl·vl·ty Mas blocked by the synthetic inhibitor, vitreous fibrinoly 1C " 
tranexamic acid, fibrin clearance from the vitreous was only slightly 
delayed (six weeks), even though FDP generation was reduced to undetect-
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able levels. Consequently, it was suggested that the poor resolution 
of vitreous haemorrhages in general may be related to the low levels of 
fibrinolytic activity in the vitreous, either directly by retarding the 
clearance of fibrin deposits, or indirectly, by failing to provide an 
adequate chemotactic stimulus through such agents as FDP or plasmin-
mediated complement fragments, both of which are known to be chemotactic 
in vitro. 
These experiments were extended to a study of the pathology of 
vitreous haemorrhage. The rabbit model described above was used, and 
the sequential changes in morphology were studied by macroscopic, histo-
logical and ultrastructural methods. Macroscopically, the vitreous clot 
remained as a discrete mass for four to six weeks, after which time it 
became considerably reduced in size. During this period, it changed 
colour from dark red to brown and eventually became a pale white mass. 
The presence of blood exerted severe destructive effects on the gel 
structure of the vitreous, including posterior detachment of the solid 
vitreous, liquefaction of the gel, the production of prominent vitreous 
bands or "membranes" and the formation ofa pseudocapsule by the detached 
vitreous around the blood clot. Small blood deposits persisted in 
several eyes for weeks or months. 
Detailed study of the inflammatory response to intravitreal blood 
revealed a low-grade cellular reaction with a notable lack of polymorpho-
nuclear cells. Mononuclear cells formed large aggregates and multi-
nucleate giant cell formation was evident. These cells were actively 
engaged in removing cellular debris mainly derived from degenerate red· 
cells, which had commenced autolysiS at an early stage. It is possible 
that this extracellular haemolysis was initiated by the relative anoxia 
and low glucose concentration within the vitreous, and sustained in the 
later stages by macrophage enzyme secretion. Furthermore, fibroblastic 
not observed in any of the specimens examined. activity was 
The ultra-
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structural evidence suggested that the so-called "fibrous" bands or 
"membranes" of clinical description resulted from co-agmer.tation of 
vitreous collagen stranlis. 
The conclusion drawn from this stuiy is that persistence of blood. 
clots in the vitreous is the consequence of a number of factors 
probably peculiar to the vitreous. The low levels of fibrinolytic 
activity, and the postulated absence of an adequate chemotactic stimu-
lus, may have been partly responsible for the low-grade, atypical in-
flammatory response. In addition, the vitreous itself may have con-
tributed to the poor cellular response, since it contains a considerable 
quantity of high molecular weight hyaluronic acid, a substance known to 
inhibit inflammatory cell function in vitro. These observations are 
not only pertinent to vitreous pathophysiology, but since hyaluronic 
acid is a ubiquitous macromolecule, they may have some relevance to the 
general field of inflammatory mechanisms. 
Finally, dense band.s or "membranes" can develop after bleeding into 
the vitreous, without the presence of fibroblast activity. It is 
suggested that fibrous organisation is an uncommon sequel to uncompli-
cated vitreous haemorrhage, and is found in ocular conditions where 
vitreous bleeding may be an incidental occurrence. 
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CHAPI'ER 1 
THE CLINICAL PROBLEM OF VITREOUS HAEMORRHAGE 
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INTRODUCTION 
Bleeding from intraocular vessels into the vitreous cavity has 
long been recognised as a cause of blindness281 • Moreover, the un-
predictable clinical pattern of vitreous haemorrhage reabsorption was 
well known to the early ophthalmoscoPists201,215,356. Lawson284 in 
his treatise on 'Diseases and Injuries of the Eye', observed that visual 
loss due to bleeding into the vitreous was often permanent since blood 
clots in the vitreous gel often failed to clear spontaneously. Regret-
tably, the clinical picture of untreated vitreous haemorrhages remains 
the same today31,270,295,342 •. 
There are many factors which affect the prognosis of vitreous 
haemorrhage resolution, some of which are related to the special nature 
of the vitreous body. A brief description of the composition of the 
normal vitreous body is therefore included in this chapter. 
THE NORMAL VITREOUS 
In most mammals, the entire space between the retina and the lens 
is filled with a transparent solid gel known as the vitreous body (Fig.l). 
In the normal eye of a young adult, the vitreous volume is about 4 ml, 
i.e. somewhat more than two thirds of the intraocular volume. With age 
and/or development, ~ certain portion of the gel becomes liquid, mainly 
in the central part. 
such as the owl monkey 
A few species have an entirely liquid vitreous 
(douroucouli Aotus trivirgatus)26 and the 
. b )299 bush baby (Galago crassicaudatus aglsym anus • Although the 
vitreous is 99% water and only 1% solids, it is regarded as a true 
tiBBuel83, since it is composed of the same constituents as other 
tissues, namely cells, fibres and interstitial groun,1 SUbstance2l • A 
Figure 1 . 1 Schematic diagram of adult human eye showing the 
topographical anatomy of the vitreous . Areas or "zones" 
are numbered after Cibis88• ~ones 1-4 (shaded areas) represent the 
vitreous . 1 , prepapillary space of Cloquet ' s canal ; 2, intermediate 
space of Cloquet ' s canal ; 3 , r etrolental space of Cloquet ' s canal ; 
4 , space around Cloquet ' s canal . Zones 6-11 represent the posterior 
chamber . 8, zonule ; 11 , lens . Zones 12-13 represent the anterior 
chamber . Berger ' s space is a potential space (zone 5) between' zones 
3 and 11 . Zone 7 represents Petit ' s canal . * area of vi t reous base . 
The cortical vitreous is a 1 mm thick outer layer of the vitreous gel 
bounded by the posterior hyaloid membrane and in close apposition to the 
retina . 
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major difference, however, between vitreous and other tissues is its 
avascularity. 
Gel formation in the vitreous is due to the fibrous protein, 
collagen26,191,315,400 which in the human occurs at a concentration of 
/ 
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about 0.3 mg ml • The distribution of collagen, however, within the 
vitreous is not uniform; liquid vitreous contains no collagen, while 
the highest concentration is found near the vitreous base, less so in 
the cortical vitreous (Fig. 1.1). ~ore recent studies of vitreous 
collagen suggest that different types of collagen may exist in different 
species (for review of collagen types, see reference 334). Bovine 
vitreous collagen appears to be Type 11492 , while rabbit vitreous col-
lagen resembles Type IV and appears to be associated with lipid materia1492 • 
Studies of vitreous collagen formation in the chick embryo using immune-
fluorescent techniques also show the presence of Type II collagen, although 
study of Type IV collagen was not possible due to lack of appropriate anti-
However, the possibility that vitreous collagen may represent a 
separate genetically distinct type of collagen has also been raised358 
It has been suggested that vitreous collagen has a dual origin from neural 
retina and hyalocytes358 (vide infra). 
Electron microscopic studies of vitreous collagen also lay stress 
on its unique nature. Vitreous structure is formed by delicate collagen 
fibrils of a width somewhere between 60Ao and 250Ao and a periodicity between 
The collagen fibrils are anchored in a basal 
lamina which lines the retina of the adult eye and is firmly attached to 
the cell membranes of the retinal Muller fibres. Detachment of the vitreous 
fibres from the retinal surface leads to rupture of the Muller cell membrane 
and produces a "posterior hyaloid membrane" composed of condensed vitreous 
. 23,146 
collagen fibrils, basal lamina and Muller cell debr~s • The basal 
t th V;treous base, and here the collagen fibrils are lamina is absent a e ~ 
j 
I 
I 
! 
I 
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directly adjacent to the epithelial cells421• The presence of a 
distinct anterior hyaloid membrane separating the vitreous from the 
posterior chamber has long been debated, but electron microscopic studies 
have failed to reveal such a structure. Instead, a concentration of 
vitreous collagen fibrils forms the posterior wall of the posterior 
chamber23• 
The ground substance of most tissues contains a variety of 
glycosaminoglycans396 • However, the interstitial matrix of the vitreous 
contains predominantly hyaluronic acid, with only traces of sulphated 
glycosaminoglycans491 • The concentration of hyaluronic acid in the 
vitreous shows considerable interspecies variation, low levels being 
found in the rabbit (0.03 rug/ml) and high values in the owl monkey 
Human vitreous hyaluronic acid concentration varies 
with age between 0.1 and 0.5 mg/ml. Hyaluronic acid is also distributed 
unevently in the vitreous, highest levels being found in the posterior 
cortical layer next to the retina, and decreasir~ towards the centre and 
anteriorly49l. The molecular weight of the hyaluronic acid molecule, 
which in cattle varies between 6 x 104 and 3.5 x 105 daltons, increases 
, th d' t' 21 ln e reverse lrec lon • Morphological identification of hyaluronic 
acid is extremely difficult since most of the material is lost in the 
fixation and dehydrating processes used for preparing tissues for micro-
scopy. Some authors have suggested that hyaluronic acid molecules can 
be detected with ruthenium red staining on electron microscopy465. 
Hyaluronic acid imparts viscosity to the vitreous and may also assist in 
22 
maintaining the stability of the three-dimensional collagen network • 
It may also act as a molecular sieve for the passage of molecules between 
200 
the vitreous and other ocular structures • 
The third macromolecular constituent of the vitreous is soluble 
protein. C t al
l07 found a vitreous protein concentration in the 
ooper e 
5 
range of 0.4 to 0.8 mg/ml and detected a wide variety of serum proteins, 
plus some that were immunologically distinct vitreous tissue antigens. 
Although serum proteins are present in the vitreous, their concentration 
ratios do not correspond to those in the serum, and this suggests that 
tley have not arrived in the vitreous merely by ultrafiltration21 ,45. The 
distribution of soluble proteins was observed to vary according to the 
locality21, 'but this may have been an artefact associated with the freez-
ing technique used491 • 
The cellular content of the vitreous is low, about one million 
cells per cattle vitreous28 (volume 8-9 ml). They occur as a monolayer 
in the cortical tissue layer of the vitreous, and electron microscopic 
studies have indicated that they may have a phagocytic function56 ,157 
since they contain numerous lysosomes. However, it is clear that 
. 21 
vitreous cells, or hyalocytes, as they have been described ,contain the 
necessary enzymes to elaborate hyaluronic acid and it is possible that 
this is their major function)11. In addition, they may be involved in 
collagen production358• At present, in spite of their having been identi-
fied over 130 years ago (cf reference 200) their primary role remains 
obscure. 
The topographical anatomy of the vitreous body is shown in figure 
1.1. The various structures and spaces are identified by number. 
Cloquet's canal is best seen in vivo, using the biomicroscopic method of 
slit lamp examination. It is composed of concentrically arranged con-
densations of vitreous collagen that form a sheath, known also as the 
plicate membrane. Numerous other channels and folds have been identified 
within the vitreous from time to time, but these are probably artefactual 
and have little proven physiological significance. 
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CAUSES OF VITREOUS HAEMORRHAGE 
Haemorrhage into the vitreous usually originates from retinal 
vessels, less frequently from choroidal or ciliary body vessels. It 
follows that diseases of the retinal vessels are likely to be assoc-
iated with vitreous haemorrhages. This association has been recognised 
since the early days of ophthalmoscopy, and indeed retinal neovascularis-
ation, associated with disorders such as retinal vein occlusion or 
diabetes, is a well-established cause of vitreous haemorrhage311,502. 
Furthermore, the clinical entity of recurrent vitreous haemorrhages in 
young men with inflammatory disease of the retinal vessels was first 
described in 1882 by Ealesl28• A causal relationship with tuberculosis 
or syphilitic disease was suggested for this condition. Vitreous 
haemorrhage in association with retinal hole formation and retinal 
detachment has also been well recognised, but the size of the bleed 
is usually very small. Occasionally, however, large intrage1 haemor-
rhages have been observed524• Similarly, an association between 
generalised bleeding disorders and vitreous haemorrhage has been 
190 
noted • 
Several reports have described the c1inico-pathologica1 features 
of vitreous haemorrhage90,255,~19, and case reports of intravitrea1 bleeding 
in a wide variety of systemic and local disorders have been recorded on 
numerous occasions. However, systematic study of the incidence and 
frequency of causes of vitreous haemorrhages is relatively recent. Jaffe
236 
classified the causes of vitreous haemorrhage into nine categories: 
(1) increased retinal venous pressure (e.g. central retinal vein 
occlusion, sickle-cell disease, subarachnoic haemorrhage, polycythemia 
vera), (2) increased retinal arterial pressure (e.g. hypertension), 
(3) inflammation of the retinal veins (e.g. in Eales' disease, or 
seconjary to uveitis), (4) retinal arteriovenous malformations (e .g. 
7 
Coats disease, Leber's miliary aneurysms, retinal angiomas), (5) 
retinal neovascularisation (e.g. diabetes,mellitus, central and 
branch venous occlusion, Eales' disease, sickle-cell disease, retro-
lental fibroplasia), (6) retinal tears or hole formation (usually 
secondary to vitreous detachment), (7) following cataract extraction 
(from anterior chamber, retina or choroid), (8) bleeding disorders 
(e.g. disseminated intravascular coagulation, idiopathic thrombocyto-
penia, and various anaemias and dysproteinaemias (e.g. Waldenstrom's 
macroglobulinaemia) and (9), tumours (e.g. malignant melanoma, retino-
blastoma). Other causes are trauma (either blunt or penetrating in-
juries) and congenital or developmental disorders of the vitreous such 
as persistent hyperplastic vitreous and congenital retinoschisis. 
INCIDENCE OF VITREOUS HAEMORRHAGE 
The incidence of vitreous haemorrhage in the general population 
is difficult to determine, since by present diagnostic classifications 
such Cases are usually recorded under the causal disease, e.g. diabetio 
retinopathy, or retinal vasculitis. Reoent studies3l ,295,342 suggest 
that diabetic retinopathy is the most common cause of vitreous haemor-
rhage at present, and in one series342 , this disorder accounted for 
more than fifty per oent of two hundred consecutive cases. In a 
separate study of 161 eyes with diabetic retinopathy, the incidence of 
512 
vitreous haemorrhage was found to be 12 per cent • Since the incidence 
of diabetes in the general population is estimated at 1.5 per cent, and 
the prevalence of diabetic retinopathy among diabetics about 50 per 
centl09 it is possible that the incidence of vitreous haemorrhage in the 
general popUlation may be as high as 0.54%. This figure is almost 
certainly an overestimation, due to selected data sampling. A more 
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rea~tic figure can be derived from the incidence of proliferative 
retinopathy in the diabetic population, which ranges between 4.43 to 
109 442 560 20.0 per cent ' , • If it can be assumed that vitreous haemor-
rhage in diabetics occurs mainly in relation to neovascularisation, and 
that seventy per cent of such patients are likely to have some degree 
of vitreous haemorrhage512 , an incidence of 0.05 to 0.35 per cent of 
the pppulation can be expected for vitreous haemorrhage due to diabetes 
alone. Statistical estimates of this nature, however, are notoriously 
inaccurate. What is more certain is that blindness due to diabetes has 
increased considerably. In 1940, 4.3~ of blindness was caused by dia-
betes, while by 1962 the figure had increased to 18.4%357. Much of 
this visual disability is associated with vitreous haemorrhage. Indeed, 
Caird72 has estimated that 31% of diabetic eyes are registered blind one 
year after the onset of vitreous bleeding. In view of the increased life 
expectancy of diabetics and the known association of retinopathy with the 
duration of diabetes, it can be expected that the incidence of vitreous 
haemorrhage will increase pari passu. 
In the absence of diabetes, the most frequent cause of vitreous 
haemorrhage is retinal tear2~5t446. Other common causes of vitreous 
haemorrhage include hypertension and retinal venous occlusion3l • The 
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remaining disorders associated with vitreous haemorrhage are much less 
frequent. In addition, although retinal haemorrhages are commonly seen 
in the neonatal period85 , vitreous haemorrhages are much rarer25l , and 
the possibility of a coagulation defect should be considered in such 
. t 566 Clrcums ances • 
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CLINICAL FACTORS ASSOCIATED WITH DELAYED RESOLUTION OF VITREOUS 
HAEMORRHAGES 
Several clinical factors may alter the prognosis for vision in 
cases of vitreous haemorrhage. These include the size, locality, 
cause, and recurrence rate of the haemorrhage, and the presence of 
complications. Large haemorrhages resolve less readily than small 
extravasations of b1ood31 ,295, and haemorrhages into the vitreous gel 
also resolve much more slowly than those into the subhyaloid (or retro-
gel) space. It has been suggested that the rapid reabsorption of blood 
from the subhyaloid space is due to the absence of clotting in this 
situation and thus the red cells sediment to the lower part of the eye 
where they are rapidly reabsorbed531 • Fluid levels within subhyaloid 
haemorrhages have long beenrecognised314 and this strongly supports the 
idea of a failure of blood clotting in the subhyaloid space. However, 
no experimental data has been produced to support this concept. Moreover, 
it is possible that subhyaloid haemorrhages produce less disability because 
they are of smaller size than intragel haemorrhages and therefore are more 
readily absorbed. Haemorrhages may also occur in other localities within 
the vitreous, such as Cloquet's canal32 or Petit's canal, or between the 
lens and the anterior hyaloid face (Berger's space)256 (see Fig.l.l). 
The cause of a vitreous haemorrhage may also influence its re-
absorption. Diabetic vitreous haemorrhages have a poorer visual prog-
nosis than non-diabetic clots, but this may be related to the presence of 
complications such as neovascu1ar or fibrous tissue in the vitreous, 
rather than to the clot itself. However, insulin-dependent diabetics 
have also been reported to have reduced fibrinolytic activity in their 
plasmal37 and this may affect the reabsorption of the blood from the 
vitreous (see summary). 
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Finally, it is self-evident that recurrent vitreous haemorrhages, 
such as occur in Eale's disease or diabetic retinopathy, have a poorer 
visual prognosis than single bleeds. 
DIAGNOSIS OF VITREOUS HAE.MORRHAGE 
The diagnosis of vitreous haemorrhage is usually simple. A sudden 
diminution of vision is accompanied by the presence of visible opacities 
in the vitreous cavity on ophthalmoscopy. A small haemorrhage may pro-
duce only a few small discrete opacities which can be seen to move in 
conjunction with ocular movements. By contrast, a large haemorrhage 
will completely obscure visible fundal details. A clot of this nature 
may persist indefinitely, but if spontaneous reabsorption occurs, visible 
strands can be detected in the centre of the vitreous, often followed in 
the later stages by the redistribution of the partially resorbed blood 
clot to the lower part of the globe. In this situation, it is common to 
see white or grey-white masses in the lower globe, interspersed with black 
or even bright-red clot material. Further reabsorption may lead to the 
development of "vitreous membranes", a term used to describe the appear-
ance of the dense bands which traverse the vitreous cavity and which may 
obscure vision. Slit-lamp examination of vitreous blood reveals a 
remarkable picture of dense "vitreous veils" in which cellular material 
can be identified even into the late stages of reabsorption. 
Diagnostic problems arise in attempting to distinguish between 
simple vitreous haemorrhage and vitreous haemorrhage associated with 
other ocular di~ease, e.g. diabetic retinopathy, retinal detachment or 
tumour. In such cases, the history and the examination of the fellow 
eye are often of great assistance, but frequently the vitreous opacities 
preclude a definitive diagnosis. The recent application of ultrasono-
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graphy to ocular diagnosis has considerably improved the evaluation of 
eyes with vitreous haemorrhage, since typical echo patterns from various 
intraocular lesions can be obtained91 ,98,150 ,313. 
COMPLICATIONS OF VITREOUS HAEM.ORRHAGE 
"Spontaneous" vitreous haemorrhages, as described by Morse et 
al342 to distinguish them from haemorrhages induced by ocular trauma, 
produce no pain and little or no inflammation in the eye. Cases have 
been observed in which no change occurred in the blood clot for several 
months or years, and then rapid and complete resolution occurred over a 
period of a few weeks with full visual recovery29. However, most 
cases of vitreous haemorrhage reabsorb slowly, if at all, and it is 
widely believed that non-resorbing blood clots can be complicated 
principally by two conditions which considerably worsen the visual 
prognosis. The first is the occurrence of fibrosis within the blood 
clot, which eventually leads to contr1ction of the vitreous, and,in areaS 
of firm vitreo-retinal adhesion, retinal hole formation and retinal 
detachment. Cases of this nature have been observed most frequently 
in eyes with retinal neovascularisation from diabetes or other retinal 
vascular disease, or in eyes which have suffered severe trauma (for 
discussion of the pathogenesis of vitreal fibrosis in vitreous haemor-
rhage, see Chapter 10). It is therefore unclear whether the fibrotic 
reaction results from the presence of the blood in the vitreous or from 
the original disorder, or both. Duke-Elder
l26 hints at this problem 
in his description of post-haemorrhagic retinitis proliferans, in which 
he states that not only is the presence of blood in the vitreous required 
to stimulate a fibroblastic reaction, but "a sufficient degree of 
irritation, neither too much nor too little", is also necessary. 
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The second complication ~hich may follo~ vitreous haemorrhage is 
glaucoma. T~o forms of open angle glaucoma have been described, haemo-
lytic and haemosiderotic. Haemolytic glaucoma is caused by large 
inflammatory cells, red cells ani haemolysed debris (erythroclasts) 
passing from the vitreous to the aqueous during absorption of the vitreous 
. 163 230 haemorrhage and blocklng the aqueous outflo~ channels ' • Haemo-
siderotic glaucoma is caused by direct toxicity of iron on the trabecular 
meshwork90 ,5l 9, while the angle of the anterior chamber remains open. 
The diagnosis of these conditions is a pathological one, ani the 
inci:ience is unknown. 
Retinal damage after vitreous haemorrhage has also been described 
mainly on patho1ogical l7 ,90 ,564 or experimentaI90,369,422grounds. 
However, the recoverY'of visual function follo~ing spontaneous ~r 
therapeutic clearance of vitreous blood would suggest that the 
incidence of such retinal damage is not high, at least to a clinically 
detectable degree. 
THERAPEUTIC CONSIDERATIONS 
Since this thesis is aimed at an understanding of the basic pathe-
physiological mechanisms in vitreous haemorrhage reabsorption, the 
treatment of vitreous blood clots is not considered at this stage. 
However, a brief summary of current trends in therapy is included in 
Chapter 15. 
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PART 2 
COAGULATION MECHANISMS WITHIN THE VITREOUS 
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CHAPI'ER 2 
REVIEW OF PHYSIOLOGY OF BLOOD COAGULATION 
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INfRODUCTION 
The classical theory of blood coagulation proposed by Morawitz338 
in 1905 and based on a concept of four interacting factors, was con-
siierably altered by the enzyme cascade theory of Macfarlane321 and 
Davie and Ratnoff l15• The latter theory was introduced to account for 
the increase in knowledge concerning blood coagulation factors which at 
that time numbered at least twelve. According to the cascade theory, 
several factors present in blood combined in an orderly sequence to 
convert soluble fibrinogen to fibrin (Figure 2.1). Surface activation 
of Factor XII initiated activation of Factors Xl and IX which in turn 
led to activated Factor VIII and produced activated Factor X in the 
presence of phospholipid and ionic calcium. Thrombin was then generated 
via activated Factor V and finally fibrinogen was converted to fibrin. 
However, clotting also occurs in the tissues and Blomback53 
proposed a similar scheme which separated coagulation into three phases, 
and included an extrinsic (tissue thromboplastin) mechanism in the second 
phase. According to this scheme, blood clotting in the tissues occurred 
via the extrinsic pathway in which Factor X was activated by the interaction 
of blood factor VII and tissue thromboplastin (T-Tbp) in the presence of 
calcium ions (Figure 2.2). A final common pathway for both intrinsic and 
extrinsic mechanism then occurred via Factor V and thrombin. 
During the last decade, detailed biochemical investigations into 
the nature and interactions of individual clotting f1'lctors have sllgrested 
that this concept, although fundamentally correct, requires modification. 
For example, several factors such as Factor VIII and V are now considered 
to act not as enzymes but as regulatory proteins by enhancing the rate of 
, of the1'r respective substrates to active factors134• In converSlon 
addition, the discovery of two asymptomatic disorders of clotting -
HAGEMAN F. ( XII ) 
P.T.A. (XI) 
__ ACT. HAGEMAN F. 
~ 
-_ .. ~ ACT. P.T.A. 
Ca ++ 
CHRISTMAS F (IX) _~.~ ACT. CHRISTMAS F • 
Figure 2.1 
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ANTIHEMOPHILIC F. (VIII) .. ACT. ANTIHEMOPHILIC F. 
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........ 
--. ACT. PROACCELERIN 
.-.. 
----4 .. ~ THROMBIN 
........ 
----4 .. ~ FIBRIN 
Intrinsic Coagulation Scheme (Enzyme cascade) 
according to Davie and Ratnoff (1964). 
Intrinsic coagulation scheme (Enzyme cascade) according 
to Davie and Ratnoff l15 • It is now known that 
Factors VIII and V act as regulatory proteins or cofactors in the 
coagulation sequence and not as shown here (see text). 
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I ~ 
Figure 2.2 Pathways in blood coagulation (from Esnouf
134) 
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Fletcher trait 208 and Fitzgerald trait 532 - has provided further in-
sight into the earliest stages of the intrinsic clotting pathway, and 
it is now generally accepted that both coagulation mechanisms interact 
in a highly integrated and balanced fashion with several other systems 
such as kinin formation and fibrinolysis. These pathways are discussed 
in more detail below. 
INTRINSIC PATHWAY 
Coagulation by the intrinsic pathway occurs via activation of 
Factor XII. Factor XII, or Hageman factor, has been purified by 
Schoenmakers et a1459 ,460 who considered it to be a sialoglycoprotein 
with esterolytic and proteolytic activity, and a molecular weight of 
80,000121• Grammens et al19l , however, studied bovine Factor XII 
and produced a homogeneous preparation with a molecular weight of 
140,000. Activation of Factor XII can be initiated by contact with 
a foreign surface, and it has been suggested that this is due to inter-
action between the high negative charge on the foreign surface (e.g. 
glass, talc, kaolin) and the positively charged amino-acid residues 
of the Hageman factor molecule4lB• l\~ore recent studies that utilised 
the technique of circular dichroism have shown that a conformational 
'th f' f 326 d change occurs in the molecule on contact W1 a ore1gn sur ace an 
this change probably confers marked hydrophobicity on the molecule. 
This activated moiety (Xlla) may then convert prekallikrein or Fletcher 
factor _ a gammaglobulin proenzyme that circulates in the plasma com-
) 310 plexed to high molecular weight kininogen (HMW, or Fitzgerald factor 
t F t XII95. This second to kallikrein, which rapidly act iva es more ac or 
f t t r urf ce activation of Factor reaction, however, differs rom con ac 0 s a 
XII in that the molecule is cleaved to produce Fragment E (mol. weight 
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Fragment E is considered to be the active principle 
involved not only in the intrinsic coagulation scheme, but also in 
the activ,"ltion of extrinsic system Factor VII and plasminogen (Fig. 
However, recent studies have shown that cleavage of 
Factor XII during contact activation of plasma yields two fragments, 
an 80,000 mol. wt. fragment known as~-HFa and a smaller, 28,000 
mol. wt. fragment designated p-HFa (Fragment E). 0\ -HFa is a two 
chain enzyme capable of activating prekallikrein and factor XI in 
either surface - bound or fluid phase, while~-HFa is a single chain 
molecule which cleaves prekal1ikrein on1y429; 
In addition to the well-known activators of Factor XII such as 
glass, kaolin and talc, several agents of biological significance have 
also been reported as activators of Factor XII. These include co1-
203 559 94 366 lagen ' , vascular basement membrane , sebum and bacterial lipe-
polysaccharides341 • The negatively charged soluble molecules, ellagic 
acid416 and chondroitin sulphate345 are also known activators of Factor 
XII. The precise mechanism of surface activation of Factor XII is 
currently in debate, particularly regarding the role of Fitzgerald 
Factor or HMW kininogen. HMW weight kininogen is a glycoprotein with 
a molecular weight of about 76,000, and a preferential susceptibility to 
plasma ka11ikrein259 • Digestion of single-chain HMW kininogen with 
kallikrein yields a kinin-free double chain molecule. Coagulant 
activity resides in the light chain of the molecule504 • In addition, 
to its role as "contact activation cofactor" in the generation of 
activated Factor Xla (see below), some workers believe that HMW kininocen 
is required for the conversion of prekallikrein and thus for Factor XII 
activation82 ,457. Moreover, high molecular weight kininogen may have 
. k ll·k . 569 This complex a role in the activation of plasminogen Vla a 1 reln • 
and unresolved subject has been reviewed recently by Ogston and Bennett 370 
{KININ) PLASMINOGEN 
PREKAlliKRElNTKAl}KREIN: 7 ~ACTIVATOR -_ .... \ 
xna-XII~xna' PLASMIN 
CONTACT ___ .~ ,'" Fitzgerald 1" --,' 1 
Abbreviations: 
PL: phospholipid 
TF: tissue factor 
" factor 
XI-XIa 
• 
Xlla': enzymically active fragment E 
Thick arrows denote the action of enzymes on their specific substrates as envisaged In the 
cascade hypothesis. Positive and negative feedback loops are indicated by Interrupted lines 
Figure 2.3 Schematic representation of interaction between blood 
coagulation factors and the kallikrein and fibrinolytic 
134) systems (from Esnouf • 
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and they have proposed a tentative scheme to outline the various inter-
actions (Figure 2.4). Undoubtedly, this concept will change and may 
have done so already since the recent report of a plasma factor which 
increases Factor XII activation in the presence of HMW kininogen but 
is apparently distinct from Factors XII and XI, prekallikrein-kallikrein, 
HMW k · . d l' l' 81 1 lnlnogen an p asmlnogen-p asmln • The positive feedback system 
(Figs. 2.3 and 2.4) inherent in these processes ensures that surface 
activation of Factor XII, whatever its mechanism, is greatly enhanced 
once it has been initiated. Activated Factor XII then converts Factor 
XI to its active form in the presence of Fitzgerald factor, or HMW 
kininogen453 • Little is known about the structure of Factor XI since 
it has been difficult to isolate, but its active form is a serine protease 
which initiates activation of Factor IX250. Factor IX is a glycoprotein 
with a molecular weight of 55,400 and it contains 26'fc., of carbohydrate in 
association with a single polypeptide chainl62 • Activation of Factor 
IX involves two stages, firstly the cleavage of the protein chain to 
yield a light chain (mol. wt. 16,600) and a heavy chain (mol. wt. 38,000). 
Disulphide bands connect the two split products250 • The second stage is 
completed by the removal of a peptide from the N-terminal position of the 
heavy chain; this produces procoagulant activity in the molecule. 
Activated Factor IXa is a serine proteasell4 which enzymically converts 
Factor X to Factor Xa and requires the presence of phospholipid, calcium 
ions and a further plasma protein, Factor VIII. In addition, it has 
been observed that incubation of Factor IX with a mixture of Factor Xa, 
phospholipid and calcium produces Factor IXa. Thus a possible link 
between the extrinsic and intrinsic pathways eXists24l (Fig. 2.3). 
Factor VIII is a complex protein which has three properties: 
coagulant activity, Factor VIII-related antigen activity, and platelet 
aggregation activity in the presence of the antibiotic ristocetin. It 
,'-
I 
Figure 2.4 
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Hypothetical scheme for the central role of high 
molecular weight kininogen in fibrinolysis, coagulation 
and inflammation (from Ogston and Bennett370). 
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is not known whether these activities occur separately within the 
molecule, but it seems likely that they do, since each activity can 
be selectively inhibited by appropriate antibody225. Biochemical 
separation of these activities has only been partially aChieved66 ,494, 
but greater separation can be obtained using immunoadsorption techniques266 • 
Preparations of Factor VIII from the cryo-precipitate fraction of plasma 
6 indicate that the molecular weight is about 1.2 x 10 , and it is composed 
of glycoprotein subunits of m.w. 1-2 x 105 , held together by disulphide 
bonds269 • Current views on Factor VIII coagulant activity suggest that 
it acts as a regulatory protein in the conversion of Factor X to Factor 
X 114 a , and that Factor VIII requires traces of thrombin before it can 
act. Thrombin has been shown to catalyse the formation of a more active 
form of Factor VIII from both the purified molecule and the low molecular 
weight procoagulant fractions of Factor VIII43l. 
EXTRINSIC PATHWAY 
In the extrinsic pathway of coagulation as originally described, 
two factors interact, namely Factor VII from blood and tissue factor, or 
tissue thromboplastin, from the tissues. The reaction product converts 
Factor X to activated Factor X in the presence of calcium ions. Tissue 
thromboplastin is a lipoprotein complex which has widespread distribution 
. th . 182 lon e organlsm When the lipid an:! protein components are dissociated, 
tissue thromboplastin loses its coagulant activity, but this can be re-
stored when the protein is relipidated487• Although tissue thrombo-
plastin was originally thought to be of lysosomal origin, it is now 
clear that it occurs mainly in the plasma membrane of cells, particularly 
vascular endothelium574 • Recent studies, however, have shown that thrombo-
plastic activity varies with cell type under tissue culture conditions. 
20 
It was shown that basal activity in endothelial cells was lower than 
for other cell types such as fibroblasts and they were also compara-
318 tively refractory to drug effects • These findings were regarded 
as consistent with the proposed role for an intact endothelium in 
haemostasis. A further recent finding of interest is that the 
reaction product of Factor VII and tissue thromboplastin may activate 
Factor IX, thus demonstrating a second link between the extrinsic and 
intrinsic coagulation pathways318. 
Thromboplastic activity also varies with the tissue. High 
levels of activity were found in the lungs, brain and Placenta556 ,551 
and also in several ocular tissues such as the retina and choroid382 • 
The vitreous, however, has minimal procoagulant activity (see Chapter 
In addition to its interaction with Factor VII, tissue thrombo-
plastin has considerable peptiiase activity and it has been suggested 
that under normal circumstances the predominant role of tissue thrombo-
plastin is the inactivation of small vasoactive peptides, while its pro-
coagulant activity is masked, perhaps by a molecular sieve mechanism 
involving the glYCOcalyx469. 
Factor VII is a single chain glycoprotein (mol. wt. 45,500) which 
forms a complex with tissue thromboplastin before it converts Factor X 
to Factor Xa. Catalytic amounts of Factor Xa then convert Factor VII 
to a diaulphiie-bonded double chain which has 80 fold specific activity 
on interaction with tissue thromboplastin, and thus markedly augments 
·t· f db k mechanism4l2• In the production of Factor Xa in a POSl Ive ee ac 
represents a third link between the extrinsic and intrinsic addition, this 
clotting pathways (Figure 2.3). Factor VII has a chemical composition 
"1 to other Vitamin K-dependent coagulation factors such as 
very Slml ar 
1 
Factors II, IX and X, and besides being activated by Factor Xa, Factor VIla can 
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be generated by kallikrein, plasmin, Hageman Factor fragment E, and 
Factor IXa. Furthermore, Factor VIla is unaffected by known inhibitors 
of coagulation, such as antithrombin III and heparin (see later). 
COMMON PATHWAY 
Factor X is a glycoprotein with a mol. weight. of 55,000 and 
comprises two chains joined by a disulphide bridge161 • It is 
activated by the intrinsic and extrinsic pathways, by insoluble 
trypsin and by Russel viper venom in a two stage process involving 
cleavage of identical peptide bonds 239 • Coagulant activity is found 
after the first stage. Factor Xa converts prothrombin to thrombin in 
the presence of Factor V, phospholipid and calcium ions. Factor Xa 
also catalyses the conversion of Factor VII (see above). 
Factor V does not participate directly in the coagulation scheme, 
but greatly accelerates the production of thrombin from prothrombin and 
may act as a regulatory protein133• Recent studies suegest that Factor 
V has a single heavy chain (mol. wt. 125,000) and two light chains (mol. 
wt. 13,000) which are split during thrombin activation242 • Factor V 
and Factor Xa are probably adsorbed to the phospholipid where they act 
as a complex to convert prothrombin. 
Prothrombin or Factor II is a single chain glycoprotein (mol. wt. 
10,000), the aminoacid sequence of which has been fully elucidated304 • 
Activation of prothrombin by Factor Xa-Factor V complex involves the 
release of various fragments. Removal of the two "Kringle" structures, 
Fragments 1 and 2 {Fig. 2.5),releases prothrombin which is cleaved by 
activated Factor X to produce the two chain molecule thrombin. Thrombin 
itself is involved in splitting Fragment 1 from the prothrombin molecule 
(Fig. 2.3) and this may represent a negative feedback control of thrombin 
Figure 2.5 
KEY: 
• ~ l' -carbo.yglutamic acid 
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CHO: 
I 
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The secondary structure of prothrombin (after Magnusson 
The length of chain representing the Kringle 
structures (two are shown) is highlighted between the unmarked arrows. 
The structures are sO called due to their resemblance to a Swedish cake. 
Cleavage points for Factors I~and Xa are shown. 
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production. Indeed, in the presence of thrombin inhibitors, the rate 
of prothrombin conversion can be greatly increased and it has been 
suggested that Fragment 1 competitively inhibits prothrombin conversion406 
and that Factor V may function by counteracting this inhibitory effect of 
Fragment 1133• 
Thrombin, therefore, has two chains, a long B chain and a short 
A chain joined by a disulphide bridge. It is a serine protease with 
trypsin-like activity, but is distinguished from the other serine pro-
teases such as pancreatic enzymes by the presence of the short A chain. 
Thrombin activity on fibrinogen has been reported to be highly specific, 
occurring at four arginyl-glycyl bonds and two arginyl-valine bonds55 • 
Recent kinetic studies indicated that this activity occurs within the 
first 23 amino-acids of the fibrinogen molecule2l8• Thrombin is not 
only directly involved in the conversion of fibrinogen to fibrin, but 
also potentiates the activity of Factors VIII and V and converts Factor 
XIII to its active form (see later). In addition, thrombin can digest 
fibrin in vitro anci produce fibrin degradation products similar to 
plasmin-releaseipeptides~43 Arginyl-lysine bonds are of considerable 
importance in this reaction. 
The final stage in fibrin production is initiated by the enzymatic 
action of thrombin upon fibrinogen. Fibrinogen is a soluble plasma 
protein with a molecular weight of 340,000 composed of two monomeric 
units, each containing an AQ(,B pand ~ chain with molecular weights of 
63,000, 56,000 and 47,000 respectively11l (Fig. 2.6). These chains are 
joined by disulphide bridges323 , as are the two monomers, through pairs 
f 
of o(and?$' chains. Although usually described as a rod-shaped molecule, 
electron microscopical evidence suggests that the molecule is spherical 
" t f 24 m346 In add1"t1"on, although fibrino-or globular, with a d1ame er 0 n • 
gen is consiiered as a symmetrical molecule, there 
of heterogeneity within the molecule, particularly 
is accumulating evidence 
of thed' chain348• 
Figure 2.6 
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portion of the dimeric fibrinogen molecule (after 
Blomback and Blomback54). 
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Indeed, Mosher .nd Blunt 344 have suggested that there may be 36 different 
forms of bovine fibrinogen. 
Thrombin releases fibrinopeptides A and B from the A~and B p 
chains, thereby producing fibrin monomer (FM). Release of fibrino-
peptide A may be associated with a conformational change in the molecule, 
which not only facilitates the end to end alignment of the fibrin monomers, 
but makes the B peptide more accessible to thrombin activity. Side-to-
side association of the molecules occurs following the release of fibrino-
peptide B54. 
The conversion of chains of FM to fully cross-linked fibrin is 
achieved through the activity of Factor XIII which itself is activated 
by thrombin. Factor XIII is a transamidase enzyme which occurs in plasma 
and platelets. Plasma Factor XIII is composed of two A and two B subunits 
whereas platelet Factor XIII, which is of separate origin, only has two 
A subunits3l9 ,462. Recent evidence suggests that plasma Factor XIII may 
receive its subunit chain from platelet Factor XIII436. Thrombin acts on 
subunit A by limited hyirolysis to release a fragment, which is the active 
principle, fibrinoligase297 • In addition, thrombin-catalysed removal of 
fibrinopeptide A is responsible for the unmasking of the fibrinoligase 
reactive site on the FM molecule296 • Polymerieation of the FM by this 
means greatly enhances the elasticity of the clot and reduces its suscepti-
bility to digestion by plasminogen-urokinase298 , although this has recently 
been disputed (see Chapter 5). In addition, fibrinogen-thrombin inter-
actions are associated with an induction period during ~hich no fibrin 
polymerisation is detected. It has been suggested on the basis of 
evidence obtained from laser fluctuation spectrometer studies that this 
is the result of a reversible complex between fibrinogen and FM which 
acts as a buffer system, preventing the concentration of free F~ from 
reaching the level necessary to initiate polymerisation, before a 
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substantial fraction of the fibrinogen has been converted to fibrin64 • 
Thus fibrinogen may act as a natural anticoagulant by delaying clotting 
through complex formation with FM~ 
Cross-linked fibrin produced by Factor XIII results from the 
formation of E.-(~glutamyl)-lysiLe isopeptHe bonds between pairs of () 
chains to form ~-~dimers, ando(chains to give anQ(.polymer322• Thus, 
crosslinked fibrin can be identified on sodiumdodecyl sulphate (SDS) 
polyacrylamide gel electrophoresis by the disappearance of the~and 
~ chains of fibrinogen and the appearance of the ~dimer. 
ROLE OF CELLULAR EL~~S IN BLOOD COAGULATION 
l(uch of the evidence for the coagulat ion mechanisms outlined above 
has been derived from in vitro studies of cell-free plasma or serum. 
However, it is axiomatic that intravascular and extravascular blood 
clotting occur in the presence of large numbers of blood cells and that 
cellular behaviour considerably influences clot formation. Intra-
vascular thrombus formation has long been known to be associated with 
platelet activity439, and in recent years there has been an upsurge in 
interest concerning the thromboplastic activity of leukocytes and mono-
cytes364• It is therefQre important to define the role of such cells 
in coagulation mechanisms. 
PLATELETS 
Platelets occur as small anuclear cell figures in the circulation. 
They are disc-shaped ellipsoids, 3)U in diameter and l)U in thickness. 
They derive as split fragments from the cytoplasm of megakaryocytes, 
The which are large, multinucleated precursor cells in the bone marrow. 
platelet has been described as having three structural zones related to 
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function; the peripheral zone, involved in adhesion, the sol-gel 
zone, which acts as a cytoskeleton and is involved in contraction, and 
the organelle zone, which is responsible for secretion (see below)554. 
The peripheral zone comprises the plasma membrane with the extracellular 
glycocalyx or glycoprotein coat and the lining canalicular system that 
penetrates the platelet substance. The sol-gel zone lies immediately 
beneath the plasma membrane and contains microtubules and microfilaments 
which are intimately involved in the shape char~es that occur on aggreg-
ation553 • The organelle zone refers to the more central area of the 
platelet and contains mitochondria and granules. ?\ granules contain lyso-
somes, cationic proteins, elastase, permeability enhancing factor, chemo-
tactic factor, mitogenic factor, fibrinogen,pthromboglobulin, and dense 
granules contain ADP, ATP, serotonin and Ca2+ ions. 
The primary function of platelets is to participate in haemostasis 
where they undergo a characteristic series of changes on contact with 
exposed vascular basement membrane41l , and form a major component of the 
primary haemostatic plug. This platelet response has been shown to 
combine several features, namely, change in shape, increased adhesivness, 
release of platelet substances (secretion) and aggregation. 220 Holmsen 
has described this response as the basic platelet reaction (BPR) and has 
outlined, as a working hypothesis, three sequential steps in this 
process, i.e. induction, transmission and execution. Induction occurs 
when a platelet activating agent reacts with the cell membrane. Trans-
mission of the response occurs on release of an intracellular transmitter, 
possibly calcium ions, which stimulates an A.T.P.-requiring process 
(probably actomyosin contraction). The platelet at this stage may be 
conditioned to perform shape change (Stage 1), to adhere to other plate-
lets (Stage 2), or to release substances from its dense granules (Stage 3) 
or from itsoC.granules (Stage 4). The stage of conditioning which the 
The Basic Platelet React ion 
~)tPGG2~ 
Vasopressin 0 C0 ot.,- Granule Secretion 
Adrenaline 0 CD Oense Granule Secretion-
Thrombin -{~', + Transmitter--~) ~u~ 
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)tSerotonin --f~ ~AOP --f~ Shape Change 
10 
Irduction 
Figure 2.1 Stages of platelet release reaction (after Holmsen220). 
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platelet reaches during transmission is directly determined by the 
concentration of transmitter and ATP. Execution of the response 
depends on the occurrence of appropriate internal and external con-
ditions (Fig. 2.1). 
Many agents are known to induce platelet activation, including 
proteolytic enzymes, glycoproteins, particulate matter, bacteria and 
, 352 V1ruses • However, most studies of platelet activation have centred 
around a small number of well-known and physiologically important mole-
cules. These include thrombin, collagen, fatty acids, prostaglandins r 
and their precursors and derivatives, serotonin, adrenaline and nor-
adrenaline and ADP. A central role for ADP in platelet aggregation 
by all agents was suggested on the basis of in vitro experiments which 
showed that aggregation did not occur when ADP was removed from the 
medium201• However, it has recently been shown that ADP, although it 
does cause aggregation164 ,165 and is released during the platelet release 
t ' 226, t t' 1 fIt reac lon ,1S no essen 1a or p atele aggregation to occur since 
collagen, thrombin and the calcium ionophore A23,181 can cause aggreg-
ation in the absence of ADP. In addition, the in vitro release of ADP 
following platelet aggregation may be a laboratory artefact due to hypo-
calcemia320• There is, however, some dispute over this suggestion, 
most recently p~t forward by Huzoor-Akbar and Ardlie23l , who deny the 
effect of hypocalcemia and propose a central role for thrombin in all 
methods of platelet aggregation. 
More recently, attention has been focussed on the prostaglandins 
and their intermediates, as final mediators of the platelet aggregation 
331 response • It is known that, during platelet activation, arachidonic 
th 1 a membrane by phospholipase A2 and rapidly acid is released from e P asm 
converted into the unstable endoperoxides PGG2 and PGH2 (Fig. 2.8)199 by 
the enzyme cycle-oxygenase. These metabolites are potent activators of 
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platelet activity and in addition may be converted to Thromboxane A2 
(TXA2) which has a several fold increase in platelet aggregability. 
TXA2 is also released by platelet aggregation and although unstable in 
vitro, is stabilised in vivo by Plasma475 • Conversely, within the 
vascular endothelium, endoperoxides are converted into prostacyclin 
PGI2 , which is a potent inhibitor of platelet aggregation
336
, and this 
suggests that prostaglandins have a central role in the control of 
platelet activation, inhibiting aggregation where it is least desired, 
i.e. within normal vascular endothelium, and promoting aggregation where 
it is useful, e.g. within platelets in a haemostatic plug. Both TXA2 
and PGI2 are thought to influence platelet aggregation by varying the 
intracellular concentration of cyclic AMP, which is known to have a 
profound effect on platelet activation188 (Figure 2.8). 
However, it has been shown that thrombin and collagen may activate 
platelets directly in the absence of both ADP and prostaglandins70• In 
arachidonic acid deprived rats, collagen at high dosage was found to cause 
aggregation of platelets, even though prostaglandin.'f?ynthesis was negli-
gible. However, the capacity of platelets to react to threshold doses 
of collagen depended on the availability of endoperoxides. Thus, 
although PGG2 and PGH2 and TXA2 are produced in very small quantities in 
vivo and are extremely short-lived, they serve to amplify the response of 
the platelet to a given stimUlatory agent454• 
Thrombin and collagen are considered to be extremely potent platelet 
aggregating agents. Although they can act directly on platelets, little 
is known about the precise mechanism of action. The platelet cell membrane 
119 b t "t is also thought that a hydro-contains thrombin-specific receptors , u 1 
t " tIt lets391 Even less is known lytiC enzyme is required to ac lva epa e • 
concerning the mode of action of collagen. Early speculation concerning 
ptor complex between glucosyl-transferase on the platelet an enzyme-acce 
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membrane and the galactosyl-hydroxylysine side chains on the collagen 
mOlecule238 is now regarded as untenable since soluble collagen is un-
able to aggregate platelets. Platelet aggregation occurs only with 
fibrillar collagen30 ,350 • In addition, studies of the effect of 
genetically distinct collagen types on platelet aggregation (for 
recent review of collagen biochemistry, see reference 334) have shown 
that Type III collagen is the most potent platelet aggregating agent 228• 
This contrasts with previous work where Type I was considered to be the 
most active331 • Other workers have shown that Type I has equivalent 
activity to Type III33 , but Type IV collagen, of basement membranes, has 
been reported as the least active33l • Type III collagen forms thin 
fibrils and is most abundant in blood vessel walls, whereas Type I occurs 
as thick collagen fibrils 334 • Finally, the possibility that collagen 
may cause platelet aggregation via activation of platelet membrane-bound 
86 
complement has recently been postulated • Complement components Cl, 
C3 and C4 are known to be tightly bound to the platelet membrane543 , 
and complement consumption by collagen has been demonstrated497• In 
addition, platelets from complement-depleted dogs are unresponsive to 
86 
autologous collagen • 
The molecular events which occur in the platelet surface membrane 
on contact with an aggregating agent are unknown, but certain conditions 
are required. Ca2+ ions are essential and a layer of adsorbed surface 
127 ·b . . 518 It h Id lobe protein , usually f1 r1nogen, 1S necessary. s ou a s 
noted that Factor VIII-related antigen has been proposed as the important 
aisorbed plasma protein in platelet adhesive reactions, e.g. to vascular 
endothelium. A requirement for platelet surface glycoprotein (gl~ 
418 
cocalicin) has also been demonstrated • Not all proteins will promote 
adhesion; 
. 331 
human serum albumin, for instance, is ineffectlve • An 
b d Physioo-chemical mechanisms, has been interesting hypothesis, ase on 
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put forward to explain the differential adhesive qualities of platelets, 
313 
as opposed to red cells • In this report, it was shown that adsorbed 
protein will reduce platelet surface potential and thus promote adhesion. 
In addition, both ADP at a concentration of 70.5 pg/ml and Ca2+ ions also 
reduce cell surface potential. 
In addition to their role in haemostasis, platelets have significant 
intrinsic procoagulant activity. As stated above, plasma proteins are 
adsorbed to their surface membrane, and these include several coagulation 
factors such as prothrombin, fibrinogen and Factors VII, IX, X, V and 
VIII2l2. Fibrinogen is also contained within the eranules and is made 
available during the release reaction. Although the amount of fibrinogen 
released is small in relation to plasma fibrinogen, it may provide a high 
concentration between platelets in an aegregate552. Platelet factors 3 
(PF 3) and 4 (PF 4) are also released during the BPR. PF 3 is phospho-
lipid and participates in several stages of the intrinsic pathway of 
coagulation (Fig. 2.2), although it is considerably less active than similar 
phospholipid obtained from brain tissue540 • PF 4 has heparin-neutralising 
t " "t 113 d h "t 1 h "11k ac lVl y ,an may ave a role in overcomlng any na ura eparln- e 
inhibitors within the system. Platelets can also contribute to the 
contact phase of clotting538 , by activating Factor XI during collagen-
induced platelet aggregation538 , and by catalysing Factor Xa activation539• 
Finally, platelets contain Factor XIII, which is distinct from plasma 
Factor XIII319 and assists in the polymerisation of fibrin. It is 
therefore apparent that wherever pla~elets are activated in the presence 
of blood coagulation factors, clotting will take place. 
LEUKOCYTES 
studies of the generalised Schwartzman reaction (GSR) have suggested 
that leukocytes may be associated with clotting activity. The GSR is an 
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experimentally-indueed response to two appropriately spaced sublethal 
injections of endotoxin, in which widespread intravascular coagulation 
occursI86 ,503. Since the aSR can be prevented in leucopenic rabbitsl44 , 
leukocytes have been implicated as causative agents in aSH-associated 
clotting mechanisms364• In addition, in vitro studies have shown that 
purified leukocytes obtained from rabbit peritoneal exudates or from 
whole blood by differential sedimentation, develop significant pro-
coagulant activity (PCA) when stimulated byendotoxin360 • UnstimUlated 
leukocytes have little or no procoagulant activity1967. The activity 
generated in leukocytes by endotoxin has similar properties to tissue 
factor activity, since it fails to occur in Factor VII-deficient Plasma291 • 
In addition, delipidation of leukocyte factor removes its clotting ability, 
while relipidation restores it36l • Human leukocytes are less responsive 
to endotoxin than rabbit cells, and in aJdition, human leukocytes require 
the presence of serum173 • Lymphocytes and macrophages can also generate 
clotting activity and indeed macrophages appear severalfold more active 
than polymorphonuclear leukocytes in this respect173. The activity 
appears to be contained within a subcellular microsomal fraction and is 
tightly bound to the organelle membrane361• 
Other agents that have been reported to induce procoagulant activity 
in leukocytes include haemagglutinins432 , artificial membranes364 , and 
, tIt' f d' It 257,450 simple adhes10n 0 p as 1C sur aces urlng cu ure • However, it 
is uncertain whether endotoxin contamination of these substrates may have 
induced these responses, since only nanogram quantities are required for 
t ' 363 leukocyte stimula lon • Procoagulant activity in leukocytes can also 
362 t' d be stimulated by platelets, or their granules during aggrega lon an 
this further emphasises the profound complexity of the inter-relationships 
between coagulation mechanisms and blood cell behaviour. The recent 
observation that leukocytes generate thromboplastic activity on adhesion 
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to vein walls may have some significance in relation to the pathogenesis 
of deep vein thrombosis290 • 
MONOCYTES 
Monocytes have been shown to generate procoagulant activity (PCA) 
after stimulation by endotoxins438 ,2l3. This activity has been likened 
t t · f t t·· t 518. . t F t VIr ddt It h o ~ssue ac or ac ~v~ y s~nce ~ was 'ac or epen en • as 
also been shown, however, that simple adhesion of monocytes to foreign 
surfaces such as glass5l8 or latex467 will lead to cellular PCA. Not 
all surfaces will activate monocytes in this way; monocytes adherent 
to a monolayer of cultured endothelial cells produce minimal PCA5l8• 
Fibrin microclots produced on glass slides by single monocytes have a 
peculiar stellate appearance which is formed by fibrin crystals radiating 
out from a central focus occupied by the cel1461• A clinical analogue of 
this has been suggested by stellate fibrin formations in the bone marrow 
of patients with myelofibrosis359• 
A recent report has described the release of PCA from purified 
cultured monocytes stimulated by guinea pig complement factor C3b409• 
Again, the PCA was similar to tissue thromboplastin in that it required 
Factor VIr and was rapidly inactivated by monospecific antiserum against 
tissue thromboplastin. Thromboplastin production by these cells was 
closely related to protein synthesis408; This link between coagulation, 
blood cell behaviour and complement activation further exemplifies the 
diverse integration between these various biological systems. 
stuiies of these inter-relationships should prove most fruitful. 
NATURAL INHIBITORS OF COAGULATION 
Future 
No discussion of coagulation mechanisms is complete without 
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reference to inhibitors of coagulation. Several naturally-occurring 
inhibitors have been identified, the earliest discovered probably being 
heparin325 • Others inc1uie the antithrombins,~2 macrog1obu1ins, ~1 
antitrypsin and C1 esterase, all of which are proteins or their 
derivatives from plasma. 
HEPARIN 
Heparins are classified within a group of long chain amino-sugars 
known as glycosaminoglycans (GAG) which occur ubiquitously throughout 
mammalian and non-mammalian tissues. Heparins differ from other GAGs 
in that their intersaccharide linkages are exclusively 1-4, that they 
contain both D-glucuronic and L-iduronic acids, that the su1phation of 
these suears is specific for heparin, and that the glycosamine residue 
is exclusively D-glucosamine36 • Anticoagulant properties, at least in 
vitro, are associated only with heparin among the GAGs and are related 
to its highly specific structural characteristics222 • In plasma heparin 
is completely bound to proteins by direct electrostatic interaction or by 
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other noncovalent mechanisms • Heparin acts by potentiating the 
action of antithrombin III l12 ,143(see below). Heparin also reacts 
directly with thrombin, which may make it more accessible to antithrombin 
Several cell types, notably basophil leukocytes and mast cells, 
contain heparin within their granules and such cells probably act as 
467 
"anticlot" cells in contrast to the "clot" cells Buch as monocytes • 
There is also considerable heterogeneity among the different tissue 
. 36 d . pl·te of technical difficulties with standardisation heparlns an, In s 
. t..t 252 
th appears t o be significant variations ln ac lVl y • of heparin assays, ere 
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ANTITHROMBINS 
Antithrombins, as presently described, are poorly characterised; 
of six known antithrombins, only three have been shown to function 
physiologically, i.e. antithrombins I,ll and III. Antithrombin I is 
associated with the reversible removal of thrombin from solution by 
its adsorption onto fibrin254 , but is probably not of great physio-
logical importance. Antithrombin II is also known as plasma heparin 
cofactor411 but it now appears that its activity, if not its structure 
is identical to that of antithrombin III, since the addition of a 
specific antibody to antithrombin III removes all the heparin cofactor 
activity from plasmal36 • Antithrombin III is a ~ globulin with a 
molecular weieht of 65,000 and its mode of action is to bind irreversibly 
to thrombin, thereby inactivating both components573 • Antithrombin III 
also competitively inhibits activated Factor X, but less rapidly than 
thrombin-inhibitionl • It appears that activated Factor Xa is protected 
from antithrombin III activity during prothrombin conversion by its 
continued adsorption to phospholiPid234 • Other inhibitory effects of 
antithrombin III have been reported in relation to Factor IXa, Xla and 
plasminll2 , but these have not been confirmed. 
also inactivate Factor VIIIBl. 
0(2 V~CROGLOBULIN 
Antithrombin III may 
0<.. macroglobulin is a plasma protein, composed of two monomers, 
2 
each with a molecular weight of 380,000. It inhibits several protein-
ases including thrombin, plasmin and kallikrein35• Inhibition of 
thrombin is time-dependent and is not enhanced by heparin. Its mode 
of action is not precisely known, but it appears that an active fragment 
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(molecular weight 85,000) is split from the subunit chains of the 
molecule202 • 
c< 1 ANTITRYPSIN 
0(1 antitrypsin is a glycoprotein with molecular weight about 
50,000 and has broad specificity. ~ antitrypsin has been reported 
to have about 25% of plasma antithrombin activity, but this has been 
d ' t d286 l.SpU e • Its role in preventing clotting is therefore unclear, 
although it has been shown to be a powerful inhibitor of Factor XIa209 • 
0<1 antitrypsin and~ macroglobulin also occur in platelets, although 
in relatively smaller concentration when compared to platelet-associated 
fibrinogen or Factor VIII antigen. It is possible that these inhibitors 
modulate protease-mediated events during the formation of haemostatic 
plugs and thrombi354 • 
CI INACTIVATOR 
CI inactivator is a glycoprotein of molecular weight 105,000 
which inhibits CI esterase, Factor XlIa and Xla, kallikrein and plasmino-
. 204 318 gen actl.vator ' • Thus it may function in the early phases of in-
trinsic and extrinsic coagulation. 
An as yet incompletely identified inhibitor of Factor XIa with a 
molecular weight of approximately 65,000 has also been reported, but sO 
far appears to be specific for Factor XIa367• 
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SUlf~RY 
Current concepts of blood coagulation mechanisms have expanded 
considerably as a result of recent advances in the identification and 
isolation of newer clotting factors. It is now recognised that the 
various clotting systems, which are reviewed in this chapter, are 
closely linked and that activation of one system may trigger coagulant 
activity in another system. It is therefore likely that blood clotting 
in the tissues occurs by more than one mechanism, although extrinsic 
system coagulation via tissue thromboplastin is regarded as the pre-
dominant one. In this thesis, an attempt is made to identify the 
mechanisms of blood clotting in the vitreous of the eye. Each system 
is not investigated in depth, since this is outside the scope of the 
thesis, but by studying the clotting activity of plasma in the presence 
of vitreous and its components, it has been possible to formulate a 
hypothesis on the most probable mode of intravitreal blood clotting. 
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MATERIALS AND METHODS USED FOR STUDY OF THE IN VITRO 
INTERACTION BETWEEN BLOOD AND VITREOUS 
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INTRODUCTION 
This chapter comprises three sections. The first section con-
tains details of the methods used to extract vitreous humour from 
enucleated eyes. In the second section, techniques for the study 
of the effects of vitreous on coagulation mechanism are described. 
The third sectio~ deals with the role of platelets in clotting mechanisms 
within the vitreous. An experimental system was devised to determine 
whether significant fibrin formation occurred within intact vitreous 
gels solely as a result of platelet activation. The materials and 
methods used for these experiments are described here. 
PROCEDURE FOR EXTRACTING VITREOUS 
It has been observed that the vitreous humour of most species 
exists as a gel un1er physiological conditions (Chapter 1). However, 
a variable proportion of normal adult vitreous consists of a viscous 
fluid, particularly its central part. The ratio of gel to fluid com-
partments varies considerably according to the species and the age of 
the specimen23 • The vitreous of animals such as cattle and sheep is 
almost entirely gel, while that of the owl monkey is completely fluid 
(Chapter 1). Human and rabbit vitreous occupy an intermediate position. 
Consequently, methods for obtaining samples of vitreous have been adapted 
to its physical state. Where it is predominantly fluid, samples can be 
obtained by simple aspiration. When the vitreous is predominantly gel-
like, special 
of these have 
techniques for its dissection have to be used, and a number 
"b d20 ,28,29,l98,49l been descrl e • 
A method commonly employed to circumvent these problems is to 
dissect the vitreous in the frozen state26 ,42,l25,158,l95. Such methods 
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have been used to study topographical variations in its components25 and 
to ensure maximum yield of tissue with minimal contamination from surround-
ing ocular structures. It should be noted, however, that freezing tech-
niques have been shown to produce artefactual variations in the distri-
bution of soluble macromolecules within the vitreous491 and should 
therefore not be used for topographical studies. 
In the present investigation, vitreous samples were obtained by 
three methods:-
(a) an aspiration technique 
(b) a dissection technique 
(c) a freezing technique 
Each method was applied to different studies according to the 
requirements of the experiment. 
~~TERIALS 
Vitreous samples from a variety of species were used in the pre-
liminary experiments described in this thesis. This was considered 
necessary in view of the considerable species differences in the'concen-
tration of vitreous tissue components2l • It was found, however, that 
species differences in the thromboplastic and fibrinolytic properties 
of the vitreous were not marked. Consequently, bovine vitreous was 
used for a majority of the in vitro studies, while rabbit eyes were 
selected as the most suitable for in vivo studies. 
Rabbit an:i dog eyes were obtained from animals which had been used 
for experiments unrelated to the present studies. In none of these 
experiments were anticoagulants used. The eyes were normal by gross 
examination. Cattle and sheep eyes were obtained from the slaughter-
house. All animal eyes were obtained immediately after death and 
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transported on ice to the laboratory within one hour. Human eyes 
were obtained from donor cadavers within 12 hours of death. Eyes 
from subjects who diei from haemorrhagic or thrombotic diseases were 
rejected. 
V£I'HODS 
Aspiration technique 
This method was applied to human ani dog eyes. The eyes were 
cleaned and all extraocular tissues removed. Samples of fluid vitreous 
were taken by aspiration through a 19 gauge needle inserted through the 
sclera, according to the method of Walker and Patrick533• In some cases, 
a 25 square millimetre window of sclera, choroid and retina was removed 
in layers and the vitreous aspirated by a modified "open sky" technique. 
This procedure wasmopted to ensure absence of contamination from other 
ocular tissues. Using this technique, a maximum of 60% of the total vitreous 
volume was obtained. 
Dissection technique 
This procedure was used for cattle and sheep eyes only, since these 
eyes have few vitreo-retinal adhesions516• The eyes were placed, cornea 
upwards, in eyecupS and a 5mm incision was made in the ora serrata with 
a razor blade. Curved dental forceps and blunt scissors were used to 
extend the incision to 3600 and the anterior segment, lens and vitreous 
were removed as one piece from the tissues of the posterior segment. With 
t ' I 't' d ep l'ncisions were made with the eye suspended in the ver lca POSl lon, e 
clean scissors into the vitreous gel, tangential to the surface of the 
lens. Pieces of gel vitreous were allowed to drop into a glass beaker, 
and were gently homogenised by aspiration through a 20 ml syringe. Vitreous 
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gels from individual sheep eyes were stored as separate samples, but 
those from cattle eyes were pooled. Contamination from other ocular 
structures was minimal. More than 90% of the vitreous was recovered 
by this techni;ue. 
Freezing technique 
This procedure was applied mainly to rabbit and human eyes. The 
eyes were cleaned, and the aqueous humour aspirated by puncturing the 
eye at the corneo-scleral limbus. a Aqueous samples were stored at -20 C. 
The eyes ~\ere then placed in polythene bags ani immersed in a solution of 
CO2 snow ("dry ice") in acetone (-40 to _60
oC) for sixty seconds. The 
outer coats of the eye were dissected in small pieces with a Thiersch 
skin-graft blade. As the globe gradually thawed from the periphery 
to the centre during this procedure, the frozen vitreous could be 
"shelled out" of the eye in the later stages as a single ice ball. In 
the same way, the lens could be shelled out of the "patellar fossa" of the 
frozen vitreous. The entire vitreous was recovered from the eye by this 
method and was free of contamination by other structures. 
EFFECT OF VITREOUS ON BLOOD COAGULATION ~iliCHANISMS 
Experiments were designed to test the effect of vitreous on coagu-
lation mechanisms. In general standard clotting tests, or modifications 
thereof, were used and any changes induced in the system by the presence of 
vitreous were observed. 
MATERIALS 
Vitreous samples from human, dog, sheep,rabbit and cattle eyes 
were obtained by one or more of the above methods in each case. 
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Whole blood was obtained from healthy human volunteers with 
0.13M sodium citrate or 1% EDTA (di-sodium salt) as the anticoagulant. 
Platelet-poor plasma (ppp) was prepared by centrifugation of the blood 
at 3000 r.p.m. for 20 minutes. Platelet-rich plasma (PRP) was pre-
pared by centrifueation of the blood at 40000 for five minutes. The 
plasma samples were used immediately after preparation or stored at 
_20oC. Non-activated platelet-poor plasma was obtained from whole 
blood by clean venepuncture. o All procedures were performed at 0-4 c. 
The first two mls of blood was discarded and the remainder was collected 
directly through a cannula into siliconised plastic tubes. The samples 
were immediately centrifuged at 11,000 r.p.m. for 30 minutes, and the 
plasma withdrawn through siliconised Pasteur pipettes. Non-activated 
o plasma was stored at -80 C unless used immediately. Serum was obtained 
from clotted human blood samples after centrifugation at 3000 r.p.m. for 
20 minutes. 
Calcium chloride was dissolved in distilled water to a final con-
centration of 0.04 or 0.025M. Calcium phosphate was used. as a 0.5 per 
cent sol ut ion. 
Phosphate-buffered saline contained 0.2M Sodium phosphate in 0.15M 
sodium chloride, pH 7.4. 
Tris-buffered saline contained 0.05M tris (hydroxymethyl) amino-
methane-HCl and O.OlM NaCl, pH 7.4. 
Trisodium citrate was used as a 3.9 per cent solution in distilled 
water. 
Tissue thromboplastin was obtained from Hyland Laboratories, 
California. 
Cephotest was supplied by Nyegaard and Co. A/S, Oslo, Norway. 
Coagulation factor-deficient substrate plasmas were obtained from 
Dade Diagnostics Inc., Miami. Coagulation factor concentrates containing 
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Factors II, IX and X were prepared according to the method of Middleton 
et a1353 from Factor VIII-deficient plasma. The samples (Defix) were 
supplied by the Protein Fractionation Centre, Royal Infirmary, Edin-
burgh. A similar protein concentrate, Factor VIII~Inhibitor Bypassing 
Activity (FEIBA), which contained Factors II, IX, X and VII, plus other 
unidentified activated components, was obtained from Immuno AG, Vienna, 
Austria. 
Ecarin was obtained from Sigma Ltd., London. 
Fibrinogen (human) was obtained from Kabi Pharmaceuticals Ltd., 
Stockholm, Sweden. It contained 90% clottable protein. Kabi also 
supplied the chromogenic peptide substrates S2302 (H-D-Pro-Phe-Arg-pNa) 
and S2222 (Bze-Ile-Glu-Cly-Arg-pNa). S2302 was prepared as a 2mM stock 
solution in buffer (Tris-HCl 50 mM, NaCl l2rrM, pH 1.8) while S2222 was 
prepared at the same concentration in buffer (Tris-HCl 50mM, NaCl 0.15M, 
pH 7.4). Aliquots (0.5 ml) were stored at -Bo°c. 
Platelet substitute (Platelin) and Russell's viper venom-cephalin 
were obtained from Diagen Labs., U.K. 
Thrombin (bovine) was obtained from Parke Davis, Detroit, 
Michigan. 
Arvin was supplied by Berk Pharmaceuticals Ltd., Shalford, 
Surrey. 
Hyaluronic acid was obtained as the sodium salt, from Miles 
Laboratory, London. It was prepared by salt precipitation from human 
umbilical cords and contained <0.3%, protein. Its intrinsic viscosity 
( ~, . d b t 59 and 62, corresponding to a molecular weight of 'Il var1e e ween 
(4-5 x 105)92• 
Dialysis casings were obtained from Visking and Co., Chicago, 
Illinois, and prepared by boiling in glass distilled water. 
Collagen suspensions were prepared from equine tendon collagen 
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and supplied by Hormon-Chemie, Munich. 
Bentonite was a gift from Dr. J.-M. Lavergne, Paris. 
Diethyl-amino ethane A50 (DEAE)-sephadex was obtained from 
Pharmacia, Sweden. 
METHODS 
The effects of vitreous and its components on blood coagulation 
mechanisms were studied in glass or plastic tubes of 8 mm internal 
diameter, unless otherwise stated. Centrifugations were performei in 
an MSE-6L centrifuge at OOC to 4°C. Ultracentrifugations were per-
formed in a Beckman L5-50 ultracentrifuge at 00 to 4°C. 
Preparation of vitreous samples 
Preliminary studies of vitreous thromboplastic activity were 
performed using untreated samples of fluid vitreous. Further studies 
were performed using collagen-free vitreous prepared by ultracentrifug-
o 
ation of the vitreous at 65,000G for 1 hour at 4 C. The supernatant, 
which contained hyaluronic acid ani soluble macromolecules, was dialysed 
for 24 hours against 100 volumes of Tris-buffered saline, pH 7.4, and 
stored at _BoaC. The pellet, which comprised mainly vitreous collagen, 
was prepared as a collagen suspension in Tris-buffered saline, pH 7.4, 
by sonication in an MSE ultrasonic disintegrator (PC-495) at medium power, 
amplitude 3, for 15-45 minutes. Bovine an,i rabbit vitreous samples only 
were used for collagen suspensions. 
Recalcification time of plasma in presence of vitreous 
Thromboplastic activity of the vitreous was studied by recording 
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the recalcification time of fresh platelet-poor plasma in the presence 
of vitreous or its separated components. Various modifications of the 
basic system were studied usine substrate deficient plasma and Tris-
saline controls (see Chapter 4). Recalcification times were performed 
o in replicates of at least six in a 31 C water bath. The effects of 
vitreous and its components on the recalcification of non-activated 
plasma were also studied. 
Assay of Factor XII activity in vitreous via prekallikrein activation 
This assay was modified from the method described by Mattler and 
316 Bang for the detection of prekallikrein in samples of plasma using 
chromogenic substrate S2302. The assay is based on the conversion of 
prekallikrein to kallikrein in the presence of activated Factor XII and 
high molecular weight kininogen. Kallikrein then releases p-nitroaniline 
(pNa) from the chromogeniq substrate S2302 as follows:-
1. 
2. 
Contact 
Factor XII • ~ Factor XIIa 
Prekallikrein 
Factor XIIa 
. ..-
t 
kallikrein 
High molecular weight kininogen 
kallikrein 
3. H-D-Pro-Phe-Arg-pNa + H20 • ~ H-D-Pro-Phe-Arg-OH + pNa 
The test system used in the present study comprised the following:-
0.1 ml buffer (50 mM Tris HCl: 12mM NaCl, pH 7.8) 
0.1 ml Factor XII deficient plasma 
0.1 ml sample (vitreous) 
0.1 ml chromogenic substrate (S2302) from stock solution 
0.1 ml cephotest 
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In this system assay, prekallikrein and high molecular weight 
kininogen were provided by the Factor XII-deficient plasma, and therefore 
any release of p-nitro-aniline (pNa) would occur as a result of contact 
activation of Factor XII which was present in the sample. Contact 
activation in the test system was achieved by cephotest. Negative 
controls were included by omitting the cephotest. The release of 
pNa was measured spectrophotometrically at optical density A405 in 
plastic cuvettes at 31°C. The time course of pNa release was plotted. 
Factor XII activity in vitreous was compared with that of normal plasma. 
Assay of Factor Xa activity in vitreous 
Factor Xa activity can be measured in coagulation factor 
concentrates by a similar method using chromogenic substrate S2222. 
The method has been described by Pepper et al (1911) and is used 
for screening Factor IX concentrates for thrombogenic activity. 
The principle is based on the release of pNa from S2222 by activated 
Factor X:-
1. Bze-ILE-Clu-Gly-Arg-pNa + H20 
Factor xa_! 
Bze-ILE-Clu-Gly-Arg-OH + pNa 
In the present system, the assay was modified to detect any Factor 
Xa or Factor Xa-enhancing activity in vitreous samples. The test system 
was as follows:- 0.1 ml Defix (coagulation factor concentrate con-
taining Factors II, IX and X) 
0.1 ml sample (vitreous) 
0.1 ml platelet substitute 
0.5 ml buffer (0.5M,Tris HCl, 0.15M NaCl) 
0.2 ml chromogenic substrate (S2222) 
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The samples were incubated for five minutes at 31°C and the 
A405 was read at two minute intervals to detect any intrinsic Factor 
Xa activity. A volume (0.05 ml) of 0.04M CaC12 was then added to the 
samples and A405 read as before. Any alteration in the generation of 
Factor Xa in the samples was detected by a shift in the time-course 
curve of pNa release. 
Assay of Factor VII-enhancing activity in the vitreous 
An identical system was used to detect Factor VII activity in the 
vitreous. However, in this case the coagulation factor concentrate 
(FEIBA) contained ~actors II, IX, X and VII, plus other unidentified 
activated components. Thus, vitreous was tested for its ability to 
enhance or diminish Factor VII activity within the system. 
Assay of prothrombin-converting activity in the vitreous 
Prothrombin-convertine activity in the vitreous was assayed using 
the following test system; O~l ml purified prothrombin (20% normal 
plasma activity), 0.1 ml Factor V (25~ normal plasma activity), 0.1 ml 
human fibrinogen (2.4 mg/ml) and 0.1 ml platelet substitute were mixed 
with 0.1 ml dialysed bovine vitreous or Tris-buffered saline, pH 1.4. 
A volume (0.1 ml) of 0.04M CaC12 was added to the mixture and the 
clottine time recorded. Ecarin at various concentrations was used as 
a positive control in a system which contained 0.1 ml ecarin, 0.1 ml 
prothrombin and 0.1 ml fibrinogen. It has previously been shown that 
t oot 264 ecarin has direct prothrombinase ac lVl y • 
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Preparation of prothrombin 
Prothrombin was prepared from human blood by the method currently 
used by Dr. J.-M. Lavergne (personal communication), which is based on 
the method described by Weilland and Soulier547• 300 mls of plasma 
were obtained in 1% EDTA and added to 54 mls of 0.6 bentonite slurry 
(35 giL, prepared 24 hours previously and kept at 4°C). The mixture 
was agitated for 15 minutes at OoC, and centrifuged at 3000 r.p.m. for 
o 25 minutes at 4 c. The procedure was repeated several times using 
decreasine concentrations of bentonite until all Factor X activity 
(less than 0.01~) was removed. 300 mls of bentonite adsorbed plasma 
was then further adsorbed with 0.5% calcium phosphate, an.d the mixture 
agitated at 3000 r.p.m. for 25 minutes at 4°C. The supernatant was 
discarded and the calcium phosphate washed twice in normal saline, 
using a volume of fluid equivalent to the volume of the discarded 
plasma. Prothrombin was then eluted from the calcium phosphate by 
agitation in a 1 in 20 volume of trisodium citrate for 15 minutes. After 
centrifugation at 3000 r.p.m. for 25 minutes, the supernatant was removed 
anri the elution procedure repeated with a 1 in 40 volume of trisodium 
ci trate. 'l'he supernatants from both elutions were recombined and 
assayed for Factor II and X (see below). The citrate elutions were 
dialysed against 0.2M sodium phosphate buffer in O.15M sodium chloride, 
o pH 7.4, at 4 c. l'he samples were applied to a 2.6 x 17 crn DEAE-sephadex 
A50 column ani eluted in a NaCl gradiant, O.l5M-O.7M in starting buffer. 
Fractions containing prothrombin activity were pooled and tested for 
homogeneity by electrophoresis on 7.5~ polyacrylamide gels containing 
soU urn dodecyl sulphate (see Chapt er 6). Homogeneity was confirmed by 
the presence of a sine1e band. 
The activity of the prothrombin was assayed by comparing the effect 
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of prothrombin, diluted 1 in 20, on the recalcification time of Factor 
II deficient plasma in the presence of tissue thromboplastin, with the 
effect of normal plasma at the same dilution. Factor X activity was 
similarly assayed using Factor X deficient plasma, in the presence of 
Russell's viper venom and platelet substitute. 
Preparation of Facto~ V 
Crude Factor V was prepared from human blood by the method of 
Breckenridge and Ratnoff65 • Human plasma was obtained in 1% EDTA, 
adsorbed three times with 10 mg calcium phosphate per ml of plasma and 
centrifuged at 2100G for 10 minutes after each adsorption. The super-
natant plasma was then fractionated at 4°C with a neutral solution of 
saturated anrnonium sulphate by dropwise addition of the ammonium 
sulphate to the plasma until the desired concentration was reached. 
After incubation for fifteen minutes at 40oC, the mixture was centri-
fuged at 20000 for 10 minutes. The protein fraction which was soluble 
at 25'lf, saturation but insoluble at 50% saturation was dissolved in a 
volume of distilled water equal to 1/20 of the original plasma volume. 
It was then dialysed against running tap water for 20 minutes until 
clear, and then against a O.lM soHum acetate buffer containing O.OlM 
o 
calcium chloride, pH 5.4, for 24 hours at 4 c. The precipitate then 
o 
formed was recovered by centrifugation and stored at -SO c. Factor V 
activity in the sample was assayed by the recalcification time of 
Factor V deficient substrate plasma in the presence of tissue thrombo-
plas"\in. Prothrombin activity was also tested on Factor II deficient 
plasma as above, and was found to be minimal. 
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CLOTTING S'rUDIES IN THE PRESENCE 01" VITREOUS GEL: 
THE ROLE OF PLATELETS 
The experiments described in this section were designed to 
evaluate the role of collagen, which is the gel-forming component 
of the vitreous2l , in generating procoagulant activity via the 
activation of platelets. 
N';ATE'RIALS 
These are described above. Other materials included sodium 
dodecyl sulphate" mercaptoethanol and crystalline urea, all supplied by 
British Drug Houses, Poole, U.K. 
lfJZTHODS 
Platelet aggregation 
The aggregation of human platelets by vitreous collagen was studied 
by the method of Born and Cross59 , using a Bryston Platelet aggregometer 
(Brown Ltd., Leicester, U.K.). 0.1 ml platelet-rich plasma was incubated 
with samples of vitreous collagen suspension, equine tendon collagen or 
saline at 37°C, and the aggregation of the platelets recorded on a Bryans 
21,000 chart recorder. 
Fibrin formation in platelet aggregates within vitreous gels 
The following experiment was devised to determine whether fibrin 
formation could occur in vitreous gel solely as a result of platelet 
activation. 
Fresh bovine vitreous was dissected from cattle eyes and pieces of 
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intact gel were placed in 20 ml glass universal containers or 15 ml 
transparent ultracentrifuge tubes. Fresh citrated platelet-rich 
plasma (0.5 ml) was slowly injected into the centre of the gel and 
clot formation assessed visually. The samples were allowed to stand 
for 30 minutes at room temperature. The presence of fibrin in the 
samples was sought using histochemical techniques and polyacrylamide 
gel electrophoresis in sodium dodecyl sUlphate (SDS). 
Histochemical technique 
Samples of vitreous gel with platelet-rich plasma were fixed for 
24-48 hours in formalin. To avoid disrupting the gel, the fixative 
was gently layered onto the surface of the vitreous in the universal 
glass containers. The samples were passed through graded alcohols, 
and conventional methods of wax embedding and staining with Martius 
Scarlet Blue (MSB) for fibrin were used (see Chapter 11). 
S.D.S. polyacrylamide gel electrophoresis 
Samples of vitreous gel with platelet-rich plasma in ultracentri-
o fuge tubes were spun at 65,000G for one hour at 0-4 c. The pellets were 
washed for 24 hours with 0.85% saline and dissolved in 1 ml of 8M urea. 
To each sample, 0.1 ml of a ten per cent solution of sodium dodecyl 
sulphate plus the same volume of ten per cent ~-mercaptoethanol were 
added. 
o The samples were incubated for 24-48 hours at 37 C and run on 
7.5% polyacrylamide gels. The preparation of polyacrylamide gels used 
for fibrin analysis is described in Chapter 6. 
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CHAPl'ER 4 
STUDIES ON THE MECHANISM OF BLOOD CLOTTING 
IN THE VITREOUS 
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INTRODUCTION 
In the review of blood coagulation outlined in Chapter 2, several 
mechanisms are described whereby clotting of whole blood m~ be initiated. 
These include the intrinsic coagulation mechanism which utilises humoral 
plasma factors, the extrinsic coagulation mechanism in which tissue thrombo-
plastin is required, and cellular mechanisms which involve activation of 
platelet or leukocyte procoagulant activity. 
Clotting in the tissues occurs by means of the extrinsic system, 
and is dependent on the release of thromboplastic activity from injured 
tissues. The level of thromboplastic activity varies with the tissue, 
and is particularly high in lung, brain and placenta556 , 551. The 
vitreous represents an unusual connective tissue in many respects (see 
Chapter 1), but clinical and experimental studies indicate that rapid 
clotting occurs after bleeding into the vitreous gel (for review, see 
reference 43). The precise mechanism of intravitreal blood clotting 
is less clear. Although early studies suggested that the vitreous had 
significant procoagulant activity413, it was later shown that tissue 
thromboplastic activity of the vitreous was minima1382 , 421. Regnault 
and Larrieu42l speculated on the unique nature of vitreous coagulant 
activity which, in their studies, was similar to activated Factor X, 
thereby resembling the venom of the Tiger snake (Notechis scutatus 
scutatus) • 
A common feature of these studies was the use of crude vitreous 
preparations where little attempt was made to control such factors as 
pH and ionic composition. In addition, contamination from other ocular 
. t·· t 582 
tissues such as the retina, which is high in thromboplastlc ac lVl y , 
413 
could not be excluded • 
More recent experiments on coagulation mechanisms in the vitreous 
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have suggested that clotting of whole blood is initiated by platelet-
collagen aggregation which indirectly triggers the intrinsic coagulation 
mechanl'sml06 ,490• H lth h 't 11 h t h owever, a oug Vl reous co agen was sown 0 ave 
considerable platelet aggregating activity, no direct evidence for fibrin 
formation in the vitreous by this means was documented. 
The present studies were therefore undertaken to determine which, 
if any, of these mechanisms was relevant to the process of blood coagul-
ation in the vitreous gel. 
MATERIALS AND METHODS 
These have been outlined in detail in Chapter 3. 
PLASMA S~PLES 
Samples of human platelet-rich plasma, platelet-poor plasma and 
non-activated platelet-poor plasma were prepared as described in Chapter 
3. 
VI'I'REOUS SA!r.PLES 
Human, bovine, dog and rabbit samples were used. The human and 
dog samples were obtained by the aspiration technique, the bovine samples 
by the dissection technique, and the rabbit samples by the freezing tech-
nique. Human and dog samples were used undialysed, but corrected for 
H (1 2 1 4) Bovl'ne samples were used for the maJ'ority of the coagul-p • -. • 
ation studies. After the removal of the collagen by ultracentrifugation 
(see Chapter 3), the supernatant vitreous was dialysed against 100 volumes 
of Tris-saline buffer for 24 hours at 4°C and stored at -SOoC. The 
pellets recovered after ultracentrifugation of rabbit and bovine vitreous 
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were prepared as collagen suspensions in Tris-buffered saline by 
sonication. fhe collagen concentration of rabbit vitreous is 
approximately twice that of bovine vitreous21 ) while the total 
yield of vitreous gel from the bovine eye was four-fold that from 
the rabbit. A~propriate volume adjustments for the final suspension in 
buffer were therefore made to give comparable results. 
COAGULATION STUDIES 
Recalcification Times of Plasma in presence of Vitreous 
These were performed in glass or plastic tubes as described. The 
recalcification times of normal human plasma and Factor XII, X, VII and 
II deficient plasmas, in the presence of vitreous or Tris-buffered saline 
were compared. The standard assay contained 0.1 ml plasma, 0.1 ml 
vitreous or Tris-saline and 0.1 ml 0.04M CaC12. The clock was started 
on the addition of the calcium, and the tubes were gently agitated in a 
waterbath at 37°C until clotting occurred. Each test was performed in 
a minimum of six replicate tubes. The effects of cOllagen-free dialysed 
bovine vitreous, bovine vitreous collagen suspension, and hyaluronic acid 
on the recalcification time of non-activated human plasma were also tested. 
The system contained 0.1 ml plasma, 0.1 ml platelet substitute, 0.1 ml 
buffer or test solution, and 0.1 ml 0.04M CaC12. 
COAGULATION FACTOR ASSAYS 
Assays of Factor XII activity, Factor Xa activity, Factor VII-
enhancing activity and prothrombin-convert in activity were performed 
on samples of dialysed bovine vitreous as described in Chapter 3. 
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CLOTTING STUDIES IN T}ffi PRESENCE OF VITREOUS GEL: ROLE OF PLATELETS 
Platelet aggregation 
Platelet aggregation studies were performed in a Bryston platelet 
aggregometer as described in Chapter 3 using human platelet-rich plasma 
and rabbit or bovine vitreous collagen suspensions. Equine tail-tendon 
collagen suspension was used as a positive control. 
Fibrin formation in platelet aggregates within vitreous gels 
Experiments were devised to detect fibrin by histochemical means 
and by SDS polyacrylamide gel electrophoresis within platelet aggregates 
which were induced in vitreous gels, by the injection of 0.5 ml citrated 
platelet-rich plasma. The experimental model is fully described in 
Chapter 3.· The experiments were performed in triplicate on two 
separate occasions. Histochemical staining of fibrin employed M.S.B. 
Normal vitreous and untreated platelet-rich plasma clots were also studied 
histologically to ensure suitable control data. The detection of the 
constituent chains of cross-linked and non-cross-linked fibrin by S.D.S. 
polyacrylamide gel electrophoresis is described in Chapter 6. Samples 
(0.5 ml) of citrated platelet-rich plasma in vitreous were solubilised 
with urea, S.D.S. and r-mercaptoethanol after ultracentrifugation as 
described in Chapter 3, and analysed by polyacrylamide gel electro-
phoresis for the presence of fibrin. Standard fibrin solutions were 
also run on polyacrylamide gels as controls. These included thrombin-
clotted fibrlnogen (0.5 ml of 1% human fibrinogen clotted with 10 u 
bovine thrombin), thrombin-clotted human platelet-poor plasma (0.5 ml 
plasma plus 10 u thrombin), and Arvin-clotted platelet-poor plasma 
(0.5 ml plasma plusOJ.ml 10d!mlArvin). A sample (0.5 ml) of non-
clotted solubilwed platelet-rich plasma was also analysed after ultra-
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centrifugation in order to provide control data on intrinsic platelet 
proteins. After solubilisation in S.D.S. and ~-mercapoethanol, the 
samples were diluted one part in fifty with 8M urea before application 
to the polyacrylamide gels. 
Effect of platelet aggregation by vitreous collagen on plasma clotting 
times 
Since the release of procoagulant activity from platelets requires 
the presence of free calcium ions (see Chapter 2), experiments were 
designed to compare the clotting time of plasma in the presence or 
absence of vitreous collagen-aggregated platelets. The experimental 
system is described in the Results. 
RESULTS 
COAGULATION STUDIES 
No reactions occurred when undiluted vitreous from all species 
tested was mixed with purified human fibrinogen (1 mg/ml) or bovine 
thrombin (10 u/ml) in equal volume. In addition, no spontaneous 
clotting was observed during a period of one hour after fluid vitreous 
was added to fresh citrated human platelet-poor plasma. 
Recalcification Tests 
The recalcification time of fresh plasma was unaffected by the 
presence of human vitreous in glass tubes (Table 4.1a), but there was 
a slight shortening of the recalcification time of human plasma in 
plastic tubes when human vitreous was present (Table 4.lb). However, 
fresh dog vitreous (Table 4.2) and dialysed bovine vitreous (Table 4.3) 
Effect of Human Vitreous on the Recalcification Time of 
Fresh Human Platelet-poor Plasma in Glass Tubes 
Sample No. 
1 
2 
3 
4 
5 
6 
Recalcification Time (sees) 
Plasma 
+ 
Vitreous 
136 
150 
90 
91 
100 
97 
Plasma 
+ 
Buffer 
117 
131 
164 
130 
130 
1 140 140 TABLE ~ .1a 
8 170 160 
9 94 130 
10 91 132 
11 115 151 
12 190 
Mean 122 137.1 
S.D. 34.5 14.5 
S.E.M. 9.9 4.3 
P value* 0.18 
*Values for P were derived using the unpaired Students' t-test 
all tables in the thesis, unless otherwise stated. 
in 
Effect of Human Vitreous on the Recalcification Time of 
Fresh Human Platelet-poor plasma in Siliconised Plastic Tubes 
Recalcification Time (sees) 
Sample No. Plasma Plasma 
+ + 
Vitreous Buffer 
1 205 240 
2 228 236 
3 233 315 
4 225 330 
5 260 264 
6 211 316 
1 140 251 
8 115 352 TABLE 1.1b 
9 235 314 
10 231 292 
11 180 
12 120 
Mean 199.1 291.0 
S.D. 48.8 48.4 
S.EiM. 14.1 15.3 
P value .0001 
Effect of Dog Vitreous on the Recalcification Time of 
Fresh Human Platelet-poor Plasma in Si1iconised Plastic Tubes 
Recalcification Time (secs) 
Sample No. Plasma Plasma 
+ + 
Vitreous Buffer 
1 260 278 
2 285 299 
3 398 301 
4 358 317 
5 335 271 TABLE ~.2 
6 229 265 
1 271 
8 280 
Mean 302 289 
S.D. 56.4 19.3 
S.E.M. 19.9 1.9 
P value 0.62 
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had no effect on the recalcification time of normal human plasma in 
plastic tubes. In addition, dialysed bovine vitreous had no pro-
coagulant effect on Factor X or Factor II deficient plasma, ani even 
had a slight inhibitory effect on Factor II deficient plasma when 
compared with a buffer control (Table 4.3). This indicated that 
vitreous contained little, if any, Factor X or Factor II activity. 
The recalcification time of Factor VII deficient plasma was signifi-
cantly prolonged in the presence of vitreous, but the reverse effect 
was observed with Factor XII deficient plasma, where vitreous caused 
a marked shortening of the recalcification time (Table 4.3). Purified 
human sodium hyaluronate at a final concentration of 0.66 mg/ml had no 
accelerating effect on the recalcification time, and if anything, 
slightly prolonged the clotting time of both normal and Factor XII 
deficient human plasma (Table 4.3). However, a significant shortening 
of the recalcification time of non-activated plasma occurred in the 
presence of sodium hyaluronate and vitreous (Table 4.4). A time-
dependent relationship in this effect could not be demonstrated un-
equivocally since there was a parallel reduction in the control values 
(Fig. 4.1). By contrast, suspensions of vitreous collagen failed to 
cause a shortening of the recalcification time of non-activated plasma 
(Table 4.4). 
COAGULATION FACTOR ASSAYS 
Assay of Factor XII activity 
The assay of Factor XII activity in samples of bovine vitreous 
was measured by the release of p-nitroaniline dye (pNa) from the chromo-
S2302 in a system which depended on the activation of pre-geniC substrate 
kallikrein by Hageman factor (Factor XII) (see Chapter 3). Figure 4.2 
TABLE 4.3 
Effect of Bovine Vitreous and Hyaluronate Sodium on the Recalcification Times of 
Standard Human Plasma 
Factor XII deficient Factor VII Factor X Factor II 
Sample Normal plasma plasma 
deficient plasma deficient plasma deficient plasma 
Buffer Vitreous H.A.* Buffer Vitreous H.A.* Buffer Vitreous Buffer Vitreous Buffer Vitreous 
1 133 151 145 716 328 904 109 224 > 3,600 )3,600 904 ~3,600 
2 135 146 142 853 325 857 98 217 '> 3,600 )3,600 932 /3,600 
3 131 120 155 901 324 810 III 256 ') 3,600 >3,600 921 ')3,600 
4 128 130 153 887 327 925 103 249 ) 3,600 )3,600 916 )3,600 
5 127 118 159 852 327 970 114 249 ) 3,600 )3,600 921 '73,600 
6 123 132 147 889 323 112 261 )3,600 )3,600 949 13,600 
Mean 129.5 132.8 150.2 849.7 325.0 893.0 107.8 242.7 ') 3,600 )3,600 923.0 (3,600 
S.D. 4.4 13.4 6.5 68.4 1.9 61.7 6.1 17.9 15.3 
S.E.M. 1.8 5.5 2.66 27.9 0.8 27.6 2.5 7.3 6.2 
P value 0.58 <.0005 <.0001 .30 ~.0001 
*HA - Hyaluronate sodium (~ 64, concentration 0.66 mg/m1. 
TABLE 4.4 
Effect of Dialysed Bovine Vitreous, Bovine Vitreous Collagen, 
and Hyaluronate Sodium on Recalcification Time of 
Non-Activated Human Plasma 
Recalcification Time (sees) 
Dialysed Vitreous Hyaluronate Sample Buffer Buffer Collagen Buffer Sodium Vitreous Suspension 0.5 mg/ml 
1 292 218 208 230 292 241 
2 352 214 203 242 352 255 
3 403 211 206 240 403 251 
4 353 238 208 230 353 210 
5 332 232 205 235 332 233 
6 314 230 201 231 314 203 
Mean 341 223 205.7 234.7 341.0 243.2 
S.D. 38.3 10.96 2.8 5.3 38.3 23.6 
S.E.M. 15.6 4.48 1.1 2.2 15.6 9.6 
P value (.0001 (.0001 (.0005 
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Incubation time (mins) 
Effect of incubating non-activated human plasma with 
hyaluronate sodium and dialysed vitreous for varying 
time periods, on the recalcification time of the plasma. Bars represent 
means plus S.E.M. of six replicate samples; * mean of duplicate samples. 
shows that vitreous caused a slow release of pNa as measured by its 
absorbance (A405 ) in the presence of the surface activator cephotest. 
The Hageman factor-like activity of the vitreous was considerably less 
than that found in plasma diluted one part in ten, as shown by the slow 
release of pNa by vitreous in the early stages of the reaction (Fig. 4.2). 
Assay of Factor Xa activity 
Assay of Factor Xa activity in bovine vitreous was determined by 
the release of pNa from chromogenic substrate S2222 in the presence of 
a protein concentrate containing Factors II, IX and X (see Chapter 3). 
No intrinsic Factor Xa activity was detected in vitreous, since pNa 
release did not commence until Ca2+ was added to the samples. In 
addition, vitreous caused a slight decrease in the rate of pNa release 
after recalcification as compared to buffer (Fig. 4.3). This indicated 
that vitreous had a slight inhibitory effect on Factor Xa generation. 
Assay of Factor VII-enhancing activity 
The assay of Factor VII-enhancing activity in vitreous was tested 
in identical fashion using a protein concentrate which contained Factors 
II, IX, X and VII, plus other unidentified activated components (see 
Chapt er 3). No intrinsio Factor VII-enhancing activity was detected 
in vitreous, nor did vitreous affect the generation of Factor VIla 
after recalcification (Fig. 4.4). 
Assay of prothrombin-converting activity in the vitreous 
A purified system containing prothrombin, fibrinogen, Factor V 
and platelet substitute was used to identify prothrombin-converting 
activity in vitreous (see Chapter 3). Three duplicate sets of 
experiments were run, using dialysed bovine vitreous. Positive (ecarin) 
1·5 
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0·5 
10 
Figure 4.2 
20 30 40 50 60 
1/10 plasma 
without cephotest 
vitreous 
without cephotest 
70 80 90 100 
Time (sees) 
Time course of p-nitro-aniline (pNa) release from 
chromogenic substrate S2302 due to Hageman factor 
(Factor XII) activation in the presence of prekallikrein. 
Ordinate: absorbance at 405 nm of pNa. Abscissa: time (secs). 
1·5 
1·0 
0·5 
Fieure 4.3 
... _ ..... - ... - -_._._----------------
30 
Time (mins) 
Time course of pNa release from chromogenic substrate 
82222 in the presence of buffer and vitreous using a 
protein concentrate which contained Factors II, IX and X (Defix). 
Calcium ions were added to samples at time zero. 
2·0 
A405 
l5 
Vitreous "'" 
lO 
0,5 
5 10 15 20 25 
Time (mins) 
Figure 4.4 Time course of pNa release from chromogenic substrate 
S2222 in presence of vitreous and buffer, using a 
protein concentrate which contained Factors II, IX, X and VII, plus 
other unidentified activated components (FEIBA). Conditions as for 
Figure 4.3. 
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and negative (Tris-saline) controls were included. In one set of 
experiments (Table 4.5, column A), vitreous produced prolonged clotting 
times in the ,system when compared to the saline (negative) control, and 
thus vitreous appeared to be inhibitory to intrinsic prothrombin-converting 
activity in the preparations. In the second set (Table 4.5, column B) 
there was no difference between vitreous and the negative control, while 
in the third set (Table 4.5, column C), the vitreous caused slight 
shortening of the clotting time, suggesting the presence of minimal pro-
thrombin-converting activity in the vitreous, equivalent to ecarin venom 
at an activity of 1 u/ml. 
CLOrTING STUDIES IN THE PRESENCE OF VITREOUS GEL 
It is known that the gel-forming component of the vitreous is its 
collagen fraction and that hyaluronic acid adds stability to the three 
dimensional collagen network (see Chapter 1). Previous studies have 
shown that isolated vitreous collagen has considerable platelet-
aggregating ability490. The present experiments confirm and extend 
th:lse observations. 
Platelet aggregation 
Addition of rabbit ani bovine vitreous collagen to human platelet-
rich plasma caused rapid platelet aggregation (Fig. 4.5, 4.6). The 
effect was dose-dependent, and could be inhibited by acetyl-salicylic 
acid. In addition, the normal lag phase seen with equine tail-tendon 
collagen suspension (Fig. 4.7) appeared to be shortened. This effect 
was not due to the sonication procedure used to suspend samples of 
vitreous collagen, since identical treatment of the equine tendon 
TABLE 4.5 
Assay of Prothrombin-converting Activity in Vitreous 
Recalcification Times (secs) 
Sample No. saline vitreous ecarin 
A 1 505 1225 59* 2 138 :>3600 51* 
B 3 ') 1800 )1800 l125~ 4 ., 1800 )1800 1140 
• l414~ c 5 ') 3600 1294 6 ,3600 1495 1495 
System contained 0.1 ml each of purified pro-
thrombin (one in five plasma activity)" fibrinogen 
(2.5 mg/ml), Factor V (one in four plasma activity), 
and platelet substitute. Saline (negative control) 
and ecarin (positive control) were included. 
* ecarin concentration. 16 u/m1. 
t ecarin concentration • 1.0 u/m1. 
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Figure 4.5 Optical density curve at 640nm for platelet aggregation 
in presence of rabbit vitreous cOllagen. Arrow denotes 
time of addition of vitreous collagen (ve). Lag phase is less than 
sixty seconds. 
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Figure 4.1 Optical density curve at 640 nm for platelet aggregation 
in presence of equine tail-tendon collagen (He). Note 
typical lag phase of approximately sixty seconds before maximal response 
is achieved. 
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collagen suspension failed to shorten the lag phase. No platelet 
aggregation was observed with the supernatant obtained from the 
vitreous humour after ultracentrifugation. It was concluded that 
platelet aggregation observed in later studies in intact vitreous 
gels was due to its collagen component. 
Fibrin formation in platelet aggregates within vitreous gels 
Slow injection of citrated platelet-rich plasma into the centre 
of intact bovine vitreous gels resulted in a clot-like, loculated mass 
of plasma, which moved as a single structure in keeping with elastic 
changes induced in the gel by gentle agitation (Fig. 4.8). The same 
effect was observed with injections of whole bloOl, but not with 
platelet-poor plasma, serum or saline injections. These substances 
remained fluid and slowly tracked through the vitreous gel by gravity. 
This indicated that the 'globule forming' effect required the presence 
of platelets. Previous studies have suggested that injections of 
citrated platelet-rich plasma into the centre of the vitreous in vivo 
causes rapid platelet aggregation490 and that this is a possible trigger 
for intrinsic system coagulation. In the present experiments, the 
possibility that a fibrin clot had occurred in the globules of citrated 
platelet-rich plasma was investigated by searching for fibrin withinlthe 
vitreous gels. 
(a) Histology 
Histological staining of platelet-rich plasma 'globules' in vitreous 
gels with Martius scarlet blue (MSB) showed considerable positive staining 
reaction in platelet masses adherent to vitreous collagen (Fig. 4.9c). 
The clot-like mass in the vitreous was composed of an outer layer of 
Figure 4. 8 Macrophotograph of a plasma ' globule ' within a bovine 
vitreous gel . This clot- like structure was obtained 
by slow injection of citrated platelet- rich plasma into the centre of 
the vitreous gel through a fine needle , in the absence of added calcium 
ions . 
Figure 4.9 Histology of citrated platelet- rich plasma ' globules ' 
with bovine vitreous gels (for explanation , see 
text) (MSB stain) . 
(a) control normal vitreous collagen. x 400 
(b) control thrombin- clotted platelet- rich plasma clot , 
showing typical reticular pattern of fibril . x 400 
(c) Positive (red) staining of platelets adherent to 
vitreous cOllagen. x 400 
(d) Section through plasma- vit r eous globule '. Intense , 
granular staining ~ithin centre of globule . No typical clotted fibrin shown. 
x 400 
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platelets and a central core of granular material, which also showed 
strongly positive staining with MSB (Fig. 4.9d). However, the 
typical reticular pattern of a fibrin clot, seen in control sections 
of a thrombil.-induced pJ.:telet-rich plasma clot (Fig. 4.9b) was not 
detected. The absence of fibrin strands within the vitreous mass sug-
gested that a true fibrin clot had not occurred. Positive rr.SB 
staining reaction of granular material within the vitreous gel may 
have occurred as a result of dye uptake by non-clotted fibrinogen 
which hali become loculated wi thin the gel and was precipitated during 
the fixation process. 'rhe possibility that the granular material 
represented an atypical form of clotted fibrin could not be excluded. 
(b) S.D.S. polyacrylamide gel electrophoresis 
Vitreous gels which had been injected with 0.5 ml citrated 
platelet-rich plasma were disrupted by ultracentrifugation (see 
~ 
Chapter 3) and the pellet was solubilised with S.D.S. and \,-mercapto-
ethanol after thorough washing in 0.9~ saline. No fibrinogen or 
fibrin chains were detected in the samples by S.D.S. polyacrylamide 
gel electrophoresis (Fig. 4.10). A number of other protein ban:is, 
whose mobility on gel electrophoresis corresponded more closely with 
in trinsic platelet prot eins, were detect ed. These results indicated 
that fibrin formation did not occur in vitreous gels in which citrated 
platelet-rich plasma had been injected. 
Effect of platelet aggregation by vitreous collagen on plasma clotting 
times 
The absence of fibrin formation in platelet aggregates in vitreous 
gels indicated that in this experimental system, platelet activation was 
a b c d e 
O{) -------------
a -----------
f3 .----------
o -----------
Figure 4 . 10 Detection of fibrin by S . O. S. polyacrylamide gel electro-
phoresis in platelet-rich plasma ' globules ' within bovine 
vitreous gels ( for explanation , see text) . 
(a) Control non-cross-linked human fibrin 
b) Control partially cross-linked human fibrin from 
washed plasma clot 
(c) Control protein bands from washed non- aggregated human 
platelets . 
(d) and (e) protein bands obtained from platelet-rich 
plasma globules in vitreous gels . , ~ ' d" and xodimer refer to con-
stituent fibrin chains (see Chapter 2) . Note absence of these chains in 
samples from plasma globules in vitreous , indicating that fibrin conversion 
had not occurred . 
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associated with any thrombin-like activity. However, the release of 
other platelet procoagulant activity may have been masked by the absence 
of free calcium ions. The present experiment was therefore undertaken 
to explore this possibility. The recalcification times of platelet-
rich plasma and platelet-poor plasma were compared after incubation 
of 0.1 ml of each plasma with 0.1 ml bovine vitreous collagen suspension 
for 2 minutes at 31°C. Control samples were incubated with Tris-saline 
buffer under identical conditions. In addition, samples of platelet-
poor plasma in the presence of platelet substitute (platelin) were 
clotted in the same manner to exclude any effect due to non-specific 
phospholipid activity as distinct from platelet aggregation. The 
results are shown in Table 4.6. The recalcification time of p1ate1et-
poor plasma was slightly shortened in the presence of vitreous collagen. 
The effect was similar in the presence or absence of platelet substitute. 
The recalcification time of platelet-rich plasma was further shortened 
in the presence of vitreous collagen, at a dose sufficient to cause 
platelet aggregation. This suggested that procoagulant activity was 
released from the platelets after aggregation and that the effect was not 
due to platelet phospholipid alone. 
DISCUSSION 
The vitreous contains three classes of macromolecules, namely 
collagen, hyaluronic acid and traces of soluble proteins, mainly glyco-
proteins, which are in part derived from the blood (see Chapter 1). In 
. t an attempt ~as made to define the role of each the present experlmen s, " 
of these constituents on coagulation mechanisms in the vitreous. In 
the first series of experiments, untreated crude vitreous and co11agen-
free dialysed vitreous humour were tested for their effect on plasma 
TABLE 4.6 Effect of Bovine Vitreous Collagen-induced Platelet 
Aggregation on Recalcification Time of Human Plasma 
Sample 
1 
2 
3 
4 
5 
6 
Mean 
S.D. 
S.E.M. 
P 
Mean difference 
in recalcifi-
cation time 
* 
PRP 
.J. ppp 
Recalcification Times (secs) 
PRP* PRP ppl 
ppp 
+ + 
+ Vitreous + Vitreous Buffer Buffer 
collagen collagen 
220 113 332 301 
221 185 329 325 
205 190 341 321 
230 181 341 308 
229 164 341 321 
223 119 311 320 
221.3 178.1 335 311 
9.0 9.2 11.8 10.3 
3.1 3.1 4.8 4.2 
<.0001 .0157 
42.1;±6.7 19.0,:±6.3 
= platelet-rich plasma 
= platelet-poor plasma 
PPP PPP 
+ 
Platelet 
substitute 
+ 
Platelet 
substitute 
+ 
Buffer 
210 
227 
225 
221 
220 
217 
220 
6.1 
2.5 
+ 
Vitreous 
collagen 
<.0001 
27.2;±3.1 
198 
195 
193 
191 
191 
189 
192 
3.2 
1.3 
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recalcification times using cell-free plasma. The vitreous had no 
effect on clotting of surface-activated normal plasma in glass tubes, 
but human vitreous caused some shortening of plasma clotting time when 
plastic tubes were used, suggesting the presence of Factor XII activity 
(Hageman factor) in the vitreous. This possibility gained support from 
experiments showing a significant shortening of Factor XII-deficient 
plasma by collagen-free dialysed bovine vitreous (Table 4.3). Further-
more, trace amounts of a Hageman-factor-like moiety were detected in 
vitreous samples which were tested for prekallikrein-converting activity 
(Fig. 4.2). These results confirmed the work of Regnault and Larrieu421 
who noted similar trace amounts of Factor XII activity in human vitreous. 
The source of this activity in vitreous was more difficult to define. 
Since Hageman factor is a glycoprotein of molecular weight 80,000 daltons 
(see Chapter 2), it is conceivable that traces of this protein could dif-
fuse through the blood-vitreous barrier by a process of ultrafiltration282 
and form part of the plasma-derived soluble glycoproteins of the vitreous 
(see Chapter 1). The lack of effect of pure hyaluronic acid, in contrast 
to the marked effect of vitreous, on Factor XII-deficient plasma would 
suggest that Hageman factor-like activity in the vitreous resides within 
its soluble glycoprotein component (Table 4.3). However, since only trace 
amounts of Hageman factor activity were detected (Fig. 4.1), its physic-
logical role is uncertain. 
Apart from any intrinsic Hageman factor activity, the vitreous itself 
may activate plasma Hageman factor, during episodes of bleeding, by virtue 
of its high content of hyaluronic acid. Although this macromolecule had 
little effect on the clotting times of surface-activated normal or 
Factor XII-deficient plasma, a significant reduction in the recalcification 
time of non-activated plasma, in the presence of vitreous and hyaluronic 
acid was observed (Table 4.4, Fig. 4.1). Hyaluronic acid shows structural 
similarity with polymeric polysaccharides such as heparin and chondro-
itin sulphate which, in common with other negatively-charged molecules, 
have been shown to activate Hageman factor and generate kinin release345 
(see Chapter 2). Hageman factor activation in the vitreous would pro-
vide a mechanism for clotting via the intrinsic pathway. 
There appeared to be few other coagulation factor activities 
in the vitreous .. Fibrinogen and thrombin activity were not detected, 
nor was there any significant Factor II or prothrombin-converting 
activity (Tables 4.3, 4.5). A search for Factor Xa activity also 
showed negative results (Fig. 4.3). Indeed, vitreous appeared to 
delay the generation of Factor Xa activity in coagulation factor con-
centrates (Fig. 4.3). 'l'hese results contrast with those of Regnaul t 
and Larrieu421 , who considered vitreous to contain Factor Xa activity 
on the basis of clotting experiments using purified prothrombin. How-
ever, the possibility of minimal contamination with Factor X in their 
samples of prothrombin, which were used at 10 fold activity of normal 
plasma, was not excluded. Moreoever, the ionic composition of the 
vitreous samples used in their study was not controlled. 
The prolongation of the recalcification time of Factor VII-
deficient plasma by dialysed bovine vitreous suggested that Factor VII 
was a requirement for intravitreal clotting. This would indicate a 
pred9minant role for extrinsic system clotting in the vitreous in spite 
of low levels of tissue thromboplastin382• However, vitreous had no 
effect on the generation of Factor VIla when compared with buffer (Fig. 
An alternative explanation for the delay in Factor VII-deficient 
plasma clotting times may be that the vitreous contained an inhibitor 
of intrinsic system coagulation since, using this plasma, extrinsic 
clotting was effectively blocked. Further studies have shown that 
traces of inhibitor (~l antitrypsin) are present in nomal vitreous 
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(see Chapter 6). There is, therefore, little direct evidence that 
clotting in the vitreous occurs via the extrinsic coagulation mechanism, 
as it does in other tissues. On the contrary, the low levels of tissue 
thromboplastin in the vitreous suggest that this is not the dominant 
mechanism, although clearly it may contribute to the clotting process 
in a minor fashion. 
The role of platelets in fibrin formation within the vitreous 
was investigated. Previous authors have reported that vitreous collagen 
possesses considerable platelet aggregating ability490, and they suggested 
that clotting in the vitreous was triggered by platelet procoagulant 
activity. In the present work, both rabbit vitreous collagen which 
is Type IV (see Chapter 1) and bovine vitreous collagen (Type II) demon-
strated a pronounced and dose-dependent ability to cause platelet 
aggregation, when prepared as a suspension by ultrasonication (Figs. 
4.5, 4.6). In addition, the normal lag phase found with similarly-
treated equine tendon collagen (Fig. 4.1) was shortened. In the 
studies reported by Swann et a1490 , who used mainly guanidine-HCI 
extracts of bovine vitreous collagen, the platelet aggregating ability 
of vitreous collagen was an all-or-none effect and the initial lag 
phase was considerably longer. Current views of the collagen-platelet 
interaction suggest that the lag phase in platelet aggregation by collagen 
is the result of a preliminary step whereby soluble tropocollagen mole-
cules co-aggregate to form microfibrils, which are considered to be 
a pre-requisite for collagen-induced platelet aggregation30• The 
shortened lag phase observed in the present study may therefore be 
explained. Since vitreous occurs as fine fibrils or microfibri1s in 
its natural state (Chapter 1), a suspension of this material may have 
required no further realignment to induce platelet aggregation. 
Although vitreous collagen caused rapid platelet aggregation, 
evidence for fibrin formation, solely as a result of this response, 
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was not found. Injection of citrated platelet-rich plasma into in-
tact vitreous gel resulted in a clot-like mass which, on histological 
examination, lacked the characteristics of a typical reticular fibrin 
clot (Fig. 4.9). Furthermore, analysis of the solid material obtained 
from the vitreous on S.D.S. polyacrylamide gel electrophoresis failed 
to reveal the typical profile of fibrin (ogen) chains (Fig. 4.10). 
These results indicated that platelet aggregation by vitreous collagen 
was not associated with any direct thrombin-like activity. However, 
platelet procoagulant activity is well recognised (see Chapter 2), and 
requires the presence of free calcium ions. It is probable, therefore, 
that platelet aggregation by vitreous collagen is coupled with release 
of procoagulant activity. Evidence to support this concept is shown 
in Table 4.6, where the recalcification time of platelet-rich plasma 
after incubation with vitreous collagen was significantly shorter than 
the recalcification times of platelet-poor plasma or platelet-poor 
plasma plus platelet substitute after similar incubation with vitreous 
collagen. These results indicate that, although platelets have no 
thrombin-like activity, clotting is accelerated in the presence of 
intact platelets and vitreous collagen, and is probably due to the 
release of platelet procoagulant activity after collagen-induced platelet 
aggregation. 
CONCLUSION 
Blood coagulation within the vitreous may occur by several 
mechanisms. Unlike other tissues, tissue thromboplastic activity 
of the vitreous is low and therefore clotting via the extrinsic system 
may not be the predominant mechanism. On the contrary, the effects of 
vitreous and hyaluronic acid on non-activated plasma suggest that plasma 
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Hageman factor may be activated by the vitreous, thereby initiating 
clotting via the intrinsic system. In addition, the vitreous con-
tains traces of endogenous Hageman factor-like activity, although its 
role in intravitreal clotting is somewhat obscure. 
Clotting in the vitreous may also be accelerated, if not initiated, 
by the considerable platelet-aggregating ability of vitreous collagen 
which, almost certainly, is associated with the release of platelet-
procoagulant activity. In addition, experiments with citrated platelet-
rich plasma in intact vitreous gels indicate that plasma may be trapped 
or loculated within the vitreous, thereby prodUCing conditions which would 
favour fibrin conversion by one or all of the above mechanisms. 
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PART 3 
ROLE OF FIBRINOLYSIS IN 
THE RESOLUTION OF VITREOUS BLOOD CLOTS 
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CRAPI'ER 5 
REVIEW OF THE PIITSIOLOGY OF FIBRINOLYSIS 
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INTRODUCTION 
The conversion of circulating plasma fibrinogen to insoluble 
fibrin during the last stages of blood cOagulation represents the 
m~in defence mechanism in haemostatic control. In addition to 
forming the major protein component of blood clots, fibrin is 
deposited in substantial quantities within fresh wounds and may be 
important in providing a scaffold for the invasion of cel1s41 ,343,447. 
During such processes as' wound healing or recanalisation of vascular 
thrombi, fibrin deposits are gradually dissolved. Over thirty years 
ago, it was recognised that fibrin dissolution was achieved by an 
enzyme which was present in normal plasma as an inactive precursor, 
plasminogen, but which could be converted to the active proteinase, 
plasmin, by a streptococcal factor249 • Since then, intensive investi-
gat ion of the fibrinolytic process has shown that several other com-
ponents participate in this system, and the recently recognised inter-
actions of fibrinolytic factors with the coagulation process, the 
complement system and the kinin-forming mechanism in inflammation, 
• 
has revealed the exquisite complexity of these homeostatic systems245 • 
As Astrupll has emphasised, although several enzymes are capable 
of degrading fibrin, "fibrinolysis" is a specific term which describes 
the limited proteolysis of fibrin to produce liquefaction of a fibrin 
clot by splitting only a few peptide bonds. It is generally accepted 
that fibrin dissolution in vivo occurs predominantly via the plasminogen-
plasmin system; the components of this system are illustrated in 
Figure 5.1. It can be seen that there is a general similarity to 
the coagulation scheme in that there are intrinsic and extrinsic means 
of achieving fibrinolysis. However, differences exist between the 
° ° d °ntrlOnsic fibrinolytic systems in the exact mechanism 
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of fibrin degradation which depends on a number of factors such as 
the affinity of the various activators, plasmin or both for fibrin 
and fibrinogen molecules. These are discussed below. 
THE PLASMINOGEN-PLASliiIN SYSTEM 
The four components of this system are plasminogen, plasmin, 
plasminogen activators and inhibitors. 
PLASMINOGEN 
The introduction in 1910 of a method for the purification of 
plasminogen from human plasma by lysine-sepharose affinity chromato-
graphy has led to a much greater understanding of the chemistry of 
this molecule120• Human plasminogen exists as a single-chain 
P-globulin of about 90,000 daltons411 ,488, but several molecular 
forms may occur. Studies of the conversion of plasminogen to plasmin 
have revealed that at least two forms of plasminogen are generated, 
differing in the Nli2-terminal portion of the molecule. Native 
plasminogen occurs with glutamic acid as its amino-terminal (Glu-
plasminogen), while limited proteolysis of Glu-plasminogen with uro-
kinase yields Lys-plasminogen, which contains lysine at its amino-
terminal. Lys-plasminogen has a shorter half_life102 , is more 
rapidly activated536 and is more readily adsorbed to fibrin than 
Glu-plasminogen. Associated with the conversion of Glu-plasminogen 
to Lys-plasminogen is a conformational change in the shape of the 
molecule472 which is also seen when e-aminocaproic acid is bound to 
472 the molecule • This change in molecular shape has been invoked 
as an explanation for the biphasic pattern of fibrinolysis-inhibition 
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of urokinase by e-aminocaproic acid507 • The primary structure of 
human plasminogen has recently been elucidated in some detail and 
the molecule consists structurally and functionally of three parts 
which are proteolytically cleaved when activation occurs305 • The 
part corresponding to the heavy chain of plasmin contains five triple 
disulphide loops (known as "Kringle" structures) which not only have 
internal homology, but are also homologous to certain regions in 
the prothrombin molecule479 (see Chapter 2). 
PLASMIN 
Limited proteolytic cleavage of Lys-plasminogen yields the 
serine protease, plasmin. There has been some disagreement concern-
ing the sequence of reactions involved in this process, mainly because 
of apparent differences in the mode of action of plasminogen activators. 
Cleavage of plasminogen with urokinase occurs at an arginine-valine bond 
in the carboxy-terminal portion of the molecule440 , This results in a 
double chain plasmin molecule, linked by a single disulphide bridge 
(Fig. 5.2). The active site of plasmin occurs on the light chain. 
Streptokinase activation of plasminogen also produces a double chain 
plasmin molecule, but unlike urokinase, it does not activate plasminogen 
directly (vide infra). Although it was previously thought that con-
version of Glu-plasminogen to Lys-plasminogen with release of a 7,000 
dalton peptide433 (pre-activation peptide, Fig. 5.2) was a pre-requisite 
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for plasmin production, it has been shown that this is not the case • 
Recent evidence suggests that plasmin production can proceed by two 
pathways, the major one involving the conversion of Glu-plasminogen to 
Lys-plasminogen by catalytic amounts of plasmin (Fig. 5.3)523. 
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Figure 5.2 Schematic representation of the chain composition 
of Glu-plasminogen, Lys-plasminogen and plasmin (Wallen535). 
Figures refer to the molecular weights of various plasminogen fractions. 
Release of a 7,000 dalton peptide (pre-activation peptide) occurs during 
conversion of Glu-plasminogen (Olu-PLO) to Lys-plasminogen (Lys-PLO). 
PLI, plasmin: -S-S, disulphide bond. 
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Figure 5.3 Two-pathway model for activation of plasminogen, pli-
catalytic amounts of plasmin: UK - urokinase; 
p.a.p. _ preactivation peptide. (Wallen,535). 
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PLASMINOGEN ACTIVATOR 
The active principle responsible for the conversion of plasminogen 
to plasmin is known as plasminogen activator. Studies of the mechanism 
of plasminogen activator interaction with plasminogen have been compli-
cated by the heterogeneity of activators, which may show both functional 
and immunological non-identity, depending on the source. Several 
plasminogen activators have been described such as tissue activator, 
plasma activator, vascular endothelial activator, Factor XII-dependent 
activator, cellular activator and urokinase. Bacteria also synthesise 
activator, of which the most studied is streptokinase. Some of these 
activators are described below. 
PLASMA PLASMINOGEN AC'rIVATOR 
Normal plasma shows a limited degree of spontaneous activator 
activity, which is labile and shows considerable inter-species varia-
b "l't 361 1 1 Y • Increased activity has been observed after a variety of 
stimuli such as venous occlusion, strenous exercise, emotional stress, 
surgical operations and administration of vasoactive amines (for review 
see reference 10), and plasma activator levels may be altered by therapy 
in systemic diseases such as diabetes mellitus137• It has been 
suggested that release of activator activity in the blood is under 
humoral and possibly hypothalamic control77• 
The origin of plasma plasminogen activator is the source of 
considerable debate. At present, at least three mechanisms appear 
to contribute to plasma activator activity; the vascular endothelium, 
the Hageman-factor activatable mechanism, and the "peptone effect". 
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Vascular Endothelial activator 
Indirect evidence, based on a stanjardised venous occlusion 
test which produces a rise in fibrinolytic activity in the blood, 
suggests that activator may be released from the vascular endothelium534 • 
It has been observed, ho~ever, that endothelial activator is strongly 
cell-bound ani stablel3 , unlike plasma activator. In this respect, 
endothelial activator closely resembles tissue activator (see below). 
Conversely, saline extracts of tissues are not entirely stable2, and it 
is possible that endothelial activator also has a labile component which 
may correspond to plasma activator activity. 
Hageman-factor dependent pathways for plasmin production 
Activation of Hageman factor by negatively-charged surfaces via 
high molecular weight kininogen (see Chapter 2) induces fibrinolytic 
activity in plasma246 • The complex inter-relationships between 
coagulation and kinin-formation are further emphasised by the observation 
that prekallikrein, which is cleaved by activated Hageman factor, also 
acts as a plasminogen proactivator since its product, kallikrein, can 
convert plasminogen directly to plasmin247 • The physiological role of 
this system is not clear, but reduced fibrinolytic activity has been 
detected in Hageman factor deficient plasma549 • 
The "Peptone Effect" 
Peptone added to guinea pie serum produces fibrinolytic activity 
in the euglobulin (inhibitor-free) fractionl4 ,5 l 5 of blood plasma which 
is independent of Hageman factor. This effect was found to be a general 
property of acid polysaccharides such as heparin, dextran sulphate, 
cellulose trisulphate and hyaluronic acid368• Several investigations 
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suggest that the "peptone effect" depends upon the presence of a 
humoral plasminogen proactivator in blood which is activated to a 
large extent on the removal of inhibitors by the polyelectrolytesl4 • 
Other mechanisms of fibrin digestion by blood factors, independent 
of plasminogen activator activity, have been proposed. These include 
a second Hageman-factor independent mechanism, possibly involving 
c3
46l
, a further separate mechanism which re~uires the participation 
of platelets, IgM, C3 and c4
50l
, and finally, fibrin removal by 
proteinases from white blood cells48• It has been suggested that 
such mechanisms may have equal, if not greater significance in the 
digestion of fibrin clots by blood or blood:, products340 • 
TISSUE ACTIVATOR 
Plasminogen activator activity has been demonstrated in almost 
all tissues of the body, either in saline extracts of tissues2 or by 
Todd's fibrin-slide histochemical technique509 • Tissue activator 
is highly stable (although a small component of the total activity 
is labile, see above), and strongly resists saline extraction. As 
a result, molar potassium thiocyanate is generally required for its 
quantitative extraction, and more recent studies using this technique 
have shown differences in activator activity among various tissues9,79. 
. 18 96 Highly purified tissue activator has been prepared from p1g heart ' 
and pregnant hog ovaries258• Molecular weight studies of plasminogen 
activators from these and other sources indicate a range of 57,000 to 
studies of molecular 
lower value corresponds more closely to similar 
weight for plasma activator37l • Tissue activator 
h · vascularised connective tissues, especially in activity is hig 1n 
392 healing wounds • Activity is highest in venous endothelium, but is 
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low in arterial endothelium while capillaries are usually inactive510 • 
However, capillary buds and areas of neovascularisation show high 
activity, ~hich subsequently disappears after scar formation274 • 
The relationship between fibrinolytic activity and degree of vascularity 
of anyone tissue has been emphasised by Astrup9. Althoueh venous endo-
thelial cells are considered to be the source of most of this activity, 
there is considerable variation in the distribution of active sites178• 
Indeed, cellular studies suggest that there may be a cycle of activator 
release. Proliferating cells are generally inactive, but during 
maturation and differentiation intracellular synthesis of the protease 
takes place, which is then released as the life cycle of the cell 
approaches the stage of involution and degenerationl2 • Fractionation 
studies of cell homogenates indicate that plasminogen activator activity 
is located in the microsomal and lysosomal fractions 277 of the cell. 
UROKINASE 
Urokinase (UK) is a r-glObulin with a single polypeptide chain 
(molecular weight 54,000) which is found in human urine and has 
plasminogen activator activity292. Although previously considered 
to be an excretion product of activator produced elsewhere in the body, 
urokinase is now believed to be secreted by the mucosal cells lining 
the kidney ductules47 • In ad·:ii tion, UK appears to differ chemically 
from tissue activator258 and to have a considerably lower affinity for 
f Ob 0 506 1 rln • The physiological role for the uniqueness of the many 
plasminogen activators in various tissues and fluids is not yet clear, 
but identity can occasionally be established between ~tivators, for 
instance, between urokinase and a plasminogen activator from a human 
ovarian carcinoma cell line8• Urokinase activates plasminogen 
directly (see above). 
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STREPrOKINASE 
Of the many fibrinolytic enzymes produced by bacteria, strepto-
kinase (SK) has been most studied. Streptokinase is an ~globulin 
of molecular weight 47,000, and is produced by ~-haemOlytic strepto-
,210 
COCCl • It activates plasminogen by a two-step process, previously 
thought to require the presence of a blood proactivator, but now known 
to involve complex formation between SK and plasminogen420• SK- plasmino-
gen undergoes a transition to SKPPlasmin19 which is ~apable of converting 
plasminogen to Plasmin456 • It has been proposed that free plasmin can 
be produced by excess quantities of plasminogen merely by exchange with 
the SK-plasmin complex263 • Recent studies have discounted this 
mechanism, and adhere to the generally held view that the SK-plasmin com-
plex cleaves the plasminogen molecule in the same way as other activators185 • 
However, the full sequence of events in plasminogen activation by SK is 
sufficiently different from other activators that it can be regarded as 
non-physiological. 
OTHER SOURCES OF PLASMINOGEN ACTIVATOR 
In addition to its association with vascular endothelium, plasmino-
gen activator activity has been detected in several cell types including 
, ,353 l' th l' 381 I' t' 353 d glandular eplthellum ,cornea epl e lum , lver lssue an 
embryonic kidney cell lines378 under specific conditions. Furthermore, 
leukocytes contain enzymes which can digest fibrin by both p1asmin-
, ,192,402 
mediated and non-p1asmin-medlated mechanlsms • Both pathways 
can be distinguished by the type of fibrinolysis products which are 
released48, and it has been suggested that the non-p1asmin-mediated 
'1 d·t· 402 pathway may be more important in pathologlca con 1 lons. In 
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addition to leukocytes, macrophages in culture can secrete large 
quantities of plasminogen activator into the extracellular fluid 
when the cells are appropriately stimulated516 , and this enzyme 
secretion can be modulated by anti-inflammato~ steroids, mitotic 
inhibitors and cyclic nucleotides521• The secretion of proteo-
lytic enzymes in this manner has been proposed as a major factor 
in the migration of cells into areas of inflammation. In addition, 
the enhanced fibrinolytic activity of malignant cells both in 
Vivo495 and in vitro437 has stimulated considerable interest in the 
possible relationship between proteolytic activity and tumour spread425 • 
INHIBITORS OF FIBRINOLYSIS 
NATURALLY OCCURRING INHIBITORS 
One of the major problems which has hindered the investigation of 
circulating plasminogen activators is the high content of naturally 
occurring inhibitors of fibrinolysis in blood. Two main types of 
inhibitor occur, namely inhibitors of plasminogen activation (anti-
activators) and inhibitors of plasmin (antiplasmins). 
Antiactivators 
Antiactivators have been identified and separated from blood 
fractions40 ; their electrophoretic mobility corresponds to that of 
0\ globulins with molecular weights of 75,000-80,000 and they can 
2 
inhibit a variety of activators, which may suggest that their action 
is on the plasminogen molecule rather than the activator. Although 
specifically designed assays are available which show that these 
79 
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activators with no effect on plasmin has not been clearly demon-
strated. 
Antiplasmins 
Within the group of antiplasmins are the broad-spectrum plasma 
protease inhibitors, i.e. 0<2 macroglobulin, ~ antitrypsin, anti-
thrombin III-heparin complex, Cl inactivator and inter- 0(- trypsin 
inhibitor. These have been briefly reviewed in Section 1. Although 
it has been generally considered that most of the antiplasmin activity 
is contained in~2 macroglobulin (reversible, rapid reaction with 
plasmin) and o{l antitrypsin (irreversible, slow reaction with 
plasmin)108, a further fast-reacting antiplasmin has recently been 
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reported and character1sed ' • It has been suggested that 
plasmin is inhibited by complex formation between the light chain of 
plasmin and the peptiie-cleaved inhibitorlOO • Most recently, it has 
been shown that plasmin and antiplasmin react in a biphasic manner, 
the first of which is reversible562 • The data suggest that circulat-
ing plasmin is rapidly neutralised, but fibrin-bound plasmin is not. 
Antiplasmins are also detectable in cells and tissues such as 
platelets240 and granulocytes567 and arterial walls145 • 
SYNTr~IC INHIBITORS OF FIBRINOLYSIS 
Several synthetic agents can inhibit fibrinolysis either as anti-
activators or, in higher concentration, "as antiplasmins. These include 
e-aminocaproic acii (EACA)327 and tranexamic acid (4-aminomethylcyclo-
hexanoic acid, A~CHA). These agents have been extensively used in 
studies of fibrinolytic mechanisms and the conformational change in 
Be 
the plasminogen molecule induced by EACA has been alluded to above. 
Trasylol (Aprotinin) is also an inhibitor of fibrinolysis which has 
been used in a similar fashion, but it is an extract of bovine lung 
and has a wide range of specificities. A full discussion of the mode 
of action of these inhibitors is beyond the scope of this thesis, but it 
has recently been suggested that these agents have their effect by re-
ducing the binding of plasminogen and plasmin to fibrin522 • 
~~CHANISM OF THROMBOLYSIS IN VIVO 
It is a widely held assumption that dissolution of whole blood 
clots and fibrin clots in vivo occurs via the plasminogen-plasmin 
system, although the contribution of other mechanisms has recently 
been explored (vide infra). The exact process of fibrin degradation 
within clots has attracted much interest and there are, at present, 
three hypotheses to explain physiological clot lysis. 
Until recently, the theory of intrinsic clot lysis4 was the 
most widely held view. According to this theory, lysis occurred 
as a result of the adsorption of plasminogen to fibrin in the clot, 
and the subsequent activation of inhibitor-free, gel phase plasminogen 
to plasmin in situ by activators which diffused through the clot. 
Evidence for this hypothesis was based on the known affinity of 
plasminogen for fibrin563 which has recently been related to the 
lysine binding sites associated with the Kringle structures on the 
l · 1 1 479 p asm~nogen mo ecu e • Plasmin formed while adsorbed to the fibrin 
molecule was free to digest the fibrin unimpeded by the presence of 
inhibitors, while any plasmin formed in the circulation was rapidly 
inactivated by inhibitors. A recent immunofluorescence study on 
thrombolysis in vivo h~s supported this hypothesis, by demonstrating 
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the specific adsorption of plasminogen to fibrin2l6 • However, the 
same study also showed strong binding of plasminogen activator to 
fibrin, a finding which the authors did not discuss. In addition, 
previous workers had shown that the plasminogen content of thrombi 
was low372 and that full lysis of artificial thrombi which were per-
fused with plasminogen activator did not occur unless plasminogen 
was present in the perfusate328• It is interesting to note that 
fast-acting antiplasmin interferes with the adsorption of plasminogen 
to fibrin339• 
The hypothesis of extrinsic clot lysis proposed by Ambrus and 
Markus5 was based on the presumption that plasminogen was activated 
in the circulation and rapidly formed a complex with antiplasmin. 
Plasmin dissociated from the complex when it came into contact with 
fibrin because it had a greater affirmity for fibrin than for anti-
plasmin. However, evidence for this hypothesis is lacking, and in 
vitro clot lysis studies with purified plasmin have sho\\:n that such 
exogenous lysis occurs only very slowly. A modified view of this 
hypothesis has been given some support on the basis of fibrinogeno-
lytic activity within the ~ macroglobulin-plasmin complex205 • 
A more recent hypothesis has been proposed which depends on the 
selective binding of plasminogen activator to fibrin87• In this 
situation, plasminogen diffuses through the clot and is converted to 
plasmin in the presence of high levels of activator. 
It is probable that the angwer to physiological clot lysis 
combines aspects of all three hypotheses. Thus some forms of 
plasminogen are strongly adsorbed to fibrin, while others are only 
weakly bound505 • Similarly, the affinity of activators for fibrin 
is variable; for instance, tissue activator adsorbs to fibrin more 
readily than urokinase506 , and plasmin has a strong affinity for fibrin 
. 1 . 168 and antlp asmln • 
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Furthermore, non-fibrinolytic mechanisms in 
fibrin degradation probably playa significant role in clot lysis, 
if not in the circulation, then at least in the tissues during wound 
repair. Considerable evidence now exists to show that leukocytes 
contain sufficient fibrinolytic and non-fibrinolytic prot eases to 
digest fibrin (see above, plasminogen activators). ~orphologically, 
fibrin deposits in the tissues induce a pronounced polymorphonuclear 
cell response211 ,434 and in vitro plasma clot lysis with streptokinase 
is greatly enhanced by the addition of viable leukocytes189• It has 
been suggested that a prerequ~site for leukocyte-induced thrombolysis 
is disintegration of the cells within the thrombus and release of their 
189 prot eases • It is also of interest to note that leukocyte fibrin-
splitting neutral protease shows considerable differences from plasmin 
in its mode of digesting fibrin, and that it does not seem to be in-
hibited by synthetic inhibitors such as EACA402 , and only partially by 
anti:activators. However, natural inhibitors of leukocyte protease 
are present within the leukocyte itself and are also probably released 
262 
on cell death • A special role for the eosinophil leukocyte in the 
lysis of early fibrin deposits associated with platelets during the re-
modelling of thrombi, has also been suggested276 ,435. Current opinion 
on the role of leukocytes in fibrin dissolution favours the view that 
intact granulocytes570 and macrophages5l6 have no direct effect on 
fibrin, but do secrete plasminogen activator, whereas lysed cells can 
degrade fibrin directlyl7l. 
FIBRINOGEN DEGRADATION BY PLASMIN 
The structure of the fibrinogen molecule has been described in 
Chapter 2. When clotting occurs, fibrinogen is converted to fibrin with 
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the release of peptide material, designated Fibrinopeptides A and B. 
Plasmin is capable of degrading both fibrinogen and fibrin to soluble 
fragments generally known as fibrin(ogen) degradation products (FDP) 
(Figs. 5.4, 5.5). Digestion of fibrinogen yields Fragments D and E 
in the final stages. Intermediate Fragments X and 1 are detectable 
after incomplete hydrolYSis166 ,l1l ,3l2,341. It can be seen that the 
process of fibrinogenolysis is asymmetric by the composition of Fragment 
1 69. In addition, one mole of fibrinogen will yield two moles of 
Fragment D and one of Fragment E, with one mole each of ~ragment X 
and Y as intermediates (Fig. 5.4). The scheme shown in Fig. 5.4, 
however, is an over-simplification of the process. Apart from the 
known heterogeneity of fibrinogen itself (see Chapter 2), there is 
considerable variation in the exact structure of the FDP, particularly 
X and D. This may, in part, reflect different metho1s of purification, 
but is also due to variable degrees of proteolytic cleavage of fibrino~en 
by plasmins, particularly in the extent of lysis of the A~chain, in 
the case of Fragment X349 and the ~-chain remnant in the case of 
Fragment D163. Irregular plasmic digestion ani interchange of di-
sulphide bonds may also explain the heterog~neity of Fragment E161. A 
consequence of such varied digestion of fibrinogen is the diversity of 
the released peptide material, which may have significant biological 
activities in vivo (vide infra). 
Digestion of fibrin by plasmin also yields FDP (Fig. 5.~), but 
of a different composition, depending on the degree of polymerisation in 
the molecule (see Chapter 2 for discussion of fibrin polymerisation). 
Non-crosslinked fibrin monomer is cleaved to produce Fragments X, Y, D 
and E, similar in 
no longer possess 
structure to fibrinogen lysis products except that they 
fibrinopeptides A and B414. Digestion of fully cross-
linked fibrin yields the unique fragment D-dimer, and also Fragment E 
c 
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Schematic representation of the polypeptide chain 
origin of the constituent subunits of each fragment. 
0(, ~, Orefer to the individual chains of the fibrinogen molecule. 
A, B refer to the peptide fragment which is removed when fibrinogen 
is converted to fibrin. Dashed lines indicate interchain disulphide 
linkages. Figures refer to the molecular weights of the individual 
molecules. N,C represent the amino-terminal and carboxy terminal ends 
of the molecules respectively. 168) (Gaffney • 
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Plasmin digestion of crosslinked fibrin yields D-dimer 
and E fragments as shown. Shaded areas represent intramolecular 
disulphide bonds between the ~,~, and ~chains of each fibrin 
molecule (Gaffney168). 
The D-dimer fragment contains crosslinkedt chains from different fibrin 
molecules, and it also may show heterogeneityl30. Partially crosslinked 
fibrin, i.e. ~ chain linkage without ~ chain polymerisation, also 
yields D-dimer and E fragments, but the lack of 0\. polymers seems to 
make the molecule much more susceptible to lysisl70 • Recent studies 
by Rampling4l 4, however, have disputed the relationship between cross-
linking of fibrin and lysability of clots, and suggest that the most 
important factor is uniform distribution of activator throughout the 
clot. Production of Fragments X and Y probably also occurs in fibrin 
digestion, but due to the extensive cross-linkages, they are probably 
n~rendered soluble, but are retained within the structure of the clot. 
In addition, there is recent evidence to suggest that fragments larger 
than the fibrinogen molecule are released during the early stages of 
digestion of stabilised fibrin. 
The view of fibrinolysis presented here is oversimplified, and 
indeed it has been shown that in aldition to D-dimer and E, several 
other fragments may occur, such as D-dimer-E complex, D-monomer, and two 
as yet unnamed fragments l72 • 
ROLE OF FIBRINOLYSIS IN WOUND HEALING AND INFLAN~TION 
It has long 'been recognised that fibrin formation is crucial for 
normal wound healing and recent studies have shown that a possible mode 
of action of fibrin in this respect could be by way of a common linkage 
protein, cold-insoluble globulin, which can cross-link to fibrin and 
.. b 343,441 Another 
also appears to reside on f1broblast surface mem ranes • 
process which is central to normal wound healing is the production of an 
appropriate inflammatory response, and in this fibrinolysis may playa 
significant role. Generation of plasmin not only leads to removal of 
fibrin deposits, but due to the wide substrate specificity of plasmin 
it promotes kinin formation241 (and thus increased vascular permea-
bility and vase-dilation), it cleaves complement components C3 and 
c5
542 (thus increasing vascular permeability and promoting chemotaxis 
of leukocytes which secrete further plasminogen activators), and it 
prod uces FDP, which are themselves chemotactic485 • Plasmin has 
other effects that may be relevant to wound healing, such as the 
ability to cleave the cold-insoluble globulin (fibronectin, LETS protein) 
discussed above233 • Plasmin may also be mitogenic and thus contribute 
to cellular proliferation within wounds544 • 
Finally, the biological activity of FDP may influence the inflam-
matory response. In addition to having chemotactic activity, FDP may 
inhibit lymphocyte transformation27l and platelet aggreg~tion484. They 
may enhance capillary permeability68 and cause contraction of smooth 
muscle in vessel walls301• They may also have an immunosuppressive 
effect in neoplasial76 • 
SUYMARY 
From this brief review, it can be seen that fibrinolysis is a 
complex process which may have many effects apart from the dissolution 
of fibrin. It is clear that, although considerable advances have been 
made in the elucidation of the plasminogen-plasmin system and its inter-
actions, much remains to be discovered, particularly in relation"to 
plasminogen activators. Moreover, the exact mechanisms involved in 
thrombolysis are still largely unknown. To study the fibrinolytiC 
process in isolation, however, is to ignore its roles in several other 
phases of pathophysiology such as wound healing and the inflammatory 
response. Recent studies have provided exciting new evidence of the 
complexities and far-reaching influence of this system, which may 
86 
have profound effects on several homeostatic mechanisms. 
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CHAPl'ER 6 
~~TERIALS AND MtTHODS FOR STUDY OF FIBRINOLYTIC MECHANISMS 
IN THE VITREOUS 
88 
INTRODUCTION 
The techniques and reagents used for experiments relating to 
fibrinolytic mechanisms in the vitreous are described in this chapter. 
Two approaches were adopted in these studies. In the first, the 
fibrinolytic activity of the normal vitreous was investigated and 
for these experiments in vitro techni~ues were used. In the second 
phase of the study, fibrinolysis within the vitreous during the re-
absorption of experimental vitreous blood clots was investigated. 
An in vivo rabbit mod.el for vitreous clot lysis was established, and 
the. extracted vitreous clots characterised for fibrin and FDP using 
biochemical and immunological techniques. 
IN VITRO TECHNIQUES 
lI.ATERIALS 
The anticoagulant used for collection of blood from rabbits by 
intracardiac puncture was acid citrate dextrose (0.085M sodium citrate; 
0.065M citric acid; 0.2% dextrose). The proportions were one part 
ACD to eight parts whole blood. The blood was centrifuged at 2000G 
o for 15 minutes and the supernatant plasma stored at -20 C. Human plasma 
was obtained from healthy volunteers, after collection of whole blood in 
o 
0.13M sodium citrate pH 1.0, and stored at -20 C. 
Human plasminogen-rich fibrinogen was obtained from Kabi Pharma-
ceuticals, Stockholm, and was 90% protein clottable. Bovine plasminogen-
rich fibrinogen was obtained from Sigma Chemical Co. Ltd., London, and 
contained 68% clottable protein. 
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Bovine thrombin 'topical' was obtained from Parke, Davis and Co., 
Detroit, Michigan, and was prepared as a stock solution of 100 NIH u/ml 
and stored at _20oC. 
Streptokinase (Varidase; streptokinase/streptodmnaselOO,OOO u/ml) 
was obtained fro~~Lederle Laboratories, and stored at _20oC. 
The following reagents were obtained from British Drug Houses, 
Poole, U.K.: casein, which was stored at _20oC as a 5 per cent solution 
in phosphate buffered saline; sodium azide; glycine; tetramethylethy-
lene diamine puriss; acrylamide and bisacrylamide which were mixed 
as a stock solution of 22.5 per cent and 0.615 per cent respectively 
in distilled water and stored at 4°C; sodium dodecyl sulphate; ~-mercaPto-
ethanol; crystalline urea; Folin Ciocaltean's phenol reagent; and 
tyrosine. 
Urokinase was supplied by Leo Laboratories Ltd., Lonion. 
Tris-saline buffer contained O.05M tris (hy1roxymethol) amino-
methane-HCl and O.OlM NaCl, pH 1.4. 
Veronal buffer (double strength) pH 1.2, was prepared by dissolving 
4.lg sodium barbitone, l1.0g sodium chloride and 161.2 ml of N/IO hydro-
chloric acid in distilled water to a final volume of one litre. 
Owren's buffer, pH 1.35, was prepared by dissolving 11.15g sodium 
diethyl barbitone, 14.1g sodium chloride, and 43 ml N hydrochloric acid 
in distilled water to a final dilution of two litres. 
Phosphate-buffered saline, pH 7.6, was prepared as a solution of 
O.25M disodium phosphate in O.~ sodium chloride. 
Polyacrylamide gel electrophoresis buffer, pH 1.2, was prepared 
by dissolvine 8.82g of sodium hypophosphate, 25.3g diso1ium hypophosphate, 
and 2.0g of sodium dodecyl sulphate in distilled water to a final dilution 
of one litre. 
Agar was obtained from Difco Laboratories, Detroit, Michigan. 
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Trasylol was obtained from Bayer Ltd., Germany. 
Ammonium persulphate was used as a 1.5~ solution in distilled 
water. 
Anti-rabbit fibrinogen serum was obtained from Hoechst Pharma-
ceut icals Ltd., Germany. 
Sepharose-4B was obtained from Pharmacia, Uppsala, Sweien. 
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All centrifugations were done in an International PR-2, Servall 
o 0 RC-2 or MSL-6L centrifuge at 0 C to 4 c. Ultracentrifugation of 
vitreous samples was performed in a Beckman L5-50 ultracentrifuge at 
oOe to 4 oC. 
Vitreous samples 
Samples of vitreous were obtained as described in Chapter 3. 
Studies of the fibrinolytic activity of normal vitreous from human, 
dog and sheep eyes were performed on samples obtained by the aspiration 
and dissection techniques (P. 39) while vitreous samples from rabbit 
eyes containing blood clots (see later) were obtained by the freezing 
method (p. 40 ). 
Estimation of fibrinolytic activity 
Two methods were used in these experiments; the fibrin plate 
method of Nillson and Olow365 and the euglobulin lysis time
67
• 
(a) The Fibrin Plate method 
This method proviies a semiquantitative assessment of plasmino-
gen activator activity in the presence of constant levels of plasminogen 
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and fibrinogen. The method is based on measuring the areas of 
lysis produced in standard plasminogen-rich fibrin layers by fibrino-
lytically active materials, which are placed as drops on the surface 
of the fibrin. The reproducibility and accuracy of the method have 
365 been demonstrated • 
1 ml aliquots of a plasminogen-rich fibrinogen solution (250 
mg/ml) in distilled water were diluted with 24 mls of Tris buffer and 
poured into planar perspex dishes (12 cm diameter). The solution was 
clotted with 0.5 ml bovine thrombin (50 NIH u/ml) using constant 
~gitation to ensure thorough mixing of the solutions. The plates were 
allowed to become firm by incubating at 4°C for One hour. 
Test samples (0.03 ml) were pipetted onto the surface of the 
fibrin plates and incubated at 37 0 C for 24 hours. Areas of lysis were 
measured and fibrinolytic activity of the samples related to a standard 
curve, using urokinase as the standard activator (see Chapter 1). 
(b) Euglobulin lysis time 
This method is based on the assumption that the euglobulin 
precipitate of plasma is free of inhibitors of fibrinolysis67• Con-
sequently, the lysis time of a clot prepared from the redissolved euglobu-
lin precipitate containing plasminogen and fibrinogen, is a reflection of 
plasminogen activator activity within the plasma sample. The method is 
used to test fresh plasma samples for plasminogen activator activity, since 
plasma activator is considerably labile. By using stored plasma, which 
has minimal activator activity, the techni~ue can be moiified to test for 
activator activity in samples added to the euglobulin precipitate before 
clotting. 
Euglobulin precipitates were prepared from human plasma by adding 
9.5 mls of 0.014% acetic acid to 0.5 ml human plasma. The tubes were 
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inverted and allowed to stand for 10 minutes at 4°C. After centri-
fugation at 6000G for ten minutes, the precipitates were redissolved 
in 0.5 ml Owren's buffer, and vitreous or buffer added. The samples 
were clotted with 0.5 ml thrombin (2 NIH u/ml) and incubated at 37°C. 
The time necessary for the clot to dissolve was noted. 
Fibrinogen estimation 
Fibrinogen was estimated in samples of vitreous by the method 
of Ratnoff and ~enzie417. In principle, this method requires prior 
clotting of fibrinogen within the sample by an excess of thrombin; the 
fibrin concentration is then measured by a protein assay using Folin 
Ciocaltean's phenol reagent and a tyrosine standard (200 me/I O.IN HCl). 
0.2 ml vitreous was added to 10 mls 0.9% saline in crushed glass and 0.05 
ml bovine thrombin added. The reaction proceeded for 10 minutes at 4°C 
after which the samples were centrifuged at 2000 r.p.m. for 5 minutes. 
The supernatant was removed and the glass beads washed twice with saline. 
One ml of 10% NaOH was added to the beads and the samples boiled for ten 
minutes. Seven mls distilled water and 3 mls 20% Na2C03 were added and 
the samples thoroughly mixed. The reaction was completed with the 
addition of 1 ml Folin's reagent. After 30 minutes at room temperature, 
the samples were centrifuged at 2000 r.p.m. and the absorbance at wave-
length 650 nm read on a SP6-400UV spectrophotometer (pye Unicam) and 
compared with a standard tyrosine solution. The concentration of 
fibrinogen (f) was calculated from the formula: 
f (mg/IOO ml) = 
Plasminogen estimation 
A650 sample 
A650 standard x 11.7 x 500 x 1 10 
. 426 
Plasminogen was assayed by the method of Remmert and Cohn as 
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modified by A1kjaersig et a14. In principle, this method is based on 
the conversion of plasminogen to plasmin, which is then measured by 
caseino1ysis. Acid-treated plasma and vitreous samples (0.5 ml N/6 
plus 0.5 m1 sample for 15 minutes; reaction stopped with 0.5 m1 N/6 
NaOH, followed by 1 ml 0.25M phosphate buffer) were added to 0.5 m1 
streptokinase and the mixture incubated with 2 ml casein at 37°C 
(total volume 5 m1s). After two minutes, 2 m1s of the sample was 
withdrawn and added to 2 m1 of 10% trichloracetic acid. After 62 
minutes, a further 2 ml of the sample was withdrawn and treated 1ike-
wise. Both tubes were centrifuged at 600G for 10 minutes, and one m1 
of the supernatant was added to 1.5 ml of diluted Folin's reagent 
(1 part: 3 parts of distilled water). The reaction was allowed to 
proceed for 30 minutes, and the extinction at 650 nm read. The values 
were compared to known values for standard tyrosine solution as for 
fibrinogen assay. 
Estimation ofo(2-macroglobulin,~l antitrypsin and fibrin degradation 
products 
The radial immunodiffusion technique of Mancini, Carbonera and 
~8 Hergmans was used for the quantitative estimation of these proteins 
in vitreous samples. The method is based on the diffusion of proteins 
in agar gels which have been impregnated with specific antiserum. Protein 
solutions in wells cut in the agar gels diffuse outwards in a radial 
fashion and produce immunoprecipitation rings which are measured visually. 
The concentration of protein in the solution is directly proportional to 
the diameter of the ring. 
Six m1s of 0.9% saline containing antiserum to the protein was 
o 
mixed with 6 mls of 2% agar in double strength Veronal buffer at 56 
for a few minutes, before being poured into a plastic petri dish, diameter 
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8.5 cms, depth 1.5 cm. 5~1 samples were placed in wells in the agar 
gel, together with dilutions of standard protein solution whose content of 
the appropriate protein were known. The plates were incubated in a moist 
chamber for 48 hours at 400 C and the diameter of the precipition rings 
measured after staining with 10% tannic acid. A standard curve for the 
square of the diameter of the precipition ring against the concentration 
of the protein was drawn, and the values for the unknown vitreous samples 
interpolated from the curve. Minor modifications in the technique were 
required for different experiments and these are described in the 
appropriate sections. 
Fibrin analysis 
The detection and quantitation of fibrin within vitreous samples 
was carried out by polyacrylamide gel electrophoresis in sodium dodecyl 
sulphate, as described by Weber and Osborne545 • This method is generally 
regarded as an accurate and quantitative method for identifying proteins 
in solution on the basis of their molecular weight. The gels were pre-
pared at 7.5% acrylamide concentration by mixing together 0.045 mls 
tetramethylethylene diamine puriss, 1.5 mls 1.5% ammonium persulphate, 
3.5 mls distilled water, 10 mls of a stock solution of 22.5% acrylamide/ 
0.675% bisacrylamide and 15 mls gel buffer in the order stated. The 
solution was applied to glass cylinders (0.5 cm x 15 cm) and allowed to 
stand for 45 minutes at room temperature. The cylinders were fitted to 
a disc electrophoresis column rack (Shandon Ltd., London) and 2;Ul Bromo-
phenol blue applied to the top of each cylinder as a reference dye. 
20;Ul samples of vitreous extracts and standard solutions of known molecular 
weight were then applied to the top of each gel, and electrophoresis pro-
ceeded at 7-8 milliamps per tube for four hours, in the presence of gel 
buffer diluted one to one with distilled water. Power was supplied with 
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a Savant Power Pack (Hocksville, New York). After electrophoresis, 
the gels were stained with 0.45~ coomassie brilliant blue in 7% glacia1 
acetic acid for 2-4 hours and destained in 7% acetic acid for 24-48 
hours. Fibrinogen and fibrin were identified within vitreous samples 
by comparing gel bands with standard solutions, and quantitated by 
densitometric scanning of the gels at 600 nm on a Gilford spectre-
photometer with scanning attachment. The Y dimer peak heights were 
compared with known concentrations of crosslinked rabbit fibrin. 
Preparation of rabbit fibrinogen 
10 pl of Trasylol (10,000 u/ml) was added to 10 mls citrated rabbit 
whole blood, and the plasma withdrawn after centrifugation at 20000 for 
10 minutes. An equal volume of a 25% saturated solution of ammonium 
sulphate was added, and the precipitate recovered after further centri-
fugation. The sample was redissolved in saline, and the procedure re-
peated. Precipitation was then effected with an equal volume of 2.7M 
glycine, and this material dissolved in Tris buffer, after recovery of 
the precipitate by centrifugation. 
Preparation of rabbit fibrin 
Rabbit fibrin clots were prepared from fresh rabbit plasma by 
incubating citrated plasma with bovine thrombin (10 NIH u/ml) in the 
presence of calcium ions at 37°C, and allowing the reaction to continue 
for 2 hours to ensure crosslinking of the fibrin. The clot was 
thoroughly washed for 24 hours in O.~ saline, ani prepared for gel 
electrophoresis in the same manner as the vitreous extracts (see below). 
Preparation of Rabbit Haemoglobin 
Rabbit red cells were obtained from whole blood after centri-
fugation of citrated blood at 400G for 5 minutes. The leukocyte-rich 
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plasma was aspirated and discarded. The red cells were lysed with 
distilled water and the sample centrifuged at. 3000G for 20 minutes. 
The haemoglobin-rich supernatant was then applied to a column of 
sepharose-4B (30 em high by 1.7 cm diameter), previously equilibrated 
with Tris-buffer, and calibrated with protein solutions of known 
molecular weight. The sample was eluted with Tris buffer and the 
eluate corresponding to the haemoglobin peak (mol. wt. 50,000 to 
100,000) collected and run on SDS-polyacrylamide gel electrophoresis 
as described above. 
IN VIVO TECHNI~UES 
MATERIALS 
Animals 
White New Zealand rabbits weighing 3-4 kgs were used. 
Anaesthetics 
Pentobarbital sodium (Abbott Ltd., London) was used for intra-
venous administration while topical anaesthesia was achieved with 
Amethocaine 1% eye drops (Smith and Nephew Ltd.). 
Other ocular solutions 
Chloramphenicol 0.5% and Atropine l~ eye drops were obtained from 
Smith and Nephew Ltd. 
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Anaesthesia 
The rabbits were anaesthetised by the intravenous infusion of 
sodium pentobarbital (20 mg/kg weight) through the marginal ear vein. 
Anaesthesia was considered adequate when the corneal reflex was no 
longer elicited, and was maintained for the duration of the experiment 
by intermittent infusion of pentobarbital and the application of topical 
amethocaine drops. Recovery from anaesthesia usually occurred 30-60 
minutes after the experiment was complete. 
Induction of vitreous clot 
The eyelids were retracted with a speculum and the right eye of 
each animal was softened by withdrawing 0.15-0.20 ml aqueous from the 
anterior chamber using a 25-gauge needle inserted through the limbus. 
The eye was immobilised by fixing the superior rectus muscle and 0.2 ml 
whole blood was withdrawn from the marginal ear vein into a silicone-
coated plastic syringe.· Under ophthalmoscopic control, the blood was 
injected immediately into the centre of the vitreous gel through the pars 
plana in the anterosuperior quadrant of the globe with a 27-gauge needle. 
A short pause was taken before the needle was sharply withdrawn from the 
eye. No tracking of blood under the conjunctiva occurred, and it was 
assumed that the entire volume of blood was retained within the vitreous. 
Chloramphenicol 0.5% and Atropine l~, drops were instilled into the lower 
fornix at the end of the operation. 2-3 hours following the operation, 
the anterior chamber was usually reformed, although in some cases a longer 
time elapsed before it was re-established to its normal depth. 
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Ophthalmoscopic Observations 
The resolution rate of the vitreous clot in vivo was followed 
by ophthalmoscopy at weekly intervals. The degree of opacification 
of the vitreous was arbitrarily scored according to the scheme shown in 
Table 6.1. 
Preparation of the vitreous extract for FDP estimation and gel 
electrophoresis 
At various stages throughout the course of the experiments, rabbits 
were sacrificed and the eyes enucleated immediately and transported to 
the laboratory on ice. The entire vitreous was removed by the freezing 
technique (p.40) and centrifuged at 2000G for five minutes. 10 )11 
of Trasylol (10,000 u/m1) and 10 NIH units of bovine thrombin were added 
to the supernates which were recentrifuged at 1750G for 15 minutes and 
o 
stored at -20 C. The residual solid vitreous clot was washed for 24 
hours in 0.85% saline, and then dissolved in 1 ml of 8M urea. To each 
sample, 0.1 ml of a ten per cent solution of sodium dodecyl sulphate 
plus a similar volume of ten per cent ~ -mercaptoethanol were added. 
o The samples were incubated at 37 C for 24-48 hours, and run on po1y-
acrylamide gels as described. 
Histology 
Selected eyes from various animals were fixed in 2-4% phosphate-
buffered glutaraldehyde for 24-48 hours and processed for histology. 
method is fully described in Chapter 11. 
The 
TABLE 6.1 
Stage 1 
Stage 2 
Stage 3 
Stage 4 
Stage 5 
CLINICAL STAGING OF VITREOUS OPACITY 
Completely opaque vitreous 
Slight increase in red reflex, but 
no fundal detail visible 
Partly visible fundal details, 
through gaps in vitreous opacity 
Central vitreous clear; residual 
small opacities present 
Completely clear vitreous. 
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CRAPrER 7 
FIBRINOLYTIC ACTIVITY OF THE NORrtillL VITREOUS 
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INTRODUCTION 
Fibrinolytic activity within ocular tissues has been described 
by several authors and, as for other organs, the degree of activity 
of any one ocular tissue can be correlated with its vascularity273. 
Thus, the choroid and the retina are known to contain high levels of 
activity while the lens and the vitreous have been described as 
fibrinolytically inactive273 ,382. It should be noted that this 
relationship does not hold true for all ocular tissues, since the 
avascular cornea contains plasminogen activator activity, located 
within the epithelium382 , a fact recently confirmed by tissue culture 
experiments279• Release of this activity is apparently related to 
cell desquamation383• In adjition, a fibrinolytic activator is 
present in primary and plasmoid. ac;ueous humour and. in the canal of 
SChlemm452 • 
A relationship between the level of fibrinolytic activity and 
the rate of tissue repair within the eye has been proposed. Thus, 
th chor I'd d t' h' h ' h' I' t' t 278,382 e 0 an re Ina, w lC are rIC In p asmlnogen ac Iva or 
undergo rapid healing when injured. Aqueous fibrinolytic activity may 
I h 1 , b t t ' 383 a so ave a ro e In keeping the outflow pathways free of 0 s rue Ion 
and in clearing blood and inflammatory exudates from the anterior 
chamber452 • By contrast, the slow resolution of vitreous blood clots 
has been attributed to low fibrinolytic activity within the sClera273 , 
but is more likely to be due to lack of activity within the vitreouS 
itself. Although the existence of a "vitreous proactivator" of 
423 l' t d' fibrinolysis has been postulated ,ear ler s u les suggested that the 
t " "t 273,382 vitreous does not contain activator ac IVI y • The present study 
undertaken t o determine whether components of the fibrino-was therefore 
lytiC system were present in normal vitreous. The study included assays 
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for plasminogen, fibrinogen, plasminogen activator and inhibitors of 
fibrinolysis. 
~~TERIALS AND N~HODS 
VITREOUS SA~~LES 
Seven human, ten dog and seven sheep eyes were used for these 
experiments. Vitreous samples were obtained by the aspiration 
technique (Chapter 3). To exclude all possibility of contamination 
from other ocular structures, fluid vitreous samples were centrifuged 
o 
at 4000 r.p.m. for 20 minutes at 4 C, and only the crystal clear 
supernatant vitreous humour used for estimation of fibrinolytic 
activity. 
PLASMINOGEN and FIBRINOGEN 
These were assayed by the methods described in Chapter 6. 
PLASMINOGEN ACTIVATOR 
Plasminogen activator activity was assessed in samples of vitreous 
by the fibrin plate technique, and by a modified euglobulin lysis time 
using stored human plasma. The principles on which these methods are 
based are discussed in Chapter 6. 
Fibrin plate method 
Bovine and human fibrin plates were prepared as described 
(Chapter 6). Triplicate samples of vitreous (0.03 ml) were pipetted 
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onto the fibrin layer and the plates incubated for 24 hours at 3',oC. 
Heated fibrin plates and plates containing e-amino-caproic acid (EACA) 
-2 
a synthetic inhibitor of fibrinolysis, at 10 molar concentration were 
also used. Tests were also performed on samples of vitreous which had 
been incubated for varying lengths of time at room temperature and at 
Plasminogen concentrations in the fibrinogen preparations were 
assayed as described (Chapter 6). For standardisation of fibrinolytic 
activity, known concentrations of a reference standard solution of uro-
kinase were tested in triplicate on human and bovine fibrin plates and 
equivalent mean values for lysis areas of vitreous interpolated on a 
log/log graph. 
Modified Euglobulin Lysis Time 
The euglobulin lysis time is a measure of the concentration of 
inhibitor-free plasminogen activator in fresh plasma. Using stored 
plasma, which has little or no plasminogen activator activity, euglobulin 
precipitates were prepared as described (Chapter 6) and redissolved in 
0.5 ml O.OIM Owren's buffer. 0.5 ml vitreous was added and the mixture 
clotted with 0.5 ml thrombin, 1 NIH unit/mI. Clot lysis times were 
then compared with controls using 0.5 ml O.OlM Owren's buffer in place 
of vitreous. -2 A further control was used which combined EACA at 10 M 
concentration with the euglobulin precipitate. 
INHIBITORS OF FIBRINOLYSIS 
The concentration of inhibitors of fibrinolysis within human 
hn " 308 vitreous samples was estimated by the radial immunodiffusion tec 1que 
(Chapter 6). Commercial diffusion plates were used (Partigen, London) 
in which antisera to~ antitrypsin and~ macroglobulin were incorporated 
into the 1% agar support at a 4% concentration. Duplicate 5)Ul samples 
10) 
of human vitreous were placed in wells in the agar, and the inhibitor 
concentrations estimated by measuring the diameter of the immuno-
precipitation rings after 48 hours and comparing this value with a 
standard curve of known protein concentration (Chapter 6). 
RESULTS 
PLASMINOGEN and FIBRINOGEN 
Neither of these proteins was detected in vitreous samples from 
any of the species tested, using the present assay methods. 
PLASMINOGEN ACTIVATOR 
Fibrin plate method 
Areas of lysis were observed in human and bovine fibrin plates 
for human, dog and sheep vitreous (Fig. 1.1) and the results expressed 
in equivalent Ploug units of urokinase as described in Materials and 
Methods (Tables 1.1, 1.2, Fig. 1.2). Some species difference in 
activator activity occurred since slightly higher levels were noted in 
human than in dog or sheep samples. Activator levels in the vitreous, 
however, were always low, ranging from 10-30 Ploug units of urokinase 
per ml of vitreous. Areas of lysis on bovine fibrin plates were 
greater than on human fibrin plates, but this may have been a refleetion 
of the higher concentration of clottable protein in human fibrin 
(Chapter 6). The plasminogen concentration of bovine and human fibrino-
gen used in this study were 0.10 and 1.13 casein units respectively. 
No lysis was obtained on heated plates, nor on plates containing 
EACA. This indicated that the activity was due specifically to 
Figure 7. 1 o Bovine fibrin plates were incubated at 37 C for 
24 hours with human vitreous samples . Areas 
of lysis on the fibrin plates are denoted by the clear zones 
(arrows) . 
RESULTS 
TABLE 7.1 
Vitreous plasminogen activator activity 
on human fibrin plates 
No. of Eyes Human Dog Sheep 
1 0.61* 0.46 0.38 
2 0.60 0.66 0.34 
3 0.56 0.46 0.47 
4 0.63 0.55 0.31 
5 0.61 0.58 0.38 
6 0.60 0.63 0.52 
7 0.55 0.64 0.52 
8 0.45 
9 0.59 
10 0.49 
Mean 0.59 0.55 0.43 
Standard dev. 0.028 0.08 0.08 
S.E.M. 0.01 0.03 0.03 
Activator activity is expressed as equivalent Ploug units 
of urokinase interpolated from Fig& 1.2. 
*Values represent mean of triplicate samples. 
P = 1.35 (human vs dog) 
P = <. 0.0005 (human VB sheep) 
TABLE 7.2 
Vitreous plasminogen activator activity, 
on bovine fibrin plates 
No. of eyes Human Dog Sheep 
1 0.61 0.31 0·91 
2 0.65 0.39 0.61 
3 0.49 0.37 0.44 
4 0.62 0.35 0.41 
5 0.68 0.36 0.56 
6 0.51 0.42 0.34 
7 0.58 0.47 0.36 
Mean 0.59 0.38 0.51 
Standard dev. 0.07 0.05 0.19 
S.E.lol. 0.03 0.02 0.01 
Activator activity is expressed as equivalent Ploug units of 
urokinase interpolated from Fig.2. 
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Figure 7.2 Standard log curves for areas of lysis on human and 
bovine fibrin plates with a reference urokinase 
solution scale. 
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plasminogen activator within the vitreous, and excluded the presence 
of other protease or plasmin activity. 
A time-course study indicated that the degree of lysis was pro-
portiona1 ~o the time of incubation of vitreous with fibrin on a 
logarithmic basis (Fig. 7.3). However, no lysis was seen for the 
first two hours of incubation, which possibly indicated complex 
enzymatic relationships during this period. 
The rate of disappearance of plasminogen activator activity 
within the vitreous of dogs was assessed following incubation of the 
vitreous for varying lengths of time at room temperature and at 37°C 
(Tables 7.3, 7.4). Some reduction in activator activity was observed 
at room temperature, which indicated that vitreous plasminogen activator 
was predominantly stable, but contained a labile component. 
Modified Euglobulin Lysis Time 
The clot lysis times noted when vitreous was incubated with 
stored plasma euglobulin precipitates were considerably shorter than 
in controls using buffer (Table 7.5). Lysis times in the controls 
represent the diminished activator activity of the stored plasma; 
therefore, the shortened lysis times of the vitreous samples su~gest 
the presence of plasminogen activator within the vitreous. When EACA 
was combined with the euglobulin-vitreous mixture, no lysis occurred 
after 24 hours. This further supported the evidence that the 
fibrinolytic moiety within the vitreous is indeed plasminogen activator. 
INHIBITORS OF FIBRINOLYSIS 
Samples of human vitreouS (5jUl) failed to produce a precipitin 
. . t antisera to human~ macroglobulin in radial immunodiffusion rlng agalnS '2 
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Figure 1.3 Areas of lysis due to vitreous samples on human fibrin 
plates were first detectable after approximately two 
hours and increased linearly with time when plotted on a log/log 
graph. 
TABLE 1.3 
Vitreous plasminogen activator activity observed 
following incubation of samples at room temperature 
Incubation period (hours) 
No. of Eyes 0 3 6 24 48 (Dog) 
1 0.46 0.0 0.33 0.36 0.12 
2 0.53 0.31 0.36 0.35 0.24 
3 0.61 0.54 0.17 0.24 0.35 
4 0.61 0.47 0.48 0.42 0.37 
5 0.48 0.53 0.50 0.44 0.41 
6 0.46 0.48 0.45 0.62 0.48 
1 0.53 0.51 0.50 0.51 0.35 
8 0.46 0.44 0.51 0.49 0.39 
Mean 0.52 0.41 0.41 0.43 0.34* 
Standard dev. 0.06 0.18 0.11 0.12 0.11 
S.E.M. 0.02 0.06 0.04 0.04 0.04 
* P <'0.001 (time 0 vs time 48) 
Activator activity is expressed as equivalent Ploug units 
of urokinase interpolated from Fig.2. 
TABLE 7.4 
Vitreous plasminogen activator activity observed 
following incubation of samples at 37°C 
Incubation period (hours) 
No. of Eyes 0 3 6 24 48 (dog) 
• 
1 0.60 0.44 0.53 0.69 0.57 
2 0.72 0.40 0.60 0.59 0.60 
3 0.64 0.47 0.38 0.44 0.59 
4 0.61 0.42 0.49 0.44 0.57 
5 0.51 0.]3 0.50 0.53 0.59 
6 0.53 0.48 0.56 0.42 0.79 
7 0.53 0.50 0.53 0.47 0.49 
Mean 0.59 0.46 0.51 0.51 0.60 
Standard dev. 0.07 0.05 0.07 0.09 0.09 
S.E.M. 0.03 0.02 0.03 0.40 0.03 
Activator activity is expressed as equivalent Ploug units of 
urokinase interpolated from Fig.2. 
TABLE 7.5 
Modified euglobulin lysis time 
Clot lysis time (hours) 
No.of Eyes Vitreous Buffer 
(Dog) sample Control 
1 1.30 15.34 
2 1.75 16.25 
3 0.75 6.45 
4 1.25 7.25 
5 1.05 7.40 
6 1.25 8.25 
7 1.30 9.25 
• 
IVlean 1.23 10.03 
standard dev. 0.30 4.04 
S.E.rIf. 0.11 1.53 
Significance P < 0.0005 
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plates, although a faint immunoprecipitation line was detected between 
human vitreous and 0(1 antitrypsin. Quantitation against the standard 
concentration curve indicated that the totalo(l antitrypsin-like protein 
concentration within the vitreous was 10± 2.3~g/ml. 
DISCUSSION 
The presence of activator activity within the vitreous, as shown 
by this study, contrasts with the findings of Pandolfi, Coccheri and 
382 273 Astrup and Kwaan and Astrup • Using a slightly different fibrin 
plate technique382 and Todd's histochemical technique273 , they reported 
high activity in the choroid, moderate activity within the retina and no 
activity within the vitreous body. Their samples were incubated for a 
o 
shorter period of time at 37 C than the samples in this study. However, 
this study has shown that lysis of fibrin under the influence of 
vitreous activator usually begins within one to two hours of incubation 
at 37°C (Fig. 7.3) and by twelve hours, appreciable iysis has occurred. 
It is probable that the present observations of vitreous activator reflect 
the improved sensitivity of the fibrin plate method of Nillson and 01ow365 • 
Activation of the plasminogen-plasmin system in vivo may be achieved 
by blood or tissue activator, each of which is identifiable by its physical 
characteristics (see Chapter 5). Blood activator is labile and is rapidly 
destroyed at room temperature, whereas tissue activator, while having a 
'd Hl5 labile component, is for the,greater part thermostable, even at aCl p • 
Tables 7.3 and 7.4 show the relative stability of vitreous activator at 
d t 37°C. room temperature an a It is possible that the slight reduction 
in activity which was observed with vitreous activator at room temperature 
may represent the labile component of tissue activator, or it may injicate 
that vitreous activator is partly derived from blood activator. However, 
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a greater proportion of the activity was retained at room temperature. 
In addition, vitreous activator caused lysis of human and bovine fibrin, 
and as such conformed with the activity of direct tissue activator, 
unlike indirect activators which only cause lysis of human fibrin. In 
this respect, vitreous activator differs from that found in aqueous, 
which causes lysis of human fibrin on1y45 2• Thus, it appears that 
vitreous activator is true tissue activator. In view of the nature of 
the vitreous body, i.e. a modified connective tissue, it would seem 
reasonable that its content of plasminogen activator should_derive 
from tissue activator. 
Current theory suggests that the source of tissue activator is 
the endothelium of blood vessels, particularly those in actively growing 
tissues (see Chapter 5). Since the vitreous is avascular, plasminogen 
activator within this tissue may be produced by the surrounding ocular 
tissues and thence enter the vitreous by diffusion. HOhever, tissue 
activator is strongly cell-bound and is not readily released by endo-
thelial cells, except when cell death occurs13. In addition, it would 
be expected that diffusion of activator into the vitreous would be re-
tarded by the molecular sieve effect of the vitreous macromolecules, 
such as hyaluronic acid403 • Since the molecular weight of tissue 
activator occurs within the range of 57,000-80,000 (see Chapter 5), 
this retardation effect would be quite marked. 
An alternative hypothesis is that the plasminogen activator of 
vitreous is related to its fixed tissue cells, since many cell types 
including blood and epithelial cells, are known to synthesise and secrete 
plasminogen activator (see Chapter 5). Freeman et al157 have demonstrated 
proteolytic activity related to the lysosomal and microsomal fractions of 
vitreous cells, and it has been further shown that such organelles are 
associated with the production of plasminogen activator277• In fact, 
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the paucity of cellular elements in the vitreous may be directly 
related to the low levels of fibrinolytic activity in the vitreous. 
The low concentration of fibrinolytic components within the 
vitreous may have considerable bearing on the physioloCical removal 
of blood and fibrin deposits. Clearly, the virtual absence of in-
hibitors of fibrinolysis would promote a more rapid removal of such 
material. It is also worth noting that the absence of inhibnors 
may be further compounded by the "peptone" effect, whereby inhibitors 
of fibrinolysis introduced into the vitreous during,bleeding may be 
effectively removed by the polyelectrolyte, hyaluronic acid, as 
proposed by Astrup and Rosa14 (See Chapter 5, "peptone effect" of 
acid polysaccharides). However, the very low levels of plasminogen 
activator activity (10 to 30 equivalent Ploug units of urokinase per 
ml in the present study, see Tables 7.1, 7.2) would militate against a 
rapid clearance of blood clots. 
SUMMARY 
The vitreous bodies of human, dog and sheep eyes were examined 
for the presence of components of the fibrinolytic system. Fibrinogen, 
plasminogen, and~2 macroglobulin were not detected in normal vitreous, 
and only trace levels of~l antitrypsin were found. Plasminogen activator 
activity of normal vitreous was also found to be low (10-30 equivalent 
Ploug units of urokinase per ml of vitreous) and it is suggested that 
this may contribute to the delayed resolution of vitreous haemorrhage 
in vivo. 
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CHAPrER 8 
IN VIVO FIBRINOLYSIS WITHIN EXPERIMENTAL VITREOUS BLOOD CLOTS 
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INTRODUCTION 
It has been shown that blood will clot in the presence of 
vitreous in vitro (Chapter 4) and other stu1ies suggest that, at 
least in the experimental situation, clotting will also occur in 
vivo when the blood invades the vitreous ge1223,421,458,490. The 
evidence for this is based mainly on the histological demonstration 
of fibrin within vitreous blood clots223 , 458. While considerable 
attention has been paid to such processes as haemolYSis l96 , phago-
cytosis224 and membrane formation (see Chapter 13) within resolving 
vitreous clots, fibrinolytic mechanisms have rarely been studied. 
Regnault422 injected 125I_labelled human fibrinogen into rabbit 
vitreous and found that the half-life of fibrinogen was four days, 
with no trace of radioactivity after twenty days. He suggested 
that "spontaneous lysis" of fibrin was the initial step in the re-
solution of vitreous clots. 
In the previous chapter, it was shown that, although plasminogen 
activator activity was present in normal vitreous, the level of activity 
was low, and it was suggested that this was a fact or in the delayed 
resolution of vitreous clots. The object of the experiments described 
in this chapter was to provide biochemical evidence for the presence 
of fibrin within vitreous blood clots in vivo, and to study the process 
of fibrinolysis by recording the progressive removal of fibrin from the 
vitreous and by searching for intravitreal soluble FDP. 
MEl'HODS 
ANIMAL MODELS 
White New Zealand rabbits (300-400 kg) were used. The method of 
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anaesthesia and the induction of vitreous blood clots has been described 
in Chapter 6. The resolution of the vitreous clots was monitored weekly 
by ophthalmoscopy for a period of eight months following the injection of 
blood into the vitreous. Rabbits were sacrificed in pairs at various 
time intervals, and the globes enucleated immediately ani transported 
on ice to the laboratory. 
PREPARATION OF THE VITREOUS EXTRACT 
This has been described in Chapter 6. The normal vitreous of the 
fellow eye was removed in similar fashion and served as a control. 
FIBRIN ANALYSIS 
The detection and quantitation of fibrin within the vitreous clot 
was carried out by SDS-polyacrylamide gel electrophoresis, using 7.5~ 
qcrylamide gel as described in Chapter 6. 
PREPARATION OF STANDARDS 
Control samples of rabbit fibrinogen, fibrin and haemoglobin 
were prepared as described in Chapter 6. These samples were run on gels 
as standards, as were samples of normal rabbit vitreous and streptokinase-
plasmin-incubated vitreous clots. 
DETECTION OF FDP 
The concentration of FDP within the supernatant from the vitreous 
clot was estimated by the radial immunodiffusion technique (see Chapter 
6). Anti-rabbit fibrinogen serum was incorporated into the 1% agar 
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support at a concentration of 0.4%. 
PLASMINOGEN ACTIVATOR ACTIVITY 
The fibrin plate technique was used to measure plasminogen 
activator activity of the supernatant from vitreous clots, while the 
normal vitreous from the fellow eye served as the control. 
RESULTS 
OPHTHALMOSCOPY 
The changes occurring in a resolving experimental vitreous clot 
have been documented by several workers 300 ,422,458. The degree of 
vitreous opacity was staged according to clinical criteria described 
in Chapter 6. Following the injection of blood, a circumscribed clot 
occupied the central vitreous for 24-48 hours. From the third day, 
however, the vitreous became homogeneously opaque (Stage 1) (Fig.8.1). 
Numerous strands gradually developed throughout the vitreous with some 
increase in red reflex occurring about 4-5 weeks after injection (stage 
2). Fragmentation of the clot with fundus details visible (Stage 3) 
usually occurred between six and ten weeks. By twelve to sixteen 
weeks, most eyes had reached Stage 4 (clear central vitreous,residual 
small opacities) or Stage 5 (completely clear vitreous). However, in 
some rabbits, residual small opacities remained for up to thirty-two 
weeks after injection of blood, although very little solid material 
was obtained from the vitreous after ten weeks. 
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Ophthalmoscopic Appearance 
of Vitreous 
• Stage 1: Completely Opaque 
[J Stage 2: Increase in Red Reflex 
~ Stage 3: Fundus Visible 
Between Fragmented Vitreous Opacities 
o Stage 4: Central Vitreous Clear; 
Residual Small Opacities 
o Stage 5: Completely Clear 
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The degree of vitreous opacification was staged by 
clinical criteria as described in the figure. Each 
bar represents one animal, and the top of each bar corresponds to 
the time of sacrifice. It can be seen that by twelve weeks, most of 
the eyes had reached stage 4 of clot resolution and by twelve to 
sixteen weeks, stage 4-5· 
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FIBRIN ANALYSIS 
Rabpit crosslinked fibrin (Fig. 8.2(a» proiuced two prominent 
bands corresponding to the ~ chain and t ({ dimer of the polymerised 
fibrin molecule (Lorand, 1972). The bands representing the 0( and i{ 
monomers indicated that the fibrin was not fully cross1iI~ed. Normal 
rabbit vitreous (Fig. 8.3(c» contained no proteins with molecular 
weights corresponding to the fibrin chains, but several other soluble 
proteins were present282 • Solubi1ised extracts from the solid vitreous 
clots of varying duration produced ban:is corresponjing to the ~ monomer 
and )5 i dimer chains, indicating the presence of strongly crosslinked 
l fibrin within the vitreous for up to five weeks following clot formation 
(Fig. 8.2(b) to (f». No fibrin was detected after this time (Fig. 
8.2(g) and (h». Several other lower molecular weight proteins were 
noted with two prominent bands appearing at molecular weights of 32,000 
and 16,000 da1tons (Fig. 8.2(x) and (y». The lower band was thought 
to represent a monomer and the upper band a dimer of the constituent 
chains of the haemoglobin molecule, since two broad bands were observed 
in identical positions when rabbit haemoglobin was run on SDS po1yacryla-
mide gel, as described in Chapter 6. It was not clear why the globin 
molecule was not fully depolymerised by the ~ -mercaptoethanol, but it 
may be related to the fact that the chain of rabbit globulin is not a 
single polypeptide but a mixture of closely related proteins229• It 
was considered that the presence of haemoglobin bands on gel electro-
phoresis of the vitreous extract probably represented protein released 
from intact red cells within the vitreous clot by the extraction pro-
cedure with 8M urea, since any free haemoglobin would have been removed 
during the preliminary washing procedure. These results indicated, 
therefore, that intact red cells were present for at least nine weeks 
yy 
a 
y 
x 
Figure 8. 2 SDS-polyacrylamide gel electrophoresis of r abbit vitreous 
clots . (a) crosslinked r abbit fibrin , (b) - (h) rabbit 
vit~ous clots solubilised with SDS and ~-mercaptoethanol , (b) 2 days , 
(c) one week , (d) 2 weeks , (e) four weeks , (f) five weeks , (g) six 
weeks (h) nine weeks after injection df whole blood into the vitreous . 
~ ,~, ~ and i~ dimer bands represent the constituent chains of the 
fibrin molecule . X, Y bands represent haemoglobin chains. 
yy 
a b c 
Figure 8. 3 SDS polyacrylamide gel electrophoresis of rabbit 
vitreous clots . (a) control rabbit vitreous clot 
showing prominent ~ and ~~dimer fibrin chains , (b) streptokinase-
plasminogen incubated vitreous clot showing absence of ~ and ~15 dimer 
fibrin chains , (c) normal rabbit vitreous . 
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after clot induction. 
Confirmation of the presence of fibrin with the vitreous clots 
was obtained by the disappearance of the ~ and <s i bands following 
incubation of the clot with streptokinase-plasminogen (Fig. 8J). The 
qUantity of fibrin estimated by gel scan spectrophotometry is shown in 
Table 8.1. Removal of the fibrin occurred progressively during the 
first six weeks of resolution. 
DETECTION OF FDP 
Precipitation rings in the radial immuno-diffusion plates sur-
rounding the wells with supernatant vitreous were observed for up to 
six to eight weeks, following the injection of the blood (Fig. 8.4). 
Inconsistent results were obtained after this time, there generally 
being no FDP after two months. The concentration of FDP was estimated 
by interpolation from a standard curve of rabbit fibrinogen concentrat-
ion VB square of ring diameter. Throughout the period of resolution 
of the clot, the level of FDP was low (Table 8.2). 
in normal rabbit vitreous (Fig. 8.4). 
PLASMINOGEN ACrrIVATOR ACTIVITY 
No FDP were found 
Fibrinolytic activity of the vitreous was similar, following 
vitreous clot formation, to that of normal control samples, irrespective 
of the age of the clot (Table 8.3). Values were expressed in equivalent 
mean values of urokinase (Chapter 7). 
TABLE 8.1 
CONCENTRATION OF FIBRIN IN VITREOUS CLOTS 
Time after 
induction of 
vitreous clot 
2 days 
4 days 
1 week 
2 weeks 
4 weeks 
6 weeks 
Fibrin 
concentration 
mg/ml 
0.105 
0.130 
0.150 
0.038 
0.021 
nil 
Figure 8.4 Radial immunodiffusion plates . Agar support contained 
O . 4~ antirabbit fibrinogen serum. The supernatants from 
extracts of rabbit vitreous clots were placed in upper wells (top row) . 
Immunoprecipitation lines were observed as shown (arrows) . Diffuse 
haloes round each well were due to non- fibrin related proteins, mainly 
haemoglobin . Lower wells contained normal rabbit vitreous . 
TABLE 8.2 
FDP concentration in supernates from 
extracts of vitreous clots 
Time after Sample FDP p.g/ml induction of 
vitreous clot No. Test Control 
2 dayS~ 1 10 nil 2 18 nil 
4 dayS~ 1 8 nil 2 8 nil 
8 dayS~ 1 5 nil 2 5 nil 
2 weekS~ 1 10 nil 2 14 nil 
4 weeks~ 1 8 nil 2 8 nil 
5 weeks? 1 8 nil 2 47 nil 
6 weeks 1 nil nil 
8 weeks~ 1 nil nil 2 10 nil 
TABLE 8.3 
Plasminogen activator activity in vitreous 
extracts during vitreous clot resolution, 
expressed as equivalent Ploug units of urokinase 
Sample Time after Test Control ind.uction of No. 
vitreous clot 
1 0.40 0.31 2 days 
2 0.41 0.39 2 weeks 
3 0.43 0.46 4 weeks 
4 0.00 0.42 4 weeks 
5 0.41 0.41 8 weeks 
6 0.41 0.38 8 weeks 
1 0.40 0.35 32 weeks 
8 0.31 0.35 32 weeks 
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DISCUSSION 
These experiments have provided biochemical evidence for the 
presence of fibrin within experimental vitreous clots and have shown 
that it took five weeks for fibrin to be removed from rabbit vitreous 
following the injection of 0.2 ml autogenous whole blood. This time 
sequence is slow in comparison with other tissue deposits of fibrin273 
and it is probably related to the low levels of plasminogen activator 
activity within the vitreous (see Chapter 7). Current theories of 
thrombolysis (see Chapter 5) suggest that the rate of fibrin digestion 
is dependent on the plasminogen activator concentrations in the surrounding 
medium, and the present results would support this. In addition, a 
second factor in the delayed clearance of blood from the vitreous is 
suggested by the type of fibrin within a vitreous clot. Lorand and 
Jacobsen298 have sho~n that crosslinked fibrin is more resistant to 
digestion by plasmin than fibrin monomer.* The experiments 
reported here clearly showed that fibrin within experimental vitreous 
clots was fully crosslinked, since there was no evidence of the 0.... or 
(( monomer on SDS polyacrylamide gel electrophoresis (Fig. 8.1). Thus, 
the rate of intravitreal fibrinolysis would have been further reduced. 
Also noteworthy was the constant level of plasminogen activator 
activity within the vitreous during clot resolution. Studies of 
fibrinolysis in other tissues have shown that there is an initial transient 
decrease in activator levels, followed by a rise in activity during the 
f h 1· 514 later stages 0 ea lng • This secondary rise is related to the in-
*FOOTNOTE: It should be noted, however, that these findings have 
d · t d414 recently been lSpU e • 
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growth of new vessels into healing tissues. The absence of this 
rise in activity in resolving vitreous clots would suggest an impair-
ment of the healing process and, in particular, absence of ingrowing 
vessels into the vitreous. The morphological studies reported in 
Chapters 12-14 would support this concept. 
Whatever the reasons for slow intravitreal fibrin digestion, it 
is clearly important to relate fibrinolysis to the whole of vitreous 
clot resolution. At least three processes are involved in the 
clearance of blood from the vitreous: haemolysis, fibrinolysis and 
phagocytosis by inflammatory cells. Horven224 has shown by auto-
radiography that red cells cannot be reabsorbed intact from the 
vitreous into the general circulation, but that they must first be 
derraded and their breakdown products reabsorbed. 
using 51Cr tagged red cells, confirmed that haemolysis is a rate-
limiting step in vitreous clot resolution. The presence of FDP within 
the soluble component of the vitreous (Table 8.2) indicates that plasmin-
mediated fibrinolysis also occurs in resolving vitreous clots and further-
more, the data suggest that haemolysis and fibrinolysis are simultaneous 
processes (Fig. 8.1), since the concentration of haemoglobin, which in 
the present study was a measure of residual intact red cells in the 
vitreous samples (see above), became progressively less. It is possible 
that the two processes are inter-related. 
The role of inflammatory cells in fibrin removal from the vitreous 
is more difficult to define. It has been noted that leukocytes may 
clear fibrin either by fibrinolytic means, or by non-fibrinolytic pro-
tease digestion (Chapter 5). In addition, stimulation of the inflam-
. 529 
mator,y response in the vitreous by short bouts of hyper-pyrexla or 
by immunogenic or non-specific uveitis44 has been reported to enhance 
the rate of clearance of vitreous blood. By contrast, suppression of 
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the inflammatory response with systemic ACTH retarded the rate of 
vitreous clot remova1458 and was associated with a reduced vitreous 
macrophage count. However, this latter finding could not be con-
firmed by Benson et a144 • 
Maberly and Chisholm300 confirmed the accelerated clearance of 
vitreous blood due to inflammation, in this Case induced by the intra-
vitreal injection of an inactivated fibrinolytic enzyme, streptokinase/ 
streptodornase. However, these authors also observed that the active 
enzyme produced an even more rapid clearance, and suggested that clot 
lysis was due to the fibrinolytic effect of the enzyme rather than the 
inflammatory response alone. These results have been confirmed by our 
own group, using the fibrinolytic enzyme urokinase148• 
It is probable that both the inflammatory response and fibrino-
lysis, either separately or by interrelation, are relevant to the 
clearance of vitreous blood. The distinction between the two processes 
within the context of fibrin digestion may be artJficial, but whatever 
the mechanism, fibrinolysis is an integral part of vitreous clot lysis. 
SUWJI,ARY 
The process of fibrinolysis was studied in resolving vitreous clots 
in rabbits. The rate of fibrin degradation and removal was considered 
to be slow in comparison with other tissues, and the expected rise in 
tissue plasminogen activator activity during clot resolution was not 
observed. The relationship between haemolysis, fibrinolysis and the 
inflammatory response, and their importance to vitreous clot lysis, are 
discussed. 
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CHAPI'ER 9 
THE EFFECT OF FIBRINOLYTIC INHIBITION ON THE RESOLUTION OF 
VITREOUS CLOTS 
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INTRODUCTION 
The data presented in' Chapters 7 and 8 suggest that the slow 
resolution of vitreous clots may be due, at least in part, to the 
low levels of plasminoren activator activity within the vitreous. 
To explore this possibility further, the experiments described in 
this chapter were undertaken. By using synthetic inhibitors of 
plasminogen activator, it was hoped that the role of fibrinolysis in 
vitreous clot removal could be isolated from other factors such as 
haemolysis and inflammatory cell activity which, it was assumed, 
would remain unaffected. It has been observed previously that such 
agents have little effect on leukocyte fibrin-splitting protease 
activity (see Chapter 5). 
This approach to the study of wound healing processes is not 
new. Indeed, the concept of fibrinolysis in the regulation of tissue 
repair originates from ideas proposed by Fleisher and Loebl~O at the 
beginning of this century (see Chapter 5). When suitable techniques 
became available, it was shown that fibrinolysis played a significant 
part in connective tissue repair274 and that inhibition of fibrinolysis 
in rats led to disordered wouni healing, with an exaggerated fibro-
blastic response275 • More recently, it has been suggested that, in 
addition to local tissue activator, secretion of plasminogen activators 
by monocytes and macrophages may prove essential for wound healing to 
proceed normally187• Leibovich and Ross294 showed that, although 
polymorphonuclear leukocytes migrated normally into skin wounds in 
monocyte-depleted guinea pigs, macrophages failed to accumulate in the 
wound area, with the result that there was a delay in the removal of 
fibrin, red cells and extracellular debris from the wound. In addition, 
fibroplasia and re_epithelialisation were retarded. Other studies have I I 
I 
l 
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shown a requirement for a normal polymorphonuclear response in fibrin 
clearance434 , and it is likely that the full expression of the inflam-
matory reaction is necessary for normal wound healinr:. Thus, although 
fibrinolysis is generally regarded as the major pathway for fibrin 
clearance from wounds (Chapter 5), the most recent evidence indicates 
that it may be difficult to separate fibrinolytic mechanisms from 
inflammatory cell activity in vivo. Indeed, the results of the present 
experiments suggest a close correlation between fibrinolysis and the 
inflammatory response in the clearance of blood clots from the vitreous. 
rtlATERIALS AND METHODS 
ANH'IAL MODELS 
New Zealand white rabbits, weighing 3-4 kgs each, received 0.5 g 
of 4 amino-methyl-cyclohexane-carbonic acid (AMCHA) in their drinking 
water daily. In preliminary experiments on six rabbits, this dose of 
AMClIA completely suppressed fibrinolytic activity of normal vitreous, 
when tested by the fibrin plate technique (Chapter 6). In the present 
experiments, 14 A~CHA-treated animals were tested, with 16 untreated 
controls. 
INDUCTION OF VITREOUS CLOTS 
This has been described in Chapter 6. The rate of clearance of 
the vitreous clot was monitored at weekly intervals by direct and in-
direct ophthalmoscopy, and the degree of vitreous opacity was graded on 
a scale of 1-5, as described (Chapter 6). Animals were sacrificed at 
the time intervals indicated in the Results and the vitreous was ex-
tracted immediately by the freezing techni~ue (Chapter 3). 
!tl,... 
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Preparation of the vitreous extract 
Vitreous extracts were prepared for fibrin analysis on 7.5% 
polyacrylamide gel electrophoresis in sodium dO.iecyl sulphate, and 
detection of FDP as described in Chapter 6. 
HISTOLOGY 
Two eyes from AMCI~-treated rabbits were prepared for histology 
(see Chapter 11) after 36 weeks of observation. The globes were fixed 
in phosphate-buffered glutaraldehyde, embedded in paraffin and stained 
with haematoxylin and eosin, periodic acid schiff reagent, Van Gieson's 
stain and Mallory's phosphotungstic acid haematoxylin for the detection 
of fibrin. 
RESULTS 
OPHT~LMOSCOPY 
The ophthalmoscopic appearances of vitreous clot resolution in 
the rabbit have been described (Chapter 8). In this study, all nine 
surviving control rabbits had reached Stage 4, and three had reached 
Stage 5, 12 weeks after the injection of blood into the vitreous (Fig. 
9.1). In contrast, none of the eight AMCHA-treated rabbits, permitted 
to survive to twelve weeks, had progressed further than Stage 2, and 
after thirty weeks, five of the six surviving rabbits had reached only 
Stage 3. 
HISTOLOGY 
After 36 weeks of observation, histological examination of the 
Figure 9.1 
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Ophthalmoscopy: Vitreous clearance rate. Each 
bar represents one rabbit. The various shades 
represent the stages of resolution of the haemorrhage (see Figure 8.1). 
The top of each bar indicates the time of killing of each rabbit. Control 
rabbits killed before 12 weeks are excluded from the figure. A significant 
reduction in the vitreous clearance rate in the AMeBA-treated group is 
shown. 
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vitreous opacities in two AMCHA-treated rabbits revealed the presence 
of clumps of intact red blood cells (Fig. 9.2) associated with a few 
large macrophages (Fig. 9.3) and surrounded by thin strands which were 
presumed to be vitreous collagen. 
FIBRIN ANALYSIS 
The presence of strongly cross-linked fibrin was observed within 
the vitreous of AMCr~-treated rabbits for up to six weeks, as shown by the 
~ and ~~dimer bands (Fig. 9.4), with no evidence of theo( or ~ monomer 
chains. This contrasted with the previous observation of fibrin within 
untreated rabbit vitreous clots for up to five weeks only (Fig. 8.2). 
After six weeks, densitometric scanning of the gels from AMeliA-treated 
rabbits failed to detect fibrin within the vitreous, in spite of the 
presence of considerable clot debris at this stage (Table 9.1). However, 
prominent gel bands representing haemoglobin were present for periods up 
to forty weeks (Fig. 9.4), indicating the persistence of numerous intact 
red blood cells within the residual material. In untreated rabbits, 
these bands had mostly disappeared by twelve to sixteen weeks (Fig. 8.2). 
DETECTION OF FDP 
While FDP at low concentration (8 to 20)Ug/ml) were detected in 
< 
control rabbit vitreous, no FDP were detected in AMeHA-treated rabbits 
at any stage up to forty weeks (Table 9.2). 
of the test was lJUg/ml. 
The limit of sensitivity 
Figure 9. 2 Histological appearance of vitreous opacity from 
AMeHA- treated rabbit after 36 weeks . Numerous 
intact red blood cells are present . Several abnormal forms of 
erythrocytes are also shown. X400 . 
Figure 9. 3 Histological appearance of vitreous opacity from 
AMeHA- treated rabbit after 36 weeks . A clump of 
large macrophages , some of which are multinucleate , is shown. X350 . 
haemoglobm 
a c d 
Figure 9.4 SDS-polyacrylamide gel electrophoresis of vitreous clot 
extracts from AMeBA-treated rabbits; (a) Typical cross-
linked rabbit fibrin from plasma , showing prominent ~ ando-~dimer bands . 
Trace amounts of 0( chain present indicate incomplete cross-linking of 
fibrin . (b) and (c) Strongly cross-linked fibrin in vitreous clot ex-
tracts is shown by- the presence of ~ monomer and 6'/ odimer bands . No 0<. 
or t monomer is present . (d) to (g) 
after six weeks , (b) four weeks ; (c) 
(e) ten weeks ; (f) 20 weeks and (g) 
Absence of fibrin bands in vitreous 
six weeks ; (d) eight weeks; 
40 weeks. Haemoglobin bands 
persist for up to 40 weeks of observation , indicating the pres ence of 
significant numbers of intact red blood cells for the duration of the 
experiment . 
TABLE 9.1 
Concentration of fibrin in extracts of vitreous clots 
Time (wks) after 
induction of 
vi treous clot 
1 
4 
6 
8 
12 
20 
40 
Fibrin concentration mg/ml 
Control AMCHA-
(untreated) treated 
0.150 not tested 
0.010 0.059 
nil 0.040 
nil nil 
nil nil 
nil nil 
nil nil 
TABLE 9.2 
FDP concentration in supernates from vitreous extracts 
during vitreous clot resolution 
Time (wks) after FDP concentration (mg/ml) 
induction of Control AMCHA-
vitreous clot ( untreated) treated 
1 20 nil 
4 8 nil 
6 14 nil 
8 10 nil 
12 8 nil 
20 nil nil 
40 nil nil 
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DISCUSSION 
This study has shown that inhibition of rabbit vitreous fibrino-
lytic activity produced a slight, but probably not significant delay in 
the removal of fibrin from the vitreous (Table 9.1). However, the 
absence of FDP within the supernatant vitreous extract from the Art.CHA-
treated rabbits confirmed tl.e inhibition of plasmin-mediated fibrinolysis 
and suggested that the removal of the vitreous clot fibrin was achieved 
by other means, such as direct macrophage activity288. Paradoxically, 
there was a significant delay in the rate of clearance of the vitreous 
opacity in the AMeBA-treated rabbits as compared to the untreated control 
(Fig. 9.1). Both histological (Fig. 9.1) ani biochemical (Fig. 9.4) 
analyses of the vitreous showed that a large proportion of this visible 
blooi mass was composed of intact red blood cells. Since red blood 
cells within the vitreous are generally removed by macrophage endo-
t . 194,224,369 th . t f· 1 t cy OS1S , e perS1S ence 0 v1treous red blood cel s sugges s 
that either the phagocytic ability of the incoming macrophages was im-
paired, or that the cellular response within the vitreous was diminishei. 
~any endogenous agents enhance leukocyte migration towards foci of 
inflammation555 including FDp34,324,485. Hence, the absence of FDP in 
the AMCBA-treated rabbits may have contributed to a reduced cellular 
response within the vitreous. Indeed, the poor resolution of vitreous 
haemorrhages in general (see Chapter 1) may be caused by a low level of 
chemotactic factors. In vitro studies have shown that maximum chemo-
/ 485 tactic effect is elicited byFDP at a concentration of 100 to 300?g ml 
In untreated rabbit vitreous clots, the FDP levels were consiierably 
lower (8-20 )lg/ml; Table 9.2). FDP concentration within the range 
lOO-400 jUg/ml have been observed in rabbit vitreous clots treated with 
the plasminogen activator, urokinase, and were associated with a 
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significantly more rapid rate of vitreous clearance148• Therefore, 
indirect evidence sug€:ests that low levels of fibrinolytic activity in 
the vitreous may be partly responsible for the poor rate of clearance 
of the vitreous clot, not only by prolonging fibrin removal, but also 
by fai ling to provide an adequate chemotactic stimulus. Such evidence 
may reflect the interdependence of fibrinolysis and the inflammatory 
response, which has already been emphasised. 
SUMMARY 
The effect of fibrinolytic inhibition on the resolution of 
vitreous clots in rabbit eyes was studied. Although there was only 
slight delay in the removal of intravitreal fibrin in AMeHA-treated 
rabbits as compared to controls, there was a significant reduction in 
the rate of red cell clearance. It is suggested that the absence of 
plasmin-mediated chemotactic factors led to an impaired phagocytic 
cellular response in the treated animals. Similar mechanisms may be 
of importance in the non-resolution of human vitreous haemorrhage. 
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PART 4 
THE PATHOLOGY OF VITREOUS HAEMORRHAGE 
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CHAPTER 10 
REV lEd OF THE LITERATURE ON PATHOLOGICAL CHANGES WITHIN 
THE VITREOUS AFTER HAEMORRHAGE 
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INTRODUCTION 
It is a long-held view that fibrous organisation takes place 
as part of the healing mechanism within non-resorbing vitreous clots, 
particularly if some "irritative" factor is present126 (see Chapter 1), 
and indeed the pathological changes that occur within a vitreous 
haemorrhage have been likened to those that occur within a healing 
wound. Experimental stuliies of skin wounds 52 , 379 have identified 
three phases in the evolution of the healing process: a phase of 
acute inflammation where an exudate of polymorphonuclear leukocytes 
and fibrin develops, a phase of demolition where tissue cells and 
inflammatory cells undergo autolysis and macrophages remove the 
debris, and a phase of granulation tissue formation where there is 
proliferation and migration of surrounding connective tissue elements. 
It is outside the scope of this thesis to review current knowledge of 
the wound healing process since this now encompasses several large 
areas of intensive scientific interest such as cell migration, 
mediators of inflammation ani endothelial cell proliferation. How-
ever, the simple concept described above is useful as a framework 
for the discussion of the process of blood reabsorption from the 
vitreous. 
Early investigators realised that little information concerning 
the pathophysiology of vitreous haemorrhage resolution could be gained 
from the study of clinico-pathological material, since in most cases, 
enucleated human eyes with vitreous haemorrhages are complicated by 
other changes, such as intractable glaucoma or severe perforating in-
juries. Experimental methods for the study of vitreous heamorrhage 
" P b t" 404 reabsorption, therefore, have been adopted, the f1rst by ro s 1ng 
and, almost exclusively, the animal model has been the rabbit. Several 
127 
aspects of this process have been investigated, incluiing the inflam-
matory cell response, red cell degradation and removal, fibrin degrad-
ation, and fibroplasia. However, as Cibis88 has observed, numerous 
technical problems have been encountered with the fixation and 
structural preservation of delicate vitreous tissue, and therefore 
non-histological techniques have often been employed. A brief review 
of previous work in this field is described here. 
THE INFLAMMATORY CELL RESPONSE 
This has been studied on several occasions since 18928),159,160,194, 
224,253,369,404,458 
• 
aray194 observed that in the first few hours after 
injection of blood into the vitreous, very little reaction had occurred. 
After twenty-four hours, inflammatory cells were seen invading the 
vitreous cavity, but there was a predominance of mononuclear cells, as 
compared to the marked polymorphonuclear cell reaction to injections of 
bacteria or dye into the vitreous. In the later stages, large macro-
phages were observed which were engaged in phagocytosis of red cells and 
detritus. Most of the other studies refer to the later stages of vitreous 
haemorrhage reabsorption, and in all cases, the presence of very large 
macrophages within the clot debris has been noted. 224 Horven drew a 
similarity between these cells and the compouni granular corpuscles of 
the brain, and was thus in agreement with WOlter568, who suggested, on 
morphological evidence alone, that such cells originated from microglial 
cells within the retina.~ 
HAEMOLYSIS OR RED CELL DEGRADATION 
Haemo1ysis has been considered an important stage in vitreous 
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haemorrhage reabsorption, and it can be regarded as the phase of 
demolition in the ~ound healing process. Radioactive tracer 
studies63 suggested that haemolysis was a rate-limiting step in 
vitreous clot resolution, although the experimental method was 
later questioned44 • Phagocytosis of red cells has been observed 
in all histological studies to date, and Horven224 sho~ed that red 
cells in the vitreous, unlike those in the aqueous, unierwent lysis 
before they were removed from the eye. Regnault422 further demon-
strated that haemoglobin was fully degraded to bilirubin and globin 
within the vitreous. This process probably occurs within vitreous 
macrophages. 
FIBRIN RElIiOVAL 
The degradation and removal of fibrin from the vitreous during 
vitreous clot lysis has rarely been studied. Occasional histological 
studies have testified to tte presence of fibrin within experimental 
vitreous clots, but fibrinolytic mechanisms per se have not been in-
vestigated. In Part 3 of this thesis, it has been shown that vitreous 
fibrinolytic activity is of a low order, and it has been suggested that 
this may be a factor in the delayed resolution of vitreous clots. The 
relationship between fibrinolysis and the inflammatory response during 
vitreous clot resolution has also been discussed (Chapter 9). 
FIBROUS ORGANISATION OF VITREOUS CLOTS 
The commonly-held belief that fibrous organisation occurs within 
non-resolving vitreous clots, is the counterpart of phase three in the 
wound healing process. However, it has not been clearly shown that 
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blood within the vitreous provides a sufficient stimulus for fibro-
blastic activity from the surrounding ocular structures. Most 
reports which described vitreous fibrosis after haemorrhage, con-
carned clinico-pathological case studies on severely injured eyes 
or on eyes that ~ere associated with retinal disease such as dia-
betic neovascu1ar proliferation or retinal vasculitis14l,255,261,281, 
330,355,401,441,513,528,546 
• Experimental attempts in animals to 
stimulate fibroblastic activity within the vitreous by injections 
of blood have had a varied response83 ,89,159,369,51l • Under these 
circumstances, vitreous fibrosis was normally associated with a 
traumatic injection procedure, involving perforation of the globe 
through the retinal layers with aspiration of vitreous159 ,404, or 
there was an associated retinal detachment83 ,159,369. In all cases 
where fibrous tissue formation was reported, the fibrosis took the 
form of an epiretinal membrane, and in no instance was fibroblastic 
activity found within the blood clot. Moreover, the incidence of 
fibrosis in the vitreous was low after a single blood injection. 
Only when cultured fibroblasts from the skin were injected intra-
vitreal1y was a high rate (7~) of intravitrea1 fibrosis achieved3• 
In contrast, several other workers have failed to report the presence 
of fibrosis after injection of blood into the vitreous194,196,300, 
422,458 ,529, and indeed on occasion have drawn attention to this 
fact194,281,)69,416. Gray194 noted that any fibroblastic activity 
in his specimens was associated with the injection wound in the 
scleral/choroidal coat of the eye, and that neither homologous nor 
heterologous blood deposits in the vitreous showed any tendency to 
fibroblastic or glial cell invasion. 
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CONCLUSION 
The pathological changes occurring within a resolving vitreous 
clot have been studied experimentally on several occasions, but con-
siderable controversy surrounds the sequence of events which typically 
occur. This is due possibly to the introduction of complicating 
factors, such as severe ocular trauma, in several of the studies. 
Little is known concerning the early stages of the inflammatory 
response, and the question of whether fibrous organisation occurs 
within uncomplicated vitreous clots remains unanswered. In addition, 
the process of intravitreal haemolysis merits further morphological 
study. The following chapters describe the histological and ultra-
structural changes within experimental vitreous clots, and the results 
are discussed in relation to the above points. 
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INTRODUCTION 
This chapter contains details of the techniques used for histo-
logical and ultrastructural studies of experimental vitreous clots. 
The difficulties surrounding the preparation and fixation of delicate 
vitreous tissue"have been referred to in Chapter 10. In adlition, 
it is common knowledge that routine sectioning of whole fresh rabbit 
eyes in the sagittal plane causes considerable tissue distortion due 
to differences in tissue hardness and shape between the lens and 
remaining ocular structures. For histological studies, therefore, 
a freezing technique was used which avoided gross tissue disturbance. 
Artefacts due to ice-crystal formation were not observed, and sat is-
factory tissue sections for light microscopy were obtained. For 
electron-microscopy, the eye was sectioned after fixation in a coronal 
plane which was chosen to avoid intravitreal structures. Pieces of 
tissue from the vitreous were then dissected under magnification. 
ANIMAL MODEL 
New Zealand white rabbits were used as before (Chapter 6). 
The rabbit is not the ideal model for comparison with the human in 
. 
the study of vitreous pathology, due to anatomical and biochemical 
differences (see Chapter 1). Rabbit vitreous contains more collagen 
and less hyaluronic acid than human vitreous, and the relative vitreous 
volume is considerably smaller. However, it was considered suitable 
for the purposes of this study, since the nature of the vitreous was 
similar in both species (i.e., a gel) and since the anatomic relation-
ships, if not the proportions, also bore a reasonable resemblance. 
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INDUCTION OF VITREOUS CLQT 
This has been described in Chapter 6. 
PRIMARY FIXATION 
Immediately after enucleation, the eyes were immersion fixed 
in 2-4% phosphate buffered glutaralde~de (Sorensen's phosphate 
buffer, 0.1M, pH 7.2-7.4) for 12-24 hours. Selected eyes for 
transmission electron microscopy were fixed in glutaraldehyde con-
taining a 3% solution of 0.2M sodium cacodylate buffer (pH 7.2-7.4). 
~~CROSCOPIC EXAMINATION 
PREPARATION OF THE TISSUES 
A freezing technique was used to avoid disturbing topographical 
relationships within the eye. The eyes were placed in polythene bags 
and immersed in a solution of carbon dioxide snow in acetone for 60 
seconis. The frozen globes were sectioned in a saggital plane through 
the pupil-optic nerve axis in most cases, using a Thiersch skin graft 
knife. A few eyes were sectioned in the coronal plane, 5 mm behind 
the lens. The frozen half-globes were placed on specially designed 
chucks and immersed in phosphate buffer. 
thaw, and photographed. 
LIGHT MICROSCOPY 
EMBEDDING PROCEDURE 
They were then allowed to 
Care was taken to ensure that the delicate vitreous tissue was 
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undisturbed during the tissue dehydration through graded alcohols 
and embedding procedures. The half-globes were embedded in Para-
o plast wax at a temperature of 15 C for 2-4 hours and 6-8)U sections 
taken. 
TISSUE STAINING 
The following tissue stains were used: 
1. Haematoxylin and eosin. 
2. Mallory's phosphotungstic acid haematoxylin (PTAH) for the 
demonstration of fibrin. In later experiments, Martius Scarlet Blue 
(MSB) was also used to detect fibrin. 
3. Masson for the demonstration of collagen. 
4. Modified Mallory trichrome for the demonstration of 
platelets76• 
5. Prussian blue for iron staining. 
6. Periodic acid-Schiff base to stain for carbohydrate. 
1. Elastic Van Giesen. 
Conventional staining procedures were followed. 
TRANSMISSION ELECTRON MICROSCOPY 
The above methods of preparing the tissues for gross and histo-
logical examination were considered unsuitable for electron microscopy 
Electron due to possible artefacts related to the·freezing technique. 
microscopic studies were therefore performed on a separate group of 
rabbit eyes. 
TISSUE DISSECTION AND PREPARATION 
After twenty-four hours in the primary fixation fluid, the eyes 
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were placed cornea down in eye cups. The posterior segment of the 
globe was removed with a Thiersch skin graft blade, 4 mm from the 
posterior pole of the eye. This plane of section was posterior 
to the vitreous clot, and thus did not interfere with the topographical 
relationships. Small segments of tissue ~ere dissected from the 
vitreous clot and membranes under magnification, using microsurgical 
scissors (Vannas) and forceps. 
SECTION PROCEDURE AND VIEWING OF TISSUE 
The tissue blocks were washed in phosphate buffer for at least 
two hours, after which they were post-fixed in 1% osmium tetroxide 
(TAAB laboratories) in cacodylate buffer. The tissue was then re-
washed in buffer, dehydrated through graded alcohols and embedded in 
Ara1dite (TAAB laboratories). Sections of tissue were cut using an 
LKB Ultratome III. Thick sections (1.0, 1.5, 2.0 um) were stained , 
with Toluidine blue and ultrathin sections (500-BoOAo with uranyl 
acetate and lead citrate. They were mounted on copper grids (100 
and 200 mesh) and viewed with a Phillips 301 electron microscope. 
ACID PHOSPHATE STAINING PROCEDURE 
Selected tissue segments were treated bya modification of the 
Gomori method for the demonstration of acid phosphatase activity, as 
described by Miller and Palade335• Sections were rinsed for twenty 
minutes to two hours in one to two changes of cold Na-cacodylate 
buffer (pH 7.4) and finally incubated for 15 minutes in fresh Gomori 
medium. This was composed of 0.12 g Pb(N03)2 in 100 ml 0.05M Na 
acetate buffer, pH 5.0, containing 7.510 0.22M sucrose to which 10 m1 
of 3% Na-f-glyceroPhosPhate was slowly added. Before use, the mix-
ture was warmed at 600 C for one hour, cooled to room temperature and 
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filtered to remove the slight precipitate which usually developed. 
After incubation, the sections were rinsed twice for one minute in 
cold 0.05M Na acetate buffer (pH 5.0) containing 1.5~ sucrose and 
2-4% glutaraldehyde, with a short rinse in 27:. acetic acid in between 
the two rinses of acetate-buffered glutaraldehyde. Controls from 
which the substrate was omitted were also run. 
SCANNING ELECTRON MICROSCOPY 
TISSUE DISSECTION 
The remainder of globe was partially sectioned in several 
meridional planes and each scleral flap was slightly stretched to 
expose the contents of the globe still further, but not to such a 
degree that rupture of the vitreous membranes occurred. In selected 
eyes, further dissection of vitreous tissue was performed to reveal 
the surface of specific structures such as the fibrin clot. 
TISSUE DRYING 
The tissue was freeze-dried using a procedure modified from 
61 that described by Boyde and Wood • The specimens were rinsed in 
distilled water and the superficial fluid removed on lint-free 
absorbent paper. They were then quenched in liquid Arcton12 
(boiling point -39°C, melting point -155°C) which had melted after 
first being solidified over liquid nitrogen. The boat was placed 
on a cold plate in the vacuum chamber of a Balzars micro BA3 freeze 
drying apparatus. 
of 1 x 10-5 Torr. 
Drying took place after eight hours at a pressure 
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COATING AND VIEWING OF THE DRIED TISSUE 
The dried specimens were mounted on standard viewing stubs 
with silver conducting paint (Acheson Colloids Co.) and coated with 
gold in a Polaron Sputter Coater E 5,000. The specimens were examined 
in a Cambridge Sterioscan S600 at accelerating voltages between 1.5 
and 25 KV. The machine was capable of an optimum resolution between 
200 and 300oA. 
138 
CRAPI'ER 12 
MORPHOLOGICAL STUDY OF VITREOUS CLOT LYSIS: 
GROSS AND HISTOLOGICAL APPEARANCES 
139 
INTRODUCTION 
Clinical and experimental studies on the pathology of vitreous 
haemorrhage have failed to establish a cause for the poor resolution of 
vitreous clots. This is partly the result of conflict of opinion 
concerning the natural history of vitreous clot lysis (see Chapter 10). 
Several aspects of the resolution process have been investigated in 
recent years, including haemolysis63 , 196 , Phagocytosis224 , membrane 
formation218 ,490 , connective tissue formation159,458,51l, fibrino-
lysis (see Part 2) and the ocular toxicity of blood422 and iron 
compounds89 • However, many years have elapsed since the last 
detailed morphological study of vitreous clot lysis194 • Although 
Regnault422 was the first to provide documentary evidence of the gross 
morphology of vitreous clot lysis, his illustrations were difficult to 
interpret and, in addition, there was no corresponding histological 
study. The present study was therefore undertaken to review the 
macroscopic and histological appearances of experimental vitreous 
haemorrhages. 
MATERIALS AND ~~HODS 
Forty-five New Zealand white rabbits were used in this study. 
The method for induction of vitreous clots is described in Chapter 6. 
The clearing of the blood from the vitreous was monitored weekly by 
direct and indirect ophthalmoscopy for per'iods up to 32 weeks after 
injection. The methods of macroscopic and histological examination 
of the eyes are described in Chapter 11. 
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RESULTS 
OPHTHALMOSCOPIC OBSERVATIONS 
The ophthalmoscopic observations of experimental vitreous clot 
lysis are described in Chapter 8 (see Fig. 8.1) in ~hich a numerical 
scoring system was used to record the degree of vitreous opacity. 
The findings are in agreement with most other studies63 ,159,196 , 
300,369,458,565 Substantial changes in the vitreous opacity began 
about four ~eeks after induction of the haemorrhage, and by 12 to 16 
~eeks, most of the surviving rabbits had reached stage 4 or 5. How-
ever, in some rabbits residual opacities remained for up to 32 ~eeks, 
~hen the experiment ~as concluded. 
MACROSCOPIC APPEARANCES 
T~enty-four hours after injection of blood into the vitreous, 
a large circumscribed clot ~as observed (Fig. 12.1a), ~ith smaller 
clotted masses delineating the needle track through the gel. No 
diffusion of blood hai occurrei, and the surrounding vitreous gel ~as 
uninvolved. After one week, however, several changes had occurred 
(Fig. l2.1b). Considerable haemo1ysis had led to uniform dark dis-
coloration of the vitreous cavity, presumably because of released 
haemoglobin pigment. The original blood clot no~ appeared as a pale 
globular mass that occupied the central vitreous. In addition, detach-
ment of the solid vitreous gel from the retina had occurred with the 
formation of many veil-like sheets of "collapsed" vitreous surrounding 
the central clot like a capsule (Fig. l2.1b, arro~s). Numerous con-
nections remained between this pseudocapsule and areas where vitreous 
Legends for Figure 12.1 
Time course of blood clearance from vitreous of rabbit: gross pathology 
(a) 24-hour haemorrhage. Circumscribed dark clot is shown in 
midvitreous space behind lens. Less dense clotted blood is 
also present as thin strands delineating the needle track through the 
gel from the injection site. 
affected. 
(b) One-week haemorrhage. 
Surrounding vitreous gel is not 
Vitreous cavity is diffusely, dark 
stained, probably due to red cell lysis. Original clot has 
become pale and globular. Extensive destruction of the vitreous gel 
has occurred, including detachment of the gel from the posterior retinal 
surface and formation of brown-stained fine sheets of tissue that appear 
to be surrounding the main clot mass. 
(c) Two-week haemorrhage. Vitreous is less darkly stained. Co-
alescence of sheets of tissue has occurred to form prominent 
single sheet or "vitreous membrane" extending across the vitreous cavity 
qnd encapsulating the clot that is now firmly adherent to the posterior 
lens surface. Detachment of the vitreous has continued, leaving a 
clear space behind the vitreous membrane. 
(d) Four-week haemorrhage. Almost complete detachment of the 
vitreous gel has occurred; only at optic nerve head does 
attachment between vitreous fibres and the posterior wall of the globe 
remain. Coloration of the vitreous is diffusely yellow-brown. 
(e) High-power view (d) showing dense pseudocapsule around the 
clot. 
(f) Six-week haemorrhage. Clot has disintegrated, leaving remnants 
of pseudocapsule surrounded by friable blood deposits. The 
Figure 12.1. 
vitreous is now fully detached and solid material is in close 
apposition to the lens surface. Posterior vitreous is clear and 
the vitreous fluid is xanthochromic. 
(g) Eight-week haemorrhage. Continued clearing of the blood 
deposits has resulted in some solid material remaining on 
lens surface and in the vitreous base. This represents remnants 
of the pseudocapsule plus associated non-resorbed blood. 
(h) Twelve-week haemorrhage. The vitreous is free of haema-
togenous material but the gel structure is considerably 
disturbed, as shown by its poor transparency. 
(i) Sixteen-week haemorrhage. Small residual blood deposits 
are seen at this stage within the vitreous, especially in 
the vitreous base and adherent to the posterior lens surface. Central 
vitreous ciear. 
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detachment was incomplete, e.g. the optic nerve ani the vitreous base. 
After two weeks, further changes had occurred (Fig. 12.10). The 
colour of the vitreous hal changed from dark red to yellow-brown. The 
original clot hai become smaller and less globular, an.i was in close 
apposition to the posterior lens surface. Vitreous detachment was now 
almost complete, and the blood clot was completely enclosed within a 
dense sheet of collapsed vitreous that often extenied across the vitreous 
cavity and was attached firmly to the region of the vitreous base (Fig. 
l2.1c,arrows); the posterior vitreous cavity behind the detached 
vitreous was clear. 
There was little change in the macroscopic appearance of the 
vitreous between two and four weeks after the original haemorrhage. The 
vitreous was stained diffusely yellow ani in some cases attachments per-
sisted between vitreous fibres and the optic nerve head (Fig. l2.ld). 
However, the remaining solid vitreous was fully detached and a well-
developed pseuiocapsule surrounded the pale clot (Fig. 12.1e). The 
clot itself now generally occupied a position in the lower half of the 
globe and the rest of the vitreous cavity was occupied by fluid. No 
gel vitreous remained. 
After six weeks, the fluid vitreous had become clearer and was 
now lightly xanthochromic. Considerable disintegration had occurred 
within the original clot, which was much reduced in size and appeared 
fibrillar, with cystic spaces (Fig. 12.1f). The pseudocapsule was 
friable and much less dense. No connections persisted between it and 
the posterior globe. Clot debris occupiei the vitreous base and the 
inferior portion of the globe, with residual material adhering to the 
posterior lens surface. The posterior vitreous cavity was clear. 
During the next four to six weeks, the amount of solid material within 
the vitreous gradually became less, with the persistence of fine 
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vitreous strands representing the remains of the pseudocapsu1e 
(Fig. 12.1g). 
After 12 to 16 weeks, the vitreous space was clear in half of 
the cases studied (Fig. l2.lh). Ho~ever, in several eyes, the re-
moval of blood was incomplete, and small amounts of clot debris per-
sisted for many weeks or months (Fig. l2.li). This material generally 
occupied the vitreous base or was adherent to the posterior lens cap-
sule and consisted of dark brown clot debris and strands. The amount 
of residual material varied considerably, and in some cases was no 
more than a very fine strand. 
HISTOLOGY 
The histological appearances closely paralleled the gross 
pathology. Thenty-four hours after blood injection, a clotted mass 
of red blood cells (RBCs) coated with a surface layer of fibrin occupied 
a distinct pocket within the gel and seemed to displace the normal 
collagenous fibrils of the vitreous (Fig. 12.2k). Sections of the 
clot stained with Masson's stain, showed large quantities of fibrin 
providing a framework for the clot (Fig. 12.2k), but there was little 
evidence of collagenous-staining material within the clot itself. The 
cellular response at this stage was minimal, occasional single round 
cells being observed (Fig. 12.2a). In particular, there were few 
polymorphonuclear (p~rn) cells. However, increasing numbers of cells 
were present in the vitreous after two days, usually in close associ-
ation with vitreous fibrils, and by the fifth day larger, more definite 
macrophage-type cells were observed, aggregated along the condensed, 
detached vitreous fibrils and in close proximity to RBC material that 
was trapped within the solid vitreous (Fig. 12.2b). 
Legend for Figure 12.2 
Time course of blood clearance from the vitreous: histology 
(a) through (g) cellular response. 
(a) 24 hours after induction of haemorrhage occasional small 
mononuclear cells are seen within the clot (Masson, x400). 
(b) By five days, greater numbers of large round cells with 
clear cytoplasm are seen adherent to vitreous fibrils near 
the ciliary processes (H and E, x400). 
(c) Ten day clot. Unusual stellate cell forms are seen within 
centre of fibrin clot, but significant inflammatory cell 
invasion of the clot has not occurred (Masson, x400). 
Three-week haemorrhage, posterior vitreous. Large 
quantities of amorphous darkly-staining material 
(PTAH, x400). Inset, cell free nuclei associated with amorphous debris 
(H and E, x400). 
(e) Four-week clot. Fresh, small mononuclear cells invading 
clot structure (H and E, x400). 
(f) Four week haemorrhage, posterior vitreous. Clump of large, 
effete macrophages associated with free, intact red cells. 
Macrophages are in various stages of aggregation, apparent fusion and 
degeneration. Total cellular infiltrate remains scanty. Few young 
monocytes observed after four to five weeks (Masson, x400). 
(g) Sixteen week haemorrhage. Residual vitreous macrophages 
form large cell aggregates and multinucleate giant cells 
(Masson, x400; inset: H and E, x400). 
Figure 12.2. 
(h) through (j) 
(h) 24 hour haemorrhage. Collagen fibrils coalesce to form 
a distinct layer round the clot (arrow), within which are 
trapped red cells and debris (Masson, x250). 
( i) Two week haemorrhage. Collagen fibrils coalesce to form 
a distinct layer round the clot (arrow) within which are 
trapped red cells and debris (Masson, x250). 
( j) Four week haemorrhage. Loose reticular clot (arrow) is 
enveloped by dense collagenous pseuiocapsule. No fibro-
blasts are noted (modified Mallory trichrome, x400). 
(k) through (n) 
(k) 24 hour haemorrhage. Large quantities of fibrin appear 
as pink fibres between compacted red cells (Masson, x400). 
(1) 
this stage. 
(m) 
(n) 
Four week haemorrhage. Reticular fibrin strands within clot 
(modified Mallory trichrome, x250). No fibrin was seen after 
Four week haemorrhage. 
cavity (Masson, x400). 
Free red cells in posterior vitreous 
Twenty four week haemorrhage. Intact red cells adherent to 
vitreous fibrils. 
several cells. 
Pykuosis and anisocytosis are evident in 
Most of the RBCs had been released from the central clot after 
one week, which, indeed, was suggested by the appearance of the clot 
as a pale globular mass on gross pathology (Fig. 12.1b). At this 
stage, the clot was characterised by a complicated entanglement of 
fibrin, with some intact RBCs and numerous smaller rounded bodies 
outlining the fibrin network (Fig. l2.2c). These probably represented 
platelet and RBC debris. Free-floating intact RBCs were found, 
especially in the posterior vitreous space, indicating that the original 
clot structure had become less compact. Cellular invasion into the 
clot itself was sparse. When cells were present, their outlines were 
indistinct and they appeared as stellate cells with projections that 
merged indefinably with the general fibrillar structure of the clot 
(Fig. 12.2c). No aggregated or multinucleated cells were observed. 
On the surface of the clot, collagenous fibres formed an outer coat, 
within the layers of which there was abundant RBC debris (Fig. 12.21). 
Apart from the appearance of several large multinucleate giant 
cells, there was little change in the appearance of two week old 
clots. There was, instead, a general increase in most of the 
features just described, namely, large numbers of degenerating, free-
RBGs within the posterior vitreous, substantial loosening of the clot 
framework suggesting clot lysis, thickening of the collagenous coat 
around the central clot, and a low-grade cellular response. 
After three weeks, however, large quantities of amorphous granular 
debris that stained differently from intact or haemolysed RBCs with 
Mallory's phosphotungstic acid-haematoxylin stain (Fig. 12.2d) were 
observed. In ajdition, loose macrophage nuclei were noted, often in 
association with this material, on staining with haematoxylin and eosin 
(Fig. l2.2d~ inset). These appearances suggested that aggregates of 
giant or multinucleate macrophages had lysed within the vitreous, 
releasing their cell contents. 
At one month, fresh mononuclear cells with very little cyto-
plasm (Fig. l2.2e) were seen in conjunction with older effete macro-
phages, which were in various stages of phagocytosis, aggregation and 
lysis, in clumps around still intact RBCs (Fig. l2.2f). The clot 
itself retained a well-defined reticular structure with some intact 
RBCs adherent to its framework, but most of the smaller debris had 
been removed from the clot (Fig. 12.21). The pseudocapsu1e which 
was very prominent on macroscopic examination was composed of con-
densed vitreous collagen with trapped RBCs forming a thick layer 
that enclosed the fibrin clot, and was continuous with collagenous 
material up to tte ora serrata (Fig. l2.2j). 
seen at any stage. 
No fibroblasts were 
From five weeks to two months after vitreous clot formation, 
RBCs, RBC debris, lysed cell prolucts, fibrin content anj the number 
of fresh macrophages decreased, whereas older macrophages in various 
stages of their natural life cycle persisted, and the collagenous 
pseudocaPsule became more prominent and adherent to the posterior 
lens capsule. 
at this stage. 
Iron staining within the macrophages was pronounced 
After two months, the histological appearances had altered con-
siderably. Almost all of the original clot had been removed, leaving 
intact RBCs and aggregates of large multinucleate effete macrophages 
in varying proportions (Figs. 12.2g and inset, 3g ani inset). The 
pseudocapsule remained, with RBCs and inflammatory cells within its 
layers, and it usually formed a membrane on the posterior lens surface 
or attached at various points to the ora serrata and the optic disc. 
No fresh invading cells were identified and all lysed cell material 
had been removed. Fibrin was not detectable after six weeks. 
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Between two and four months after clot formation, there was a 
reduction in the amount of residual material, but the response was 
variable. Several eyes became completely free of clot remnants, 
but in some, blood elements remained for many months. This usually 
took the form of intact, abnormally shaped RBCs (Fig. 12.2n), plus 
some very large, "spent" macrophages which were contained within a 
dense collagenous framework. 
No other ocular pathology was noted in any eye throughout the 
duration of this study. In particular, the retinal architecture, 
seen by light microscopy, remained unaffected. No new vessel form-
ation was observed on the retinal surface or the disc, and the retinal 
vessels themselves were normal. The first inflammatory cells that 
appeared in the vitreous after clot formation were noted in the area 
of the ciliary processes, in which the vessels were moderately dilated 
at this stage (two to three days). Iris, cornea and angle structures 
were unaffected by the presence of the vitreous clot. Some large in-
flammatory cells containing RBC debris and iron were occasionally seen 
within the stroma of the iris, but greater numbers of macrophages were 
noted within the trabecular meshwork and canal of Schlemm from the 
third to the twenty-eighth day. The time cours~ varied from rabbit 
to rabbit, these figures representing the range of values. Vitreous 
clot material adhered firmly to the posterior lens capsule in all cases 
as already described, but the body of the lens was not affected. 
DISCUSSION 
Several aspects of the pathophysiology of vitreous haemorrhage 
resolution are unusual, which may be a reflection of the unique nature 
of this connective tissue. For instance, although the tissue thrombo-
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plastic activity of the vitreous was found to be very 10w382 ,42l, 
whole blood clotted rapidly within gel vitreous (Fig. 12.1), in this 
case possibly as a result of Hageman factor activation by the vitreous 
(for a discussion of clotting mechanisms within the vitreous, see 
Chapter 4). In aidition, platelet aggregation by vitreous collagen 
may be important in loculating the blood mass within the vitreous gel. 
It has previously been shown that when purified platelet preparations 
were injected into rabbit or owl monkey vitreous, instantaneous plate-
let aggregation occurred on contact with the collagen fibrils l06• 
The fate of the various blood components after initial clot 
formation, and their effects on the structure of the vitreous have 
been reported on several occasions (see Chapter 10). Most of the 
RBCs that were released from the clot diffused into the posterior and 
inferior fluid vitreous where they were either phagocytosed by macro-
phages224 or underwent haemolysis and caused the generalised opacifi-
cation of the vitreous seen ophthalmoscopically. The RBCs appeared 
to be the seat of most of the phagocytic activity, but as has been 
shown biochemically in Chapter 8, their removal from vitreous was 
a slow process and was usually incomplete. The survival of RBCs 
within the vitreous for long periods of time has been recognised for 
many years455 , but the reason for their failure to excite an adequate 
cellular response remains unknown. 
The cellular response to vitreous blood clots was also unusual 
in several respects. The early p~m cell reaction typical of most 
o t 482,483 0 thO t dy Tho con forms of inflan~at1on was no seen 1n 1S S u. 1S -
firmed the differential cell counts of Gray194, who observed that mono-
nuclear cells accounted for more than 90%, of all leukocytes in the 
vitreous during the early stages of the cell response to vitreous blood 
deposits. This contrasted with other forms of vitreous inflammation, 
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such as those resulting from injection of bacteria and foreign 
particles, where PMN cells predominated at least in the early 
stages. In addition, the cellular response after vitreous haemor-
rhage in this study was sparse and was concentrated around isolated 
clumps of RBCs, while the main mass of the fibrin clot was poorly 
penetrated by cellular elements. Ho~ever, an interesting cell 
type was observed within the fibrin clot, ie. a stellate or dendriti-
form cell (Fig. 12.2c and Fig. 12.21). Recent in vitro studies have 
shown that such cell forms occur when blood monocytes are induced to 
generate clotting of fibrinogen. Indeed, monocytes have been de-
scribed as the "pro-clot" cell in contrast to basophils, which are 
known as "anti-clot" cells (see Chapter 2). It is possible that the 
appearances seen in vitreous clots represented the in vivo demonstration 
of such monocyte behaviour, although absolute identification of the cell 
type in the vitreous was not possible. 
As to the origin of inflammatory cells in the vitreous, it is 
generally recognised that most macro phages present in inflammatory re-
actions are derived from precursors in the bone marrow5l7• The kinetics 
of this system have been extensively investigated for lesion of the 
. t 525 . 1 d265 k' 481 db' 260 Th ., f perl oneum ,splna cor ,s ln an raln. e orlgln 0 
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vitreous inflammatory cells is not known, although Gloor has 
suggested that the cells which appear within the vitreous after photo-
coagulation lesions of the retina are marrow-derived. It is possible 
that the macrophages that appear in the vitreous after haemorrhage are 
also marrow-derived, although the role, if any, of the tissue histiocyte, 
in this case the hyalocyte of Balazs496 has not been fully investigated. 
In the present study, mononuclear cells first appeared in the region of 
the ciliary processes and rapidly increased in size as they ingested 
vast quantities of RBCs and detritus. Some of these cells later 
148 
migrated to the area of the trabecular meshwork44 , but the majority 
remained within the vitreous until by three weeks, having attained 
very large proportions, they underwent lysis. The appearance of 
fresh mononuclear cells within the vitreous at this stage suggested 
that a further chemotactic response had occurred. It is tempting to 
correlate this with the products of cell lysis which are known to be 
h t t ' , 't 58 c emo ac 1C 1n V1 ro • After approximately six to eight weeks, 
however, no new cells were seen by light microscopy and large effete 
macrophages were found in association with unphagocytosed RBCs in 
residual clumps, many weeks and months after the original haemorrhage. 
Electron microscopic studies have shown that occasional young mono-
nuclear cells were observed as long as eighteen months after haemor-
rhage (see Chapter 14). 
The fate of the fibrin component has been investigated bie-
chemically (see Part 2 of this thesis). The present histological 
study confirms the slow removal of fibrin from the vitreous (four to 
five weeks) and suggests that this delay may have been due not only to 
the low tissue fibrinolytic activity of the vitreous (see Chapter 7), but 
also to the absence of PIvlN leukocytes (see Chapter 5)434. In addition, 
the observation that platelet-fibrin aggregates within the vitreous 
106 160 , initiate a poor macrophage response ' was conflrmed in this study. 
The effects of haemorrhage on the gel structure of the vitreous 
are well recognised, especially detachment of the solid gel vitreous 
from the retinal surface43 ,159,369. However, the formation of a 
pseudocapsule by endogenous vitreous collagen has not been reported, 
, 217 369 
although reference has been made to an "endothel1al membrane" , • 
In addition, as the main clot mass was cleared away, the pseudocapsule 
remained as a dense collagen sheet with non-resorbed blood elements 
within its layers. It is noteworthy that in 45 consecutive blood 
U9 
injections into the rabbit vitreous, no fibrosis or fibroblasts were 
seen. The controversy surrounding the concept that blood can stimulate 
fibroblastic activity Las been discussed in Chapter 10, with the evidence 
for both aspects being considered. In the present study, despite the 
persistence of blood deposits in the vitreous for several months, no 
fibroblastic activity was detected. Collagenous material found in 
these cases appeared to be derived from a condensation of vitreous col-
lagen forming a pseudocapsule around the clot that remained after most 
of the clot was reabsorbed. 
CONCLUSION 
The present study of the pathology of vitreous clot lysis has 
revealed a number of interesting features. After initial clot formation, 
the blood mass remained as a discrete structure for four to six weeks, 
after which it became considerably reduced in size. In the vitreous, 
several changes occurred, including liquefaction of the gel, posterior 
detachment of the solid Vitreous, the appearance of prominent vitreous 
membranes, and the formation of a pseudocapsule around the clot. 
blood deposits remained in several eyes for many weeks. 
Small 
The cell response to blood in the vitreous was slow to develop, 
was low grade, and was predominantly mononuclear from the onset of 
inflammation. Mononuclear cells developed into giant macrophages 
which formed large aggregates and multinucleate cells were frequently 
observed. The reasons for this atypical inflammatory cell response 
to blood in the vitreous are not known, but its effects may be to delay 
the reabsorption of blood from the vitreous. 
The development of vitreous membranes and, in particular, the 
l~ 
pseudocapsule, appeared to result from coalescence of endogenous 
vitreous collagen fibrils, since fibroblasts ~ere not observed in 
any tissue sections. It is suggested that fibroplasia is an un-
usual sequel to uncomplicated vitreous haemorrhage, and is associated 
~ith ocular diseases in ~hich vitreous haemorrhage may be an incidental 
occurrence. 
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CHAPTER 13 
ELECTRON lIlICROSCOPY OF VITREOUS CLOT LYSIS: 
HAEMOLYSIS AND VITREOUS MEMBRANE FORMATION 
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INTRODUCTION 
In the previous chapter, analysis of the gross pathological 
and microscopic changes which occurred within the vitreous during 
clot resolution iniicated that at least four morphological processes 
were taking place simultaneously, i.e. red cell destruction or haemo-
lysis, fibrin removal or fibrinolysis, an inflammatory cell response, 
and the development of vitreous membranes, in particular a pseudo-
capsule around the clot. At least two of these changes were note-
worthy; firstly, the inflammatory response was atypical in cell con-
tent and degree, and secondly, vitreous membranes developed in the 
absence of significant fibroblastic activity. 
The lack of fundamental knowledge concerning the formation and 
structure of vitreous membranes has been alluded to by Freemanl55 • 
Several blood components such as Platelets106 , 1eukocytes278, lympho-
cytes329 and haemoglobin422 have been shown to proiuce vitreous membranes 
or strands, but such membranes were unlike those produced by whole blood 
(see Chapter 12) in that they were non-progressive, i.e. they remained 
unaltered for many months. There have been no ultrastructural studies 
of vitreous membrane formation during the process of vitreous clot 
resolution, although Smith et al476 described the electron microscopic 
features of human vitreous membranes from specimens obtained at 
Yitrectomy surgery. These membranes were composej of degenerating red 
cells, collagen fibres, and phagocytic cells of uncertain origin. In 
a separate ultrastructural study, Constable et a1l06 described p1atelet-
induced membranes in the owl monkey as strands of amorphous material in 
an unidentified matrix. 
This chapter describes the ultrastructural appearance of vitreous 
membranes as they occurred during vitreous clot resolution in the rabbit. 
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In addition, the processes of intravitreal haemolysis and fibrin re-
moval, which also have not been described previously at this level, 
are documented. In Chapter 14, a separate description of the 
cellular response to vitreous blood deposits is given, since several 
aspects of the cellular exudate were unusual and required separate 
analysis. 
~~TERIALS AND ~~HODS 
ANI~~LS 
Seventeen mature New Zealand white rabbits were used in this 
study. The light micro5co~e study reported in Chapter 12 indicated 
that the following time periods would provide useful material for 
examination: 5 minutes, one day, six days, three weeks, four weeks, 
six weeks, nine weeks, twenty weeks, and eighteen months after injection 
of blood into the vitreous. Accordingly, two animals were killed at 
each of these times, except for the five minutes stage, when one animal 
was studied. 
INDUCTION OF VITREOUS CLOT 
This has been described in Chapter 6. The enucleated eyes were 
Q 
fixed in 2-4% cacodylate-buffered glutaraldehyde at 4 c. 
TISSUE DISSECTION and PREPARATION for electron microscopy has been 
described in Chapter 11. 
ACID PHOSPHATASE ACTIVITY within selected tissue segments was demonstrated 
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by the method described in Chapter 11. 
RESULTS 
FIVE MINUTES 
Clot formation occurred immediately after the blood was injected 
into the vitreous cavity. Clots of five minutes duration presented 
as discrete clumps which, on thick section, contained masses of normal 
packed red cells. The surrounding vitreous was clear and apparently 
unaffected by the presence of the blood. In particular, there was no 
evi1ence of red cell diffusion within the vitreous (Fig. 13.1). 
TWENTY-FOUR HOURS 
The surface of the clot consisted entirely of red cells which 
were less closely packed, but were connected to each other by thin 
strands (Fig. 13.2,13.3). Most of the cells had lost their biconcave 
appearance and were approximately spherical. Occasional smaller, 
rounded bodies, possibly platelets, were noted. Clefts and indent-
ations on the clot surface were observed (Fig. 13.2), but the surround-
ing vitreous gel was normal. Transmission electron microscopy confirmed 
the alteration of red cell shape (Fig. 13.4) within the 24 hour old clots, 
and also demonstrated a considerable variation in electron density from 
cell to cell (Fig. 13.5). Some cells had surface blebs (Fig. 13.4), 
while others showed vacuolation of the cell cytoplasm (Fig. 13.6). In 
addition, the cytoplasm had a faintly inhomogenous granular appearance 
(F ' 13 7) A few erythrocyte ghosts were seen, but in general red 19. • • 
cell lysis was at an early stage. A thin continuous membrane surroun1ed 
Figure 13 . 1 Thick section of vitreous clot five minutes 
after injection of blood into the rabbit vitreous . l.': 500 
Figure 13 . 2 Twenty-four hour vitreous clot , S. E. M. * 
Clot surface consists of masses of packed red cells . 
Surrouhding vitreous gel (v) is normal . 
seen on clot surface (arrows) . x 200 
Clefts and indentations are 
*Footnote : S. E. M.; scanning electron microscopy . 
Figure 13. 3 Higher power view of Fig . 13 . 2 . Red cells are 
spherical and interconnect by fine strands (arrows) . 
Smaller round bodies (arrowhead) also seen. x 500 
Figure 13.4 Twenty- four hour vitreous clot , T. E. M* Red cells 
within the clot show variable shape and some have 
surface blebs (arrow) . A thin continuous membrane is seen on 
the surface of the clot (arrowheads) . f , fibrin . x 3, 500 . 
* Footnote : T. E.M.; transmission electron microscopy . 
Figure 13 . 5 
density . 
Twenty-four hour vitreous clot , T. E. M. Red cells 
within the clot show marked variation in electron 
x 2 , 800 
Figure 13. 6 Twenty- four hour vitreous clot , T. E. M. A red cell 
in the centre of the figure shows several small round 
vacuoles containing electron dense bodies . p, platelet; f , fibrin ; 
b , bleb ; m, membrane . x 10 , 400 
Figure 13 . 1 Twenty-four hour vitreous clot , T. E. M. Red cell 
cytoplasm has a faintly granular inhomogeneous appearance . 
Surface membrane (m) appears to be composed mainly of fibrin . x 21 ,000 
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the clot (Fig. 13.4) and considerable quantities of fibrin were seen 
on the inner surface of this membrane and also in the interstices of 
the clot. The nature of the surrounding membrane was less clear, 
but it appeared to be composed mainly of fibrin, intermingling with 
ill-defined fine vitreous collagen fibres (Figs. 13.6,13.1). Occasional 
lysed cell figures, possibly representing degranulated platelets or 
leukocytes, were present. No cellular invasion of the clot was seen. 
SIX DAYS 
Considerable liquefaction of the vitreous had occurred, and vitreous 
detachment was suggested by the presence of a distinct fibrous layer or 
"membrane" situated in the posterior vitreous between the retina and the 
clot (Fig. 13.8). Transmission electron microscopy of this layer re-
vealed a double membranous structure, to which several electron dense 
round bodies were attached on its posterior surface (Fig. 1).9). Other 
electron lucent vacuolar structures resembling cytoplasmic organelles 
were seen. Numerous fine collagen fibrils were observed between this 
"membrane" and the clot surface, but none were seen on the retinal aspect 
of the membrane. Large quantities of electron dense amorphous debris 
intermingled with the fine fibrils in the region between the clot and 
t'he det.ached posterior vitreous face (Figs. 13.8, 13.9). This debris 
presumably resulted from changes occurriI~ within the clot, and suggested 
that considerable red cell lysis had taken place. Scanning electron 
microscopy of the clot confirmed the marked loss of intact red cells, 
and also demonstrated the presence of a loose reticular membrane on the 
clot surface (Fig.l).lO). Large cells, which were considered to be 
macrophages with extended processes and smooth contours, were seen on 
the surface of the clot, and were surrounded by numerous smaller rounded 
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Figure 13 . 8 Six day old vitreous haemorrhage , thick section. 
A distinct fibrous layer is noted posterior to the 
clot . Considerable clot debris ( d ) is s een between this layer and 
the clot , but none is shown on the retinal aspect of this layer 
(upper field) . x 340 
Figure 13 . 9 Six day old vitreous haemorrhage , T. E.M. UI tra-
structure of fibrous layer posterior to clot . A double 
membranous structure is shown , with numerous electron dense particles 
and electron lucent vesicles on its retinal aspect (upper and extreme 
right fields) . C, fine collagen fibrils . x 13,000 
Figure 13 . 10 Six day old vitreous clot , S. E. M. Clot surface has 
acquired a loose reticular appearance . Note marked 
variation in size of residual red cell bodies . 
are shown. x 1 , 000 . 
Few intact red cells 
Figure 13 . 11 Six day old v itreous clot , S. E. M. A smooth-surfaced 
spread macrophage is shown on the surface of the clot . 
RBC , red cell . Arrow , unidentified round body , probably residual red 
cell body. x 2 , 000 . 
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bodies whose identity was unclear (Fig. 13.11). At higher magnifi-
cation, the matrix of the surface membrane was seen to be composed of 
a complicated network of interconnecting strands (Fig. 13.11) with 
particles of amorphous debris bridging the inter-strand spaces. 
Considerable char~es were also observed in the red cells which 
remained in the centre of the clot. Closely packed cell figures 
were still identifiable, but their markedly inhomogeneous and 
granular cytoplasm indicated that extensive haemolysis had occurred 
(Fig. 13.12). In some areas, red cell membranes were easily de-
tected (Fig. 13.13), whereas in others cell membrane disruption was 
clearly evident (Fig. 13.13). Intact cells and partially haemolysed 
residual cell bodies were also noted within the clot (Fig. 13.12). 
However, intact cells were more commonly found in the posterior 
vitreous cavity some distance from the original clot. By this 
stage, a monoruuclear cell response was established (see Chapter 12), 
but transmission electron microscopy showed no evidence of invasion 
of the clot substance. Inflammatory cells were noted only on the 
surface of the clot (Fig. 13.11). Acid phosphatase activity was 
prominent within the macrophages, but none was present on the red 
cell membranes. 
THREE TO SIX WEEKS 
During this period, vitreous detachment proceeded to completion. 
The clot became enclosed in a prominent sheet of tissue, mainly derived 
from the posterior hyaloid surface. This layer has previously been 
described as a pseudocapsule (see Chapter 12). Scanning electron 
microscopy of the pseudocapsule showed that it varied in density, 
over different areas of the clot, from a well formed, thick structure 
Figure 13 . 12 ix day old vitreous clot , T. E. M. View shown is from 
centre of the clot . Lysed red cell figures are present , 
many with intact cell membranes . Intact red cells and residual red 
cell body also seen . x 4,100. 
Figure 13.13 Six day old vitreous clot , T. E. M. Lysis of red .cell 
membranes is shown (arrows). x 16,000 
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to a membrane with a loose reticular framework (Fig. 13.14). By 
transmission electron microscopy the pseudocapsule was seen to 
comprise parallel bundles of thin fibrils, presumably vitreous 
collagen, which enclosed red cell debris and other amorphous 
material (Fig. 13.15). No fibroblasts were seen associated with 
the pseudocapsule, but cellular activity was observed in the form 
of rounded cells, with the appearance of macrophages, which were 
adherent to the surface of the vitreous membranes and pseudocapsule 
(Fig. 13.16). Numerous residual red cell bodies, and a few intact 
red cells, were also adherent to the markedly irregular surface of 
the pseudocapsule (Fig. 13.14). The attachment of this material 
to the pseudocapsule may have occurred during the rapid freezing 
process used for scanning electron microscopy, particularly since 
most of the lysed red cells now occupied a position in the posterior 
vitreous cavity behind the detached vitreous face (Fig. 13.17). In 
addition to ghost cells and electron dense haemolysed particles 
(Fig. 13.18), intact red cells in the posterior vitreous showed 
various signs of degeneration such as intracellular vacuolation 
and sickling (Fig. 13.11). Acid phosphatase activity was prominent 
on these cells, and also within the vacuoles (Fig. 13.19). Between 
four and five weeks, the clot was still recognisable as a pale mass 
enclosed by the pseudocapsule (see Chapter 12). A surface view of 
the clot was obtained by dissecting the pseudocapsule from the clot 
while the globe was in the fixation fluid. At this stage of resolution, 
cellular elements were absent from the clot, which presented instead as 
a loose honeycombed structure (Fig. 13.20). The alveolar spaces or 
lacunae of the honeycomb were empty, and the walls of each lacuna 
were formed by a thin layer of amorphous debris. Interalveolar com-
munication was complete by a complex system of small tunnels. Previous 
Figure 13 . 14 Three week vitreous haemorr hage , S. E. M. Surface 
view of pseudocapsule around clot , shown here as a 
dense irregular sheet of tissue . rb , residual red cell body ; rbc , 
intact red cell . x 2,000 
Figure 13.15 
thin fibrils . 
Three week vitreous haemorrhage , T. E. M. Section 
taken through pseudocapsule . Note parallel array of 
Arrows outline surface of pseudocapsule . d , red cell 
debris within macrophage cytoplasm. x 26 , 800 
Figure 1) . 16 Four week vitreous clot , S.E. M. Rounded macrophages 
on surface of pseudocapsule around clot . x 2 ,000 
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Figure 13. 17 ffour week vitreous haemorrhage , T. E. M. View of 
posterior vitreous cavity , behind the clot . Note 
numerous red cell ghosts and sickling and vacuolation of intact red 
cells . x 3,400 
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Figure 13 . 18 Four week vitreous haemorrhage , T.E •• View of 
posterior vitreous cavity , behind the clot . Note large 
numbers of residual red cell bodies and electron dense haemolysed particles . 
x 3,300 
.. 
Figure 13 . 19 Three week vitreous haemorrhage , T. E. M. Note strong 
acid phosphatase reaction product on red cell surface 
and within a vacuole . Ghost cells are negative for acid phosphatase . x 13,300 
Figure 13 . 20 Four week vitreous clot , S. E. M. The pseudocapsule 
has been removed from the clot to obtain a surface view 
of the clot itself. ote the absence of cellular elements and the 
unusual honeycombed appearance . The lacunae of the honeycomb are 
empty and interalveolar communication exists via short tunnels . x 1,000 
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. studies have shown that the framework of this structure consisted of 
fibrin (see Chapter 12). By the sixth week, the clot was no longer 
recognisable as an intact structure and it was presumed that clot 
lysis had finally occurred. There was, however, still considerable 
clot debris within the vitreous, mostly as loose vitreous "membranes", 
the most prominent of which was the pseudocapsule. 
NINE TO TWENTY WEEKS 
During this period, there was a progressive reduction in the 
amount of haematogenous material in the vitreous. Generally it took 
the form of vitreous "membranes" which varied greatly in size and 
composition. The pseudocapsule remained as a dense sheet of tissue 
(Figs. 13.21, 13.22) which enveloped a mass of red cell debris. 
Transmission electron microscopy (Fig. 13.22) showed that the pseudo-
capsule was composed of interwoven bundles of thin fibrils, presumably 
vitreous collagen. Fibroblasts were not observed in the pseudocapsule. 
Other vitreous membranes were less dense than the pseudocapsule and two 
types of membrane were identified, namely cellular and acellular. 
Cellular membranes (Fig. 13.23) occurred as aggregates of macrophages 
enclosed within a thin layer of collagen-like material. Such aggregates 
often assumed very large proportions and contained essentially pure 
populations of giant macrophages. Numerous phagocytic inclusions were 
observed by transmission electron microscopy within the cytoplasm of 
these cells (Fig. 13.24). In addition, the shape and size of the 
phagosomes was extremely variable and included recently ingested intact 
red cells, lipid droplets, myelin whorls, electron lucent vacuoles and 
electron dense bodies (Fig. 13.24). In contrast, acellular membranes 
were formed by the coalescence of vitreous collagen fibrils, which 
Figure 13. 21 Ten week vitreous haemorrhage , S. E. M. Surface view 
of pseudocapsu1e . Note r esidual clot ebris in 
upper half of field . x 2 ,000 
Figure 13 . 22 Ten week vitreous haemorrhage , T. E. M. Section 
through pseudocapsule . It is composed of interwoven 
bundles of thin fibrils , most likely derived from coalescence of vitreous 
collagen fibrils . x 3,800 
Figure 13 . 23 Twelve week vitreous haemorrhage , S . E. M. Cellular 
vitreous membrane composed of a mass of aggregated 
macrophages (me) enclosed by a thin sheet of tissue , presumably 
collagen. rbc , intact red cell . x 180 
Figure 13. 24 Twenty- week vitreous haemorrhage , T. E. M. Aggregate 
of five macrophages within a cellular membrane . 
n , nucleus ; cf , collagen fibrils ; arrows , outline of cell limits . 
x 8,400 
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occurred during the process of vitreous detachment. Acellular mem-
branes occurred more frequently in areas remote from the original clot 
and presented as cords of fibres, frequently spanning the distance 
between the posterior lens capsule and the vitreous base or the peri-
pheral retina (Fig. 13.25). Later, they retracted into a retrolental 
position, in close apposition to the more cellular membranes which were 
associated with the amorphous remains of the clot. The composition of 
the acellular membranes consisted of dense bundles of poorly banded 
parallel thin fibrils coursing in a three-directional network (Fig. 
13.26). No fibroblasts were seen in association with either the 
cellular or acellular membranes. Complete detachment of the vitreous 
cortex was confirmed by surface scanning electron microscopy of the 
retina (Fig. 13.21). Loose strands of cortical vitreous fibrils were 
seen in some areas of the retina, but most of the surface was free of 
fibrillar material. Occasional intact red cells and large macrophates 
were still observed up to twenty weeks after vitreous clot formation 
(Fig. 13.21). 
EIGHTEID~ MONTllli 
A residual pseudocapsule could not be identified. Only very fine 
vitreous membranes were observed and these were both cellular and 
acellular in type, although the latter predominated. Their ultra-
structural morphology differed only in degree from the appearances 
of membranes which occurred between nine and twenty ~eekB. In general, 
there was a gradual reduction in the cellularity of membranes with time. 
Figure 13. 25 Twenty week vitreous haemorrhage , S. E.M. Acellular 
membrane , composed of thick cord-like fibrils and 
closely apposed to posterior lens surface (L) . x 75 
Figure 13. 26 Twenty week vitreous haemorrhage , T. E. M. Acellular 
membrane composed of thin collagen fibrils , without 
clear banding pattern . Note absenoe of fibroblasts . x 20 , 200 
Figure 13 . 27 Twenty- week vitreous haemorrhage , S. E. M. View of 
retinal surface showing detached vitreous fibrils 
(vf) , intact red cells (rbc) and maerophages (me) . x 250 
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DISCUSSION 
During the reabsorption of blood from the vitreous, several 
repair processes are known to occur simultaneously, including haemo-
lysis196, fibrinolysis (see Chapter 8), and the initiation of an 
inflammatory response194• Previous experimental studies have 
emphasised the importance of haemolysis in this process196 ,223,424, 
but although Regnault424 has described the intravitreal degradation 
of haemoglobin, there have been no reports which specifically follow 
the course of red cell lysis at an ultrastructural level. In the 
present study, evidence of haemolysis was detected as early as twenty-
four hours after the intravitreal injection of blood, by changes in 
red cell shape and size, by vacuolation and inhomogeneity of the cell 
cytoplasm, and by variation in electron density of the red cells. 
Progressive haemolysis continued for some time and led to the removal 
of most of the red cells from the vitreous by ten weeks, but significant 
numbers of intact red cells were present after several months (Fig. 13.27). 
The prolonged survival of red cells within the vitreous has already been 
noted (see Chapter 12). 
The mechanism whereby red cells undergo lysis within the vitreous 
is not clear. Experimental studies have shown that in other tissues 
and organs such as the spleen470 , bone marrow 500 , bronchial treel03 ,104 
and subarachnoid space306 , red cell lysis is an intracellular process, 
subsequent to the engulfment of whole red cells by mononuclear phago-
cytes. The present study has shown that this process also occurred in 
the vitreous, and the pattern of cell lysis was similar to that described 
by Edwards and Simon13l• Digestion of engulfed red cells was often in-
complete, however, with the result that large numbers of residual red 
cell bodies were observed in mature macrophages (Fig. 13.24). These 
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macrophages eventually underwent lysis within the vitreous (see 
Chapter 12), thereby releasing numerous partially digested red cell 
fragments into the extracellular space. 
In addition to intracellular red cell lysis by macrophage 
phagocytosis, considerable extracellular lysis (autolysis) of red 
cells was noted. A similar haemolytic process has been reported 
for blood deposits in rat peritoneum135 and Papadimitrou et a1385 
have described the progressive extracellular degraiation of red cells 
induced by phagocytes. Although it is generally accepted that extra-
cellular lysis is a less common means of disposing of red cell materia1410 
in the vitreous, it appeared to constitute the major pathw~ for red 
cell removal. Lysis of red cells began before the appearance of 
inflammatory cells, and may have been due to the unfavourable environ-
ment provided by the vitreous. Although it is unlikely that differences 
in the osmo1ality124, pHl17 , or ionic composition419 between plasma and 
vitreous had an effect on red cell survival, it is possible that the 
significantly lo~er oxygen tension235 and reduced glucose concentration4l9 
within the vitreous initiated autolysis of red cells466 • The ability of the 
red cells to withstand these conditions probably varied with the age of 
the cell, and would therefore have been reflected by different cellular 
rates of lysis, as is suggested by their varying electron density at 
24 hours (Fig. 13.5). This concept was further supported by the sickling 
of red cells within the vitreous (Fig. 13.17). 
Extracellular lysis of red cells continued after the appearance of 
inflan~atory cells in the vitreous, and by this stage macrophage exocytosis 
may have contributed to the haemolytic process, particularly since lysis 
was prominent on the surface of the clot after six days, where most of 
the macrophage activity was observed. Macrophages are known to secrete 
lysosomal enzymes selectively in response to inflammatory stimulil16 ,550 
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and lysosomes contain specific haemolytic enzymes l18• In the present 
stu~, it was interesting to note that acid phosphatase activity was 
not detectable on red cell membranes until three weeks after vitreous 
clot formation, by which time similar activity was particularly high 
within macrophage lysosomes. Although some of the activity on the 
red cells probably represented endogenous red cell acid phosphatase, 
the changing pattern of activity suggested that the enzyme was partly 
derived from other sources, the most likely source being macrophage 
secretion. In addition, many of the vitreous macrophages contained 
partially digested endocytosed material, which has been described as 
a prerequisite for the induction of lysosomal enzymes, particularly 
acid phosphatase16• 
Although both extracellular and intracellular red cell lysis were 
seen to occur in the vitreous, the prolonged survival of a proportion of 
the red cells suggested that these cells were able to adapt to the un-
favourable milieu and that inflammatory cell activity was insufficient 
to remove the red cells completely. 
In addition to haemolysis, fibrinolysis occurred, albeit slowly, 
during the process of vitreous clot removal. The appearance of the 
clot after four weeks, as a fibrin skeleton devoid of red cells, has 
already been documented (see Chapter 12). Scanning electron microscopy 
of this material revealed an unusual honeycombed appearance (Fig. 13.20) 
and it is suggestei that this structure was formed by cytoplasmic mem-
branes of collapsed red cells filling the interstices of the fibrin net-
work. Although fibrin deposits of this nature cenera11y attract a po1y-
4~ ( morphonuclear response ,they failed to do so in the vitreous see 
Chapters 12,14). Since tissue fibrinolytic activity of the vitreous 
is low (see Chapter 1), fibrin removal is probably achieved by other 
means such as macrophage activity, particularly as elicited macrophages 
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are known to secrete plasminogen activator5l6• The de1~ed removal 
of fibrin probably reflected the low-grade mononuclear response3• 
The progressive changes in the structure of the clot and its 
components were accompanied by marked changes in the gel struct~e of 
the vitreous. The formation of vitreous "membranes" during vitreous 
clot resolution commenced with detachment of the vitreous from the 
retina, a process similar in ultrastructural appearances to that 
described for age-related posterior vitreous detachment l1l ,146. 
This was followed by condensation of vitreous collagen fibrils, 
particularly around the clot, and resulted in loss of the gel state 
of the vitreous, and the formation of dense bundles of parallel, inter-
woven fibres. Such acellular "membranes" differed from cellular membranes 
which consisted of collagen-coated macrophage clumps, whose morphology 
changed during the course of time. Acellular membranes predominated 
in the later stages of clot resolution, when vitreous detachment was 
complete and their structure was similar to pelleted collagen from 
normal rabbit vitreous after centrifugation at 30,oooa492 • No fibro-
blasts were observed, nor was any 640Ao banded collagen detected, in 
contrast to the vitreous menlbranes which occurred after the intra-
vitreal injection of autologous fibroblasts3• 
The pathogenesis of vitreous detachment in this condition is not 
known, but since its commencement coincided with the peak cellular in-
flux at about 5 days (see Chapter 12) rather than with the physical 
trauma associated with the experimental technique, it is possible that 
this process also resulted from macrophage lysosomal enzyme secretion, 
as is suegested for the processes of haemolysis and fibrinolysis 
degcribed above. Y.acrophages are known to secrete collagenase at 
neutral pH in vitro60 ,55 l , and this may initiate the process by dis-
rupting the fine three-dimensional collagen matrix22• The removal 
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of interfibrillar collagen bridges would have destabilised the net-
work and permitted the individual fibrils to approximate each other, 
thus forming a dense collagen sheet. It is also possible that clot 
retraction exerted a physical influence on the surrounding collagen 
with which it was in intimate contact. However, in vitro studies did 
not support this concept (see Chapter 4). 
The persistence of vitreous membranes within the vitreous is 
intriguing. Platelet-induced vitreous membranes are known to elicit 
105 only a moderate macrophage response , and the cellular response to 
vitreous haemorrhage is also reported to be low-grade (see Chapters 
12, 14). The normal process of repair and remodelling by macrophages 
and fibroblasts which occurs when other connective tissue matrices are 
disrupted70 , 272 does not seem to occur so readily in the vitreous. This 
may in part be related to the high concentration of macromolecular hyal-
uronic acid which is known to modulate the behaviour of inflammatory 
cells considerably24,147,449. Similar mechanisms may be operative in 
the persistence of intact, healthy red cells within the vitreous for 
many weeks or months after haemorrhage. 
CONCLUSION 
In this chapter, the processes of haemolysis and vitreous membrane 
formation during vitreous clot lysis were studied in the rabbit eye by 
transmission an1 scanning electron microscopy. Haemolysis in the 
vitreous was predominantly an extracellular process, perhaps as a 
consequence of the unfavourable microenvironment. Macrophage activity 
was directed at clearir~ red cell debris. 
Two forms of vitreous membrane developed during vitreous clot 
lysis, i.e. cellular and acellular. Neither of these were associated 
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with fibroblastic activity. Instead, they were composed of condensed 
vitreous collagen fibres. This evidence supports the view that fibro-
blastic activity within uncomplicated vitreous heamorrhages is an un-
common occurrence and that haematogenous vitreous membranes are composed 
of endogenous vitreous collagen with variable quantities of red cell 
debris and inflammatory cells. 
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CHAPl'ER 14 
ELECTRON MICROSCOPY OF VITREOUS CLOT LYSIS: 
CELLULAR RESPONSE TO BLOOD IN THE VITREOUS 
161 
INTRODUCTION 
Blood within the vitreous cavity elicits a well-defined inflam-
matory response194 ,224,369, but it has been suggested in this thesis 
that the degree of cellular activity is insufficient to remove the 
blood clot completely (see Chapter 12). In the few morphological 
studies which have described the early phase of the inflammatory 
response to vitreous bloodI94 ,369,486, significant cellular invasion 
of the vitreous was not observed until two or three days had elapsed194 , 
and only became fully established between the fifth and seventh day 
(see Chapter 12). This was in contrast to the brisk acute inflam-
matory response which ensued in experimental blood clots in other 
connective tissues52 ,93. In the vitreous, the cellular response to 
vitreous clots is predominantly mononuclear from the onset l94 (see 
Chapter 12). It thus appeared that the initial phase of marked 
polymorphonuclear cell migration which occurred in experimental 
thrombi in blood vessels115 ,211 and in fibrin clots in the skin389 ,434 
had been suppressed. Furthermore, it has been suggested that the 
delayed clearance of fibrin from the vitreous durinB the course of 
reabsorption of vitreous clots may have been due in part to the lack 
of an adequate polymorphonuclear cell reaction (see Chapter 12). 
workers have reported a similar poor cellular response to platelet-
fibrin deposits in the vitreousl06 ,160. 
Other 
The mechanisms responsible for the poor cell response to blood 
in tl.e vitreous are not known. It is possible, however, that the 
inflammatory response is modified by the specialised nature of the 
vitreous connective tissue matrix, which differs from other inter-
cellular matrices in several respects (see Chapter 1). For instance, 
the resting cell content of the vitreous is extremely low, being re-
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stricted to a single monolayer in the peripheral cortex of the ge1496 
and it is not known what proportion of these cells represent true 
tissue macrophages. It is likely that few, if any, of these cells 
participate in the inflammatory process. The collagen content of 
the vitreous is also considerably lower than in other tissues, and 
vitreous collagen fibrils are extremely fine and have a particular 
spatial orientation (see Chapter 1). Such fibrils may provide an 
unfavourable surface for the migration of inflammatory cells. The 
absence of blood vessels in the vitreous may also influence the cell 
response by reducing the availability of plasma factors, such as 
opsonins, which are required for the full expression of the inflam-
matory response448• Furthermore, it has been proposed that the 
glycosaminoglycan composition of the vitreous gel, which is 
predominantly hyaluronic acid with minimal sulphated proteoglycans491 
may have an inhibitory effect on cell influx into the vitreous, 
pqrticularly since hyaluronic acid in high dosage has been shown to 
suppress leukocyte motility in vitr024. Other factors may contribute 
to the inadequate cell response to vitreous blood, such as absence of 
appropriate chemotactic stimuli (Chapter 9). 
The ultrastructure of phagocytic cells in inflammatory exudates 
has been studied in several tissues52 ,184,387,444, but there have been 
no similar reports of inflammatory cell responses in the vitreous. In 
view of the unusual nature of this response, as shown by light micro-
scopy, the present ultrastructural study was undertaken. Scanning 
electron microscopy was also used since it was considered that this 
was a uni~ue opportunity to stu~ the surface morphology of inflammatory 
cells in an atypical connective tissue matrix~ 
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~~TERIALS AND METHODS 
The materials and methods used for the study of the inflam-
matory cell response to vitreous blood were the same as those used 
for the studies described in Chapter 13, since both stuiies formed 
a part of the same ultrastructural investigation. A full description 
of the methods and materials for this part of the thesis is given in 
Chapter 11, including the methods for inducing vitreous clots in the 
rabbit eye and for the dissection and preparation of tissue for ultra-
structural analysis. 
ANI~~LS 
Sixteen mature New Zealand white rabbits were used in this 
study. The following time periods provided material for examination: 
one day, three days, six days, three weeks, six weeks, nine weeks, 
twenty weeks, ani eighteen months after injection of blood into the 
vitreous. Two animals were killed at each of these times. 
RESULTS 
There was little evidence of cellular invasion into the vitreous 
cavity twenty-four hours after the introduction of whole blood. The 
clot, which formed immediately after the injection of blood into the 
vitreous, remained as a discrete mass within a normal vitreous gel. 
Some changes in the shape and electron density of the red cells within 
the clot were found and a few red cells showed cytoplasmic blebs and 
vacuolar changes (Fig. l4.la). The surface of the clot comprised a 
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Figure 14 . 1 'l'wenty-four hour vitreous clot , T . E . M. 
(a) clot , in lower half of the field , shows masses of 
relatively normal red cells . There is some variation in electron 
density of th red cells , plus bl bbing of cytoplasm (arrow) and 
formation of small vacuole ~arrow neaa). A sing~e membrane surrounds 
the clot . ibrln (r) and degranulated cell forms (presumably platelets) 
are also pre ent . hree polymorphonuclear leukocytes are seen in the 
upp r field , in advanced etages of degeneration and surrounded by 
fibrill r material . x 2 , 900 . 
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single continuous membrane which enclosed both the red cells and 
fibrin deposits (Fig. 14.la). Fibrin was not found outside this 
layer. A few polymorphonuclear leukocytes were dispersed randomly 
throughout the clot and its immediate vicinity (Fig. 14.la). These 
cells were in various stages of cytolysis, as seen by their extreme 
cytoplasmic rarefaction and organelle disruption (Figs. 14.la,14.lb). 
They were generally surrounded by fine unbanded fibrils which presumably 
were vitreous oollagen. 
cytosis by these cells. 
There was little evidence of active phago-
After three days, few changes had occurred in the clot itself; 
in particular, there was no evidence of inflammatory cell invasion of 
its structure. Some young mononuolear cells with a thin rim of cyto-
plasm were seen, initially surrounding the ciliary processes and later 
within the vitreous gel. By the sixth day, these oells were more 
numerous, but were still relatively immature, as shown by the prominent 
margination of the nuclear heterochromatin, the moderate nucleus to 
oytoplasm ratio, and the pauoity of cell organelles (.t<'ig. 14.2). They 
were intimately associated with surrounding fibrillar material and small 
electron dense particles. 
cells was minimal. 
Acid phosphatase activity within these 
Scanning electron microscopy showed that the surface of the clot 
after six days had acquired a loose network of strands and fibres which 
formed an incomplete sheet (Fig. 14.3). This represented a considerable 
thickening of the single layer which surrounded the clot at twenty-fOur 
hours. Ho .. ever, the six-day-old clot was still intact and showed little 
evidence of undergoing clot lysis. When the clot was viewed at higher 
magnification, moderate numbers of single rounded macrophages were found 
on its surface (iig. l4.4a). These cells varied considerably in size, 
and they possessed well developed ruffled plasma membranes and elongated 
Figure 14 . 1 Twenty-four hour vitreous clot , T. E. M. 
(b) higher power view of two polymorphs within the 
clot, showing cytoplasmic rarefaction and organelle disruption . x 4 ,400 
Figure 14 . 2 Six day vitreous haemorrhage , T.E.M. Young macro-
phage within the vitreous , near vitreous base . Nucleus 
shows prominent margination of the heterochromatin . Organelles are few ; 
no primary 1ysosomes or phagosomes are seen . x 9,900 
Figure 14 . 3 Six day vitreous clot , S. E.M. Surface of vitreous 
blood clot is composed of a loose network of strands 
an fibres formi an incomplete sheet . x 180 . 
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microvilli (Fig. l4.4b). It was unusual, however, to fin1 spread 
cells or cells with obvious larnellipodia. The clot surface on which 
these cells rested was composed of a complex lattice of smaller fibres. 
Most of the holes in this fine grid were devoid of electron dense 
material, but some contained variably-sized roun1 bo1ies and other 
amorphous debris. 
level. 
Few intact red cells were seen at this surface 
From this stage onwards, the macrophage population increased 
slowly until by three weeks the vitreous contained sUbstantial 
numbers of large cells showing numerous granules within their cyto-
plasm (Fig. l4.5a). The granules varied in size and density, often 
having a diameter of more than 30~um. Thick section analysis also 
suggested that some of these cells were multinucleate (Fig. l4.5a). 
Electron microscopy indicated that the granules in these cells were 
phagocytic inclusions, or secondary lysosomes, which almost filled 
the cell cytoplasm (Fig. l4.5b). There was marked variation in 
electron density, size and shape of the inclusions; some showed 
a homogeneous dark matrix, whereas others had a highly variegated 
appearance with a granular background (Fig. l4.6a,14.6b). Several 
myelin whorls were seen and some cells contained numerous lipid 
droplets (Fig. l4.6a). Occasionally, a recently ingested intact 
red cell was found within the macrophage cytoplasm (Fig. l4.6a). 
Electron-lucent vacuoles and micropinocytotic vesicles were commonly 
observed, and less frequently, dilated intracytoplasmic channels, 
which suggested intracellular oedema (Fig. l4.6b). Acid phosphatase 
activity varied within the phagosomes, but was especially marked in 
primary lysosomes at this stage (Fig. l4.6b). Occasionally, a 
primary lysosome was found in close association with a phagosome, 
which gave the appearance of fusion of the two organelles (Fig. l4.6b). 
Figure 14 . 4 Six day vitreous blood clot , S. E. M. 
(a) Cells on clot surface are single and rounded , 
and vary in size . The substratum is composed of complex lattice of 
small fibres . x 500 
(b) Higher power view of Fig . 4(a) showing ruffled 
plasma membrane and microvilli. 
backgroun (arrow) . x 1 , 200 
A single red cell is seen in the 
Figur e 14.5 Three week vitreous clot . 
( a ) Thick section light microscopy . The cells are 
very large and have a densely granular cytoplasm . Some cells appear 
to be multinucleate (arrow) . x 450 • 
. (b) Transmi ssion electron micrograph of macrophage s within 
the vitreous . The cytoplasm i s filled with phagosomes which show great 
var iation in shape and electron density . Eccentrically placed nucleus 
contains two nuc leol i . x 6,500 . 
'. 
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Figure 14 .6 Three week vitreous haemorrhage , T. E.M. 
(a) Marked heterogeneity of the macrophage cytoplasmic 
inclusions is shown . Intact red blood cell (rbc) , myelin whorl (wh) , 
lipid droplets (1) , granular inclusion (g ) . x 1) , 600 
Fi gure 14 .6 Three week vitreous haemorrhage 
(b) Acid phosphatase staining of inclusions is especially 
mar ked in primary lysosomes (ly) . Intracytoplasmic channels (ch), me mbrane 
bound phagoBomes (arrow) , granular inclusion (g ) . Apparent fus ion of 
pr i mary lys osomes wit h phagosomes is observed (arrow head ). x 18 , 800 
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Several secondary lysosomes were enclosed in a single or double membrane, 
but in others it was difficult to identify a membrane. 
Few other organelles were identified in these large cells, such 
as mitochondria, endoplasmic reticulum or Golgi complexes. The 
eccentrically placed nucleus often showed one or more nucleoli and 
margination of nuclear heterochromatin (Fig. l4.5b). 
Between three and six weeks after induction of the vitreous clot, 
several morphological changes occurred in the cell exudate. A striking 
feature was the formation of massive cell aggregates (Fig. l4.7a) which 
occurred in various loci within the vitreous. Since the main clot 
structure had disintegrated by this stage (see Chapters 12,13), it is 
possible that these large cell clumps represented fragments of the 
original clot. The cells in these clumps were uniformly very large, 
sometimes with a diameter of more than 100 pm, and between the cells 
lay small accumulations of amorphous debris (Fig. l4.1a). Fine fibrous 
strands radiated from the clumps of cells, but it was difficult to identify 
the nature of the substratum to which the cells adhered. It is likely 
that this layer was composed of residual clot debris. The surface 
morphology of the cells at this stage was notably uniform. They were 
generally rounded or oval, and smooth-surfaced, and where microvilli 
were present, these were short and thick (Fig. l4.1b). Some cells 
showed pits and indentations, measuring 0.1-2 pm, of their surface 
membranes, while other cells had a complex system of ridges, flaps and 
folds. Filiform extensions of the peripheral cytoplasm were seen in 
only a few cells, and it was rare to find distinct lamellipodia. Several 
cells showed prominent bulges of the surface membranes, while others had 
a cobblestone appearance (Fig. l4.1b). 
Between six weeks and eighteen months after the injection of blood 
into the vitreous, total cell numbers gradually decreased, but their 
-----_._--- ... 
Figure 14. 7 Six week vitreous haemorrhage , S. E. M. 
(a) Aggregate of cells . The cells are very large and 
generally roun ed . Amorphous debris noted between the cells. A fibrous 
strand is observed attached to the cell mass . 
seen at the top of the field (arrow) . x 600 . 
A single spread cell is 
Figure 14 . 7 ix week vitreous hae orrhage , S. E. M. 
(b) The cell surface is variably smooth or cobblestone . 
Microvilli are short and thick when present . Some cells have filiform 
exten ions (arrow) . Pits and indentations are seen in other cells 
(arrow heads) . Occasional intact red cells are present in the cell 
mass (curved arrow) . x 900 
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morphology was similar to that at six weeks. IIlost of the cells were 
very large, sometimes measuring more than 200JWD in diameter, and they 
contained very large numbers of phagosomes similar to those described 
above (Fig. l4.8a). However, some cells with prominent microvilli 
contained numerous small (3JWD) round inclusions of uniform size, 
whereas the inclusions in other cells were extremely variable in size. 
These latter cells also had fewer microvilli (Fig. 14.8a). Acid 
phosphatase activity within the cells also varied, and was most marked 
in those cells with the smaller inclusions (Figs. l4.8b and inset). 
These appearances suggested that there was considerable variation in 
the phagocytic capacity of the cells. In addition, electron dense 
material, which closely resembled the intracellular inclusions, was 
frequently encountered in the extracellular space (Fig. 14.9), 
particularly in association with healthy macrophages. This suggested 
that some of the cells had undergone cytolysis with release of their 
cell contents which were then rephagocytosed by other active cells 
(Fig. 14.9). 
Few other cell types were observed. The proportion of young 
cells in the cell exudate was low after three weeks,-although fresh 
cells were found even in the late stages of blood clearance (Fig.14.10a). 
It was more common, however, to find multinucleate giant cells, usually 
as members of a large cell aggregate (Fig. 14.10b). These cells con-
tained numerous phagolysosomes, similar to those in conventional macro-
phagesj their nuclei often showed one or more nucleoli and a thin rim 
of nuclear heterochromatin. Primary lysosomes were few. There 
appeared to be segmental condensation of the cytoplasm in areas where 
there was intimate contact between the cell membranes of two cells, 
but no fusion of cell membranes was seen between mature cells (Fig. 
l4.l0b) • Only when young cells were present in association with large 
Figure 14 . 8 Nl ne week vitreous haemorrhage , T. E. M. 
(a) Aggregate of macrophages . Inclusions are similar 
to those seen earlier . However , some cells show uniform small inclusions , 
while others show marked variation in size of inclusions . Recently 
in ,ested red cell (rbc) . x 3 , 800 
(b) Marked acid phosphatase reaction product in a 
macrophage with small inclusions . x 3 , 700 . 
Particularly high activity was observed in primary 
lysosomes (inset) . x 90 ,000 
Figure 14 . 9 Twenty-week vitreous haemorrhage , T. E. M. 
Considerable amorphous debris is noted in the extra-
cellular space surrounding an active vitreous macrophage . This 
material is similar to the cytoplasmic inclusions , and appears to 
be undergoing phagocytosis (arrow) . x 3 , 800 
Figure 14.10 (a) Young vitreous macrophage eighteen months after 
injection of blood into the vitreous . The cell 
shows a high nucleus to cytoplasm ratio , and contains few phagosomes . x 6,400 . 
(b) Cell aggregate twenty weeks after injection of 
blood into the vi t reous . A large multi-nucleate 
cell is shown . Tunnelisation (see discussion) is particulary well seen 
in th se cells as sickle- shaped and rine- like inclusions (arrows) . Con-
densations of cell membrane are seen in areas of close contact between 
cells (arrowhead) . x 2, 800 . 
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mature macrophages was fusion of the plasma membranes suggested by the 
bridging of cytoplasmic contents between the two cells (Fig. 14.11). 
The cellular response to blood in the vitreous was therefore com-
posed largely of mature macrophages, and to a lesser extent, multi-
nucleate giant cells and young round cells. Epithelioid cells and 
fibroblasts were not seen. Some of the round cells could not be 
distinguished from lymphocytes by morphological means, but their 
numbers were few after three weeks. 
DISCUSSION 
Previous studies of the inflarrmatory response to vitreous blood 
clots have described the slow emigration of cells into the vitreousl94 
and the relative lack of polymorphonuclear leucocytes within the initial 
exudate l94 (see Chapter 12). These findings have been confirmed in the 
present study. The few polymorphonuclear cells which were seen twenty-
four hours after the injection of blood into the vitreous occurred within 
and around the original clot, and probably represented cells which had 
been introduced with the blood at the time of injection. This was 
further suggested by their advanced state of degeneration and their 
absence of active phagocytosis. Alternatively, if these cells did 
correspond to the initial phase of polymorphonuclear leucocyte emi-
gration, their numbers were considerably fewer than was reported in 
the inflammatory exudates to similar blood clots in the vascular 
tree175 ,2ll or dermis52 , or in fibrin clots in the skin389 ,434. The 
central role of polymorphs in the clearance of fibrin deposits in in-
flammatory exudates has been amply demonstrated48 ,389,405, and this 
mechanism, in association with the intrinsic fibrinolytic activity 
of most tissues (see Chapter 7) provides a means of rapidly clearing 
Figure 14.11 ( a) Cell exudate twenty weeks after blood injection into 
the vitreous . An immature round cell is seen in 
close association with a mature macrophage . 
poss ible fusi on of cell membranes . x 12 , 300 
Arrows indicate an area of 
Figure 14 . 11 (b) Cell exudate eighteen months after blood injection 
into the vitreous . Fusion of cell membranes 
between a young mononuclear cell and a mature macrophage is suggested 
by bridging of cytoplasmic contents between the two cells . x 10 , 900 
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fibrin from injured tissues and ensuring a return of structural in-
tegrity. Indeed, within hoUrs of placing fibrin clots on cover slips 
into the skin of rabbits, Riddle and Barnhardt389 observed massive 
accumulation of polymorphonuclear leucocytes, not only surrounding 
the clot, but invading its depths and forming pockets within its 
substance. Clearly, the response to blood clots in the vitreous 
was different. Penetration of the blood clot by inflammatory cells 
did not occur, and indeed the clot remained as a discrete mass for at 
least four weeks. 
The low levels of tissue fibrinolytic activity in the vitreous 
(Chapter 7) and the failure of vitreous blood to generate an adequate 
polymorphonuclear cell response both probably militate against the 
removal of blood clots from the vitreous. Even after one month, when 
most of the red cells had either been lysed or had diffused aw~ from 
the clot (see Chapter 12) a fibrin framework of the original haematoma 
remained. Additional biochemical evidence has shown that up to six 
weeks elapsed before fibrin was removed from an experimental vitreous 
clot (see Chapter 8). It would thus appear that both the inadequate 
polymorphonuclear cell response and the low fibrinolytic activity of 
the vitreous contributed to this delayed fibrin clearance. 
The inflammatory response to blood in the vitreous has thus been 
shown to be predominantly mononuclear. Mononuclear cell invasion was 
observed seventy-two hours after blood injection and gradually increased 
until the third week. After this time, fresh cells were infrequently 
observed, ani the lesion consisted of mature macrophages and multi-
nucleate giant cells in large cell aggregates. The small numbers of 
fresh cells, and the characteristic ultrastructure of the long-lived 
macrophages, namely masses of ingested insoluble material within the 
phagosomes and paucity of primary lysosomes, were similar to the 
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appearances of cells in a "low-turnover"granuloma387• 
The insoluble material wit hin the cells represented partially 
degraded red cells which showed all stages of lysis from recently 
ingested erythrocytes to myelin whorl formation (Fig. 14.6c). This 
process of intracellular haemolysis in alveolar macrophages has been 
fully documented by Collett and Petrik103,104. Both the granular 
and the haemolytic pathways of red cell breakdown recently described 
by Zilies575 were noted in vitreous macrophages, although t he former 
was much more common. In several cells, however, the degradation 
process seemed to have ceased at the stage of "tunne1isation", a term 
coined by Edwards and Simon1)1 to describe the inspissation of phago-
cytic cell cytoplasm into the erythrophagosome (Fig. lOb). Crystalline 
structures within the inclusions were rare. The digestive capacity of 
the cells varied and many cells appeared to be metabolically inert, a1-
though the contained numerous partly digested inclusions. Such cells 
probably underwent cytolysis with release of their cell contents into 
the extracellular space. These particles were then rephagocytosed by 
other cells. 
It has been stated that the degradation of red cells in vivo 
occurs entirely within the cytoplasm of mononuclear phagocytic cells, 
following engulfment of the whole red cel1398• This was shown to be 
true for the physiological removal of senescent red cells from the 
circulation by spleen macrophages398 and for the removal of red cells 
from experimentally-induced blood deposits in the bronchial tree lO), 104. 
However, within the vitreous, in addition to the usual process of macro-
phage erythrophagocytosis, considerable extracellular lysis of red cells 
was observed (see Chapter 13). Such haemolysis began before the onset 
of cellular invasion, as shown by changes in electron density of the 
red cells and vacuole formation (Fig. 14.1a). Similar electron micro-
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scopic observations of extracellular red cell lysis were noted in 
peritoneal blood clots135• 
The formation of multinucleate giant cells during the inflam-
matory response to vitreous blood is interesting for several reasons. 
Recent studies have suggested that the phagocytic ability of cell 
populations containing giant cells is lower than similar pure mono-
nuclear cell populations385• Both the surface morphology and the 
ultrastructure of vitreous macrophages would support this concept, 
since their appearances were similar to other poorly phagocytic macro-
phages ani giant cells15 ,8O,385. In aidition, the formation of multi-
nucleate giant cells appeared to occur by the fusion of young cells to 
older mature macrophages (Fig. lla,b). Support for this proposed 
mechanism of giant cell formation comes from the recent kinetic studies 
of Chambers19• Although macrophages and giant cells in inflammatory 
exudates are derived from precursors in the marrow386 ,511, it has been 
suggested that the formation of one cell type is exclusive of the other386• 
It would therefore appear that not only is the cell response to blood in 
the vitreous atypical in terms of cell type and cell numbers, but the 
preferential formation of multinucleate giant cells and the appearances 
of the macrophages suggests that those cells which were engaged in 
vitreous red cell breakdown had impaired phagocytic ability. 
There are several possible reasons for this unusual cell response 
to vitreous blood. During experiments on the mononuclear cell response 
to blood clots in the skin, Ghani175 observed a similar pattern of cell 
activity, with the formation of large macrophages, epithelioid cells and 
giant cells, when the clot was sequestered in a millipore chamber. Thus, 
an artificial barrier to the invasion of inflammatory cells, but not to 
solutes or nutrients was created. A similar situation may obtain 
naturally in the vitreous where components of the connective tissue 
178 
matrix may provide a barrier to the ingress of cells. Thus, the 
high content of polydisperse hyaluronic acid in the vitreous may 
inhibit inflammatory cell movement in vivo, as it has been shown 
to do in vitro24 (Forrester and Wilkinson, experiments in progress). 
It is well established that modifications of the inflammatory 
process occur in various specialised tissues54l• The present in-
vestigation of the cell response to vitreous clots provides a further 
example of this altered response and raises a number of interesting 
questions conce~ing the role of connective tissue components in the 
evolution of the inflammatory response. 
CONCLUSION 
This study of the inflammatory response to vitreous blood 
deposits has confirmed previous investigations which showed that 
the cell response was slow to develop, was predominantly mononuclear, 
and remained low-grade. The formation of large aggregates of giant 
macrophagea and multinucleate cells was also observed. It is sug-
gested that tte atypical cell response to blood in the vitreous may 
be due to the unique nature of the vitreous as a connective tissue, 
particularly to its high content of hyaluronic acid, which has been 
shown to inhibit inflammatory cell activity in vitro. 
In addition, the scanty cellular response to blood in the 
vitreous may be a contributory factor to the delayed resolution of 
intravitreal haemorrhages. 
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INTROOOCTION 
Since vitreous haemorrhage was first recognised as a cause of 
blindness, its treatment has proved difficult. Spontaneously re-
solving small vitreous haemorrhages usually require no intervention. 
On the other hand, the problem of the dense and persistent vitreous 
clot has brought forth a multitude of clinical and experimental 
methods designed to promote its reabsorption. Indeed, Jaffe231 
pointed out that the wide variety of treatments for this condition 
attested to the inefficacy of most of them. Until recently, the 
common a~proach to vitreous haemorrhage was conservative, and only 
in rare cases was any surgical intervention, such as cryotherapy or 
vitreous aspiration, contemplated. Consequently, numerous patients 
~ere permanently blinded by this condition. However, the explosion 
of interest in surgical techniques of vitreous removal and replacement 
has altered radically the approach to the patient with a vitreous clot. 
The purpose of this chapter is to view the basic pathophysio-
logical atudies described in the previous chapters against the back-
rround of current trends in therapy. Three therapeutic approaches to 
vitreous haemorrhage have been adopted which involve the use of surgical, 
biophysical or clot-lysing techniques. 
SURGICAL TECHNI~UES 
A surgical approach to opaque vitreous is not a new concept. Von 
Graefe 527 was the first to report on the surgical dissection of vitreous 
"membranes" and later, Ford142 aspirated opaque vitreous. Ford's lead 
formed the basis of surgical intervention for more than half a century, 
with only minor modifications51 ,519,580 , particularly in relation to 
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replacement of the opaque vitreous110 • Their failure to· gain universal 
support was a reflection of the high inciience of complications and 
generally unfavourable results. Following the introduction of 
the operating microscope and intensive research during the 1950s and 
1960s, pars plana vitrecto~ became a practical procedure. This 
operation utilises a custom-built instrument, the vitreous infusion 
suction cutter (VISe) which requires the use of an operating micro-
scope and corneal contact lens for vitreous surgery. Subsequently, 
a large number of vitrecto~ instruments have been designed122,156,256, 
269,301,375,393,511 and numerous papers, notably from the U.S.A. on the 
indications, complications, techniques and other aspects of vitreous 
surgery have appeared. From the beginning, it has been shown that 
simple vitreous haemorrhage is a firm indication for vitreous surgery. 
Machemer and Norten302 reported that eighteen of twenty cases of simple 
vitreous haemorrhage gained some degree of visual improvement after 
vitrectomy. Follow-up of these cases ranged from one to twelve 
months. Diabetic vitreous haemorrhages with extensive proliferative 
retinopathy did less well, visual improvement occurring in sixteen of 
twenty-three cases (eighty per cent), while the presence of retinal 
detachment militated against successful surgery (two of eight cases). 
Similar findines were reported by Mandelcorn et a1309 , who claimed a 
seventy-one per cent success rate for simple vitreous haemorrhage, but 
only a thirty-one per cent rate of improved vision in complicated 
vitreous haemorrhage. Peyman et a1394 reported an overall improvement 
in vision in sixty-eight per cent of cases with forty-five per cent 
gaining a vision of 20/300 or better. A more recent study by this 
group395 reported similar figures of sixty-six per cent improvement 
for cases of simple vitreous haemorrhage and forty-two per cent for 
cases of vitreous haemorrhages complicated by retinal detachment. 
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A further large series was reported by Michels et a1 332 with an 
overall success of sixty-five per cent, although a different method 
of visual acuity standardisation was used. 
It is clear that a majority of patients with uncomplicated, 
non-resolving vitreous haemorrhage can expect some degree of visual 
recovery from this form of surgery. However, numerous complications 
associated with vitrectomY have become apparent following the publi-
cation of these series302 ,309,332,295. Complications may be either 
intraoperative or post-operative (Table AI). The inciience of major 
complications such as phthisis bulbi and rubeosis iridis varies from 
sixteen to twenty-five per cent. The risk of worsening the visual 
- - ------... 
status has been emphasised by other groups, particularly among diabetics 
with proliferative retinopathy314,512• It is apparent, therefore, 
that while this form of treatment can afford enormous benefit to the 
patient, it is not to be embarked upon lightly. 
BIOPHYSICAL TECHNIQUES 
A number of physical modalities have been applied to the 
treatment of vitreous haemorrhage. These include.diathermY. cryo-
therapy, photocoagulation and ultrasound. 
Diathermy was first used to treat clinical vitreous haemor-
rhage in 1954153• Forgacs163 later described an experimental 
study of rabbit vitreous haemorrhage, in which a faster rate of 
clot removal was observed in eyes treated with diathermY than in 
untreated control eyes. The significance of these results is, how-
ever, in some doubt, since only three rabbits were studied in each 
group at two different time periods after treatment (15 days and 
120 days), and no account was taken of the considerable interanimal 
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variation in physiological clearance rates of vitreous clots (see 
Chapter 7). The necessity for including this variable in studies 
of vitreous haemorrhage has been emphasised by Jaffe237 • In spite 
of this, diathermy has been used widely, particularly by European 
221 b t . t I' t . surgeons u 1 s va ue 1S uncer a1n. 
More popular, however, is the use of cryotherapy in the treat-
ment of vitreous haemorrhage248,430,445,508. Ricci et al430 found a 
beneficial effect in forty-one per cent of cases of vitreous haemor-
rhages, but Rousselie445 suggested that it was useful only in cases 
that were already clearing. 424 Regnault advocated that cryotherapy 
should be used as a first approach and, if it failed, was to be 
followed by simple aspiration of the vitreous, and then as a last 
resort total vitreous removal by vitrecto~. 
Baum39 suggested the use of ultrasound in the treatment of 
vitreous haemorrhage, since it was found that this form of energy 
could cause dispersal of vitreous opacities. Difficulties were 
experienced in concentrating the sound waves on the vitreous 
opacities without causing damage to surrounding ocular structures. 
filore recent experimental work, however, with focussed transducers 
has been encouraging99 , and it is likely that clinical trials will 
soon commence (Coleman, personal communication). 
High energy laser beams have also been used to clear vitreous 
blood. Daily administration of xenon photocoagulation for ten days 
was reported to.hasten the resorption of rabbit vitreous clots, but 
the study contained insufficient data on the behaviour of control 
vitreous Clots46 • 
It is possible that the above physical methods have a potential 
use in the management of vitreous haemorrhage, since they induce focal 
tissue damage anj will thus elicit an inflammatory response. The 
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studies described in Chapters12 and 14 suggest that the low-grade 
inflarr.matory response to vitreous blood m~ be a contributory 
factor to the delayed resolution of vitreous haemorrhage and thus 
methods of augmenting this response may enhance reabsorption of 
the vitreous clot. However, clinical studies have failed to 
provide good evidence of the value of these methods; it m~ be 
that a mucn greater inflammatory response is required, but this 
would introduce major risks to the eye itself. 
Finally, a report of the value of the r~perosmotic agent, 
mannito157 , in the clearance of experimental vitreous haemorrhage 
has remained unconfirmed. It has been suggested that such agents 
may promote reabsorption of vitreous clots through an increase in 
aqueous flow by an as yet undetermined mechanism (ref. 237). 
CLOT-LYSI~G AND ENZY¥~TIC TECHNIQUES 
The use of clot-lysing and enzymatic techniques has been con-
fined mainly to experimental studies. Several substances have been 
tested, including agents promoting liquefaction of the vitreous gel, 
agents which cause lysis of the blood clot, and a miscellaneous group 
of substances directed at other aspects of vitreous haemorrhage ab-
sorption (Table A2). The most effective agent within this group was 
streptokinase-streptodornase458, but the enzyme w~s found to cause 
cataracts and ocular inflammation (uveitis) as had been observed by 
, 1 t' 62, 193 others uSlng ess pure pre para lons • Streptokinase has been 
used clinically to clear blood clots from the anterior chamber of the 
eye (hyphaema) but its use was discontinued due to its high toxicity 
154,376 
• 
It was suggested that the marked uveitis which~occurred in 
the human eye after streptokinase injection was the result of the 
l~ 
strongly antigenic nature of this bacterial protein. A similar 
fibrinolytic agent, urokinase, which is non-antigenic in man was 
found to be highly effective in the treatment of traumatic hyphaemata 
and had no significant toxic ocular effects399 ,4l3 (the nature and 
mode of action of urokinase are described in Chapter 5). More 
recently, urokinase has been applied to the treatment of persistent 
't h h 'h The ;nl't1'al favourable results123 ,152,558 Vl reous aemorr age ln umans. ~ 
contrasted with similar studies which suggested that urokinase was of 
little benefit in the treatment of human vitreous clots9l ,2l9. A 
later study by Chapman-Smith and Crock84 reported that urokinase 
caused subjective and/or objective improvement in vision in nineteen 
of twenty-seven patients. These authors advocated the use of urokinase 
as a first line of attack in persistent vitreous haemorrhage, with 
vitreous surgery reserved for those who fail to respond. 
Since the failure of vitreous clots to resolve naturally may be 
partly due to low levels of fibrinolytic activity wit~in the vitreous 
(see Chapters 1,8,9), the use of urokinase in this condition would 
appear to have a rational basis. Although Koziol et a1268 found that 
urokinase was ineffective in clearing experimental vitreous clots in 
monkeys, recent experiments in rabbits have shown that a significantly 
more rayid rate of vitreous clot lysis occurred in eyes treated with 
intravitreal urokinase than in saline-treated control eyes or in eyes 
in which uveitis was induced by non-fibrinolytic agents l48• The 
effect of urokinase on rabbit vitreous clots was associated with high 
fibrinolytic activity and was dose-dependent, suggesting that there 
was a critical level of fibrinolytic activity, below which clot lysis 
failed to occur. 
The mode of action of urokinase in clearing human vitreous 
haemorrhage is less clear. Recent editorial comment emphasised that 
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fibrin has not been detected in human vitreous haemorrhage and thus 
urokinase is unlikely to act as a fibrinolytic enzyme in this 
situation l2~. On the contrary, electron microscopical studies 
have shown that fibrin does occur, at least within recent human 
vitreous haemorrhages577(Forrester, unpublished observation). Con-
sequently, a substrate for plasmin-mediated fibrinolysis via uro-
kinase may be present in fresh vitreous clots. Urokinase has, 
however, proved of value in cases where the vitreous opacity was 
present for over four years84 ,152 and it is difficult to conceive of 
fibrin remaining unaltered in the vitreous for this length of time. 
The lack of suitable human pathological material for study must leave 
this question unanswered. 
The role of urokinase in promoting clearance of red cells and in 
the dissolution of fine collagenous membranes with vitreous clots is 
also difficult to explain. Plasmin-mediated chemotaxis and the 
resulting inflammatory response (see Chapter 9) may be important during 
this phase of resolution, since inflammatory cells are known to secrete 
haemolysins and collagenase (see Chapter 14). Patients treated with 
intravitreal urokinase frequently develop a marked uveitic response 84 ,152 
and it is likely that this inflammatory reaction influences the clearance 
of the vitreous opacity. A determining factor, therefore, in the 
response to urokinase is the extent to which vitreous membranes develop 
after clot formation (see Chapters 12,13). The use of ultrasound in 
the selection of cases for treatment increases the rate of success84 • 
Complications which may arise from the use of urokinase in 
vitreous haemorrhage include a sixty-seven per cent incidence of 
hypopyon uveitis which is transitory, and a twelve per cent incidence 
of cataract84 ,152• In their series of thirty-four treated eyes, 
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Chapman-Smith and Crock observed a worsening of the visual status 
in three cases. 
CONCLUSION 
Current methods of treatment now offer a measure of hope to 
the patient blinded by a non-resolving vitreous haemorrhage. The 
place of vitreous surgery in the treatment of simple vitreous haemor-
rhage seems well established, but this must be offset by the considerable 
risk of surgical complications. The value of urokinase therapy has not 
been critically tested by controlled clinical trial. Nevertheless, 
there is increasing evidence of its efficacy when used in open trial 
conditions, and current opinion supports the view that it can be 
effective in the treatment of vitreous haemorrhagel30 • For the 
future, urokinase merits further evaluation in appropriately selected 
patients under rigorous screening procedures. 
TABLE 15.2 
CLOT-LYSING AND ENZYNillTIC AGENTS USED 
IN TREATMElJT OF EXPERIMENTAL VITREOUS HAEKORRHAGE 
VITREOUS GEL LI~UEFACTION 
Collagenase 
hyaluronidase 
trypsin 
0<... -chymotrypsin 
CLOT-LYSING AGENTS 
Streptokinase-streptodornase 
fibrinolysin 
urea 
MISCELLANEOUS 
Saponin 
phenyl-hydrazine 
thyroxine 
deferoxamine 
REFERENCE 
62 
62,193,458,529 
62,8),351 
388,451 
62,300,458 
351 
62 
62 
62 
529 
565 
TABLE 15.1 
CO~~LICATIONS OF VITREOUS SURGERY 
INTRAOPERATIVE COMPLICATIONS 
Ciliary body laceration 
lens damage ) 
corneal lesion in aphakie eyes l 
uncontrollable intraocular haemorrhage) 
retinal tears or dialYSeS~ 
vitreous incarceration ~ 
POSTOPERATIVE COMPLICATIONS 
retinal traction from sclerotomy 
fibrous/fibrovascular ingrowth from sclerotomy 
endophthalmitis 
phthisis bulbi 
elevated intraocular pressure 
rubeosis iridis 
major intraocular haemorrhage 
recurrent small haemorrhages 
persistent corneal oedema 
) 
) 
) 
1 ) 
l ) 
~ 
cystoid macular oedema and macular pucker) 
hypotony ~, 
---------~----~--- --~~- -
REFERENCE 
498 
302,309 
332,395 
302,309,332,395,498 
499 
498 
410,499 
302,309,332,395 
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